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9General introduction
1The genome is the blueprint of life. Mutations in genomic DNA may cause disease by affecting morphogenesis, function and homeostasis of cells and tissues. One special category of disease-causing mutations are the so-called microsatellite expansions, whereby a DNA 
segment consisting of a repeat of short nucleotide sequence motif becomes abnormally 
long. Such repeat expansions can exert gain- or loss-of-function effects, in cis or in trans. 
Myotonic dystrophy type 1 (DM1) is an archetypical example of the class of disorders that is 
caused by these peculiar DNA alterations.
 DM1 is caused by an unstable (CTG)n triplet repeat in the dystrophia myotonica 
protein kinase (DMPK) gene. Disease features are multisystemic and highly variable, 
affecting skeletal muscle, heart and the nervous and endocrine systems [1], all with usually 
late onset and with a progressive nature. Since the discovery of the causal mutation in 1992 
[2–4], considerable progress has been made in deciphering the molecular mechanisms 
that determine DM1 problems. However, the exact cascade of events that underlie disease 
manifestation is still unknown.
 By the different studies described in this thesis, I aimed to gain improved 
understanding of fundamental factors influencing DM1 disease mechanism. Attention was 
therefore specifically focused on the production and processing of transcripts from the 
DM1 locus and a comparison of fate of RNAs with and without an expanded trinucleotide 
repeat. Before reporting on the experimental findings of my PhD study, I will first describe 
and discuss background knowledge on transcript processing in higher eukaryotes, disease 
etiology of DM1 and other repeat expansion disorders in this introductory chapter.
1  A transcript’s life
1.1  RNA polymerase II transcripts
Transcription, the process by which genetic information stored in DNA is copied into RNA, 
occurs within the nucleus of every eukaryotic cell. Different RNA polymerases (RNAPs) 
are responsible for the synthesis of different types of transcripts. Together, the transcripts 
produced by RNA polymerase II (RNAP II) represent by far the largest and most diverse group 
of RNAs, of which the protein encoding mRNAs are until now the most intensively studied 
category. All mRNAs are formed as premature messenger RNA transcripts (pre-mRNAs). 
Upon transcript maturation by 5’-end capping, splicing and 3’-end polyadenylation, mRNAs 
are transported into the cytoplasm as ribonuclear particles (RNPs) (Fig. 1). Processing 
events may occur co- and/or post-transcriptionally and differentially influence the fate of 
an individual transcript in each step. In the cytoplasm, the mRNA serves as template for 
translation into protein and will eventually be degraded. Detailed analysis has revealed that 
alternative choices exist for these processing events for the majority of mRNAs. Combined, 
the processes of alternative transcription, alternative splicing, alternative polyadenylation 
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and alternative translation initiation expand the genome’s coding capacity enormously [8]. 
 The role and life cycle of many other RNA species is less well understood. For 
example, one recently discovered group of RNAs important for our studies, coined long 
non-coding RNAs (lncRNAs), forms a loosely classified category of transcripts of >200 
nucleotides with no apparent protein-coding role. lncRNAs are also transcribed by RNAP 
II and share many structural features with protein-coding mRNAs, but they are generally 
expressed in much lower copy numbers and are predominantly found in the nucleus, often 
in close association with chromatin [9,10]. Although frequently polyadenylated and spliced 
like regular mRNAs, lncRNAs mostly contain fewer and lesser evolutionary conserved exons, 
and - as their name indicates - no overt open reading frames [9,10]. The current knowledge 
about the function and biological significance of individual lncRNAs is still scarce (with a few 
exceptions, e.g. MALAT1, NEAT1 and XIST). Nevertheless, they all seem to share a role in 
control of gene expression and are the modulators of a wide range of functions in cellular 
and developmental processes [10]. Below I will discuss some of the fundamental principles 
involved in synthesis, maturation, processing and decay of mRNA. These principles may also 
be involved in the specification of fate of lncRNAs, but are simply less well studied for the 
members of this new class of RNAs.
Figure 1. Life of an mRNA. RNA polymerase II (RNAP II) mediated transcription of any protein-encoding 
gene is initiated by assembly of a preinitiation complex (not shown) at the core-promoter sequence, which 
is close to the actual transcription start site (TSS). During the elongation phase (co-transcriptionally) and 
after its formation (post-transcriptionally), the premature mRNA is processed into a mature mRNA by 5’-end 
capping (m7G), splicing by the spliceosome and 3’-end polyadenylation by poly(A) polymerase (PAP) at the 
poly(A) site (pA). Multiple isoforms of a transcript may be produced by the use of alternative initiation 
and termination sites (indicated with an asterisk), and alternative exon/intron and intron/exon junctions 
(not shown, see Fig. 2 for details). Nuclear speckles, membrane-less organelles enriched for pre-mRNA 
splicing factors, are important for the functional compartmentalization of the nucleus. Various proteins 
associate with the (pre-)mRNA, like the cap-binding complex (CBC), the exon junction complex (EJC), the 
transcription-export complex (TREX) and nuclear poly(A) binding protein (PABPN1), ultimately forming an 
export-competent messenger ribonucleoprotein (mRNP). The mRNP is exported to the cytoplasm via the 
nuclear pore complex (NPC) [5]. In the cytoplasm, the mRNA will be decorated with other proteins, like 
factor eIF4F and cytoplasmic poly(A) binding protein (PAPBC). In turn this enables association with a large 
pre-initiation complex (not shown) that includes the small ribosomal subunit, followed by scanning of the 
5’ UTR, assembly of the complete ribosome at the AUG-start codon and activation of the actual translation 
[6]. Under certain physiological conditions translation can be blocked, by storage of mRNAs in processing 
bodies (P-body), which are enriched for RNA degradation factors, or in stress granules, where mRNPs 
are stalled for later use in translation in preinitiation complexes. Ultimately, the mRNA will be degraded, 
initiated by shortening of the poly(A) tail. The transcript is decapped and subsequently degraded by XRN1 
exonuclease (5’ to 3’ degradation) or degraded by the exosome (3’ to 5’ degradation). Of note, lncRNAs are 
also transcribed by RNAP II and may undergo the same nuclear processing steps as mRNAs, like capping, 
splicing and polyadenylation, but are generally not translated into protein. Inspired by [7].
«
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1 1.2  Transcription initiationTranscription of eukaryotic protein-encoding genes requires the molecular assembly of the 
preinitiation complex at the ‘core promoter’, the region just around the transcription start 
site (TSS) [11]. To recruit RNAP II, carefully orchestrated binding of several transcription 
factors to both proximal and distal regulatory elements is essential [11]. Transcription then 
initiates and RNAP II pauses immediately downstream of the TSS [11,12]. A key event in the 
switch to transcription elongation by RNAP II may be the addition of the 5’-cap, described 
further below [12,13].
 Transcription initiation is strongly regulated and represents the first layer of control 
in gene expression during mRNA biogenesis [8,14]. Use of alternative TSSs yields transcripts 
that differ in their 5’ end. These transcripts thus contain alternative 5’ untranslated regions 
(UTRs), which may differentially regulate translation or encode proteins with alternative 
N-termini [8]. TSS usage is thought to be cell-type specific, mediated by the activity of the 
specific set of transcription factors in every cell [14].
 A large proportion of the genome is pervasively and bidirectionally transcribed 
from both strands of the genomic DNA. An originally annotated transcript is usually called 
the sense transcript, while a transcript from the opposite strand is the antisense transcript 
[15,16]. Formation of antisense transcripts can be driven from independent promoters, 
shared bidirectional promoters or cryptic promoters situated within the transcribed genes. 
Promoters in gene-dense areas of the genome are appropriately classified as head-to-head, 
tail-to-tail or internal (fully covered by the sense transcript) with respect to the orientation 
of the sense gene [16]. Antisense transcripts are often classified as lncRNAs. However, 
some protein-coding antisense genes with only partial overlap with sense genes have been 
described [17,18].
1.3  5’-capping
5’-end capping is the first processing event that a pre-mRNA undergoes. Capping requires 
the enzymatic activities of three different enzymes: RNA triphosphatase, guanylyltransferase 
and 7-methyltransferase [12,13]. The mammalian capping enzyme complex is recruited to 
the nascent transcript by RNAP II [13,19], in particular its carboxy-terminal domain (CTD), 
which is besides this role also important for regulating splicing and polyadenylation [13,19]. 
The CTD is composed of conserved heptapeptide repeats (Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-
Ser7), which are subject to reversible phosphorylation [13,19]. These phosphorylation 
marks are critical for proper progression of transcription and are required for coordinating 
the different steps in RNA processing [13,19]. It is thought that the transcription complex is 
stalled at the promoter until capping occurs, after which RNAP II switches into the elongation 
mode [13,20]. Release of the capping enzyme is correlated with Ser5 dephosphorylation in 
the CTD, which occurs during transcription before the nascent transcript is 500 nucleotides 
13
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1long [13,20]. The 5’-cap provides stability by protecting the transcript against 5’-3’ exonucleases in the nucleus and the cytoplasm [13]. In the cytoplasm, a mature mRNA will eventually be 
subject to degradation, which involves decapping by DCP1/DCP2 and degradation by 5’-3’ 
exonuclease XRN1 [13]. Furthermore, the cap is important in mediating mRNA recruitment 
to ribosomes in the cytoplasm. The eIF4F protein complex recognizes the cap before 
translation and facilitates mRNA circularization via an interaction with cytoplasmic poly(A)-
binding protein (PABPC), which aids in translation re-initiation and hence the enhancement 
of protein synthesis [13] (Fig. 1).
1.4  Constitutive and alternative splicing
While still in the nucleus, during and after elongation by RNAP II, a pre-mRNA transcript is 
subject to splicing, a process in which introns are removed (Fig. 2A). Splicing is essential for 
transcript maturation, nuclear export and protein expression. The reaction is catalyzed by 
the major spliceosome, a large and dynamic RNA-protein complex consisting of a collection 
of U-type small nuclear RNPs (snRNPs), among which U2 snRNP, and a large number of 
additional proteins [13,21]. Approximately 95% of the introns are processed by this major 
spliceosome, while a small subset of introns is processed by the minor spliceosome, based 
on involvement of a set of other U-type snRNAs, among which U12 snRNP [22].
 Primary transcripts are cleaved at conserved splice sites, which span the exon-
intron and intron-exon borders. Cleavage within these sequences occurs directly 5’ adjacent 
to a GU and 3’ adjacent to an AG dinucleotide pair that specify the beginning and end of 
every canonical U2-type intron, which is targeted by the major spliceosome. In the rare non-
canonical U12-type introns, which are targeted by the minor spliceosome, both GU-AG and 
AU-AC borders are found [24].
 The spliceosome carries out splicing via two transesterification reactions. First, the 
2’-OH of the branch-point nucleotide performs a nucleophilic attack on the phosphodiester 
backbone at the 5’ end of the intron, forming a lariat intermediate. Second, the 3’-OH of the 
released exon performs a nucleophilic attack on the last phosphodiester bond of the intron, 
which joins the two exons and releases the lariat intron [13,25].
 Usage of putative splice sites by the spliceosome is influenced by cis-acting 
regulatory sequence elements called enhancers and silencers. These elements recruit 
trans-acting splicing factors like Serine/Arginine-rich proteins or heterogeneous nuclear 
ribonucleoproteins (hnRNPs) or form RNA secondary structures to regulate splicing 
[13,23,26,27]. Splice site usage is thus a cumulative and combinatorial effect of binding 
by multiple modulating factors. Alternative splicing, the differential inclusion of subsets or 
parts of exons, is a common event to expand the diversity in gene expression, occurring in 
approximately 95% of mammalian genes [28,29]. There are five major types of alternative 
splicing: exon skipping, use of alternative acceptor and/or donor sites, mutually exclusive 
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exons and intron retention (Fig. 2B) [8,22]. As a result, alternative splicing can affect the 
open reading frame (ORF).  Also the sequences of 5’ and 3’ UTRs may be differentially 
determined by splice variation.
 Like in capping, the CTD of RNAP II has a central role in splicing when occurring 
co-transcriptionally. Phosphorylation of the CTD can thereby act to recruit splicing factors 
to the nascent transcript and ensure rapid splicing [13,20]. CTD-independent coupling of 
transcription and splicing has also been described. For example, RNAP II elongation rate 
influences alternative splicing, as 5’ splice sites are more likely to pair with newly transcribed 
3’ splice sites [13]. Interestingly, this coupling is reciprocal, as splicing may also influence 
transcription, for example by enhancing transcriptional elongation [13,20,30].
 Since splicing dysregulation can lead to potentially harmful transcript or protein 
variants, mRNAs are subjected to quality control in the nucleus to prevent export of defective 
transcripts [13,23]. Quality control can act at numerous stages during the splicing process, 
resulting in nuclear retention or degradation of defective transcripts [13]. One specific 
form of quality control is nonsense-mediated decay (NMD). Newly synthesized mRNAs are 
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Figure 2. RNA splicing. (A) During splicing, two adjacent exons are coupled by removing the intervening 
intron from the mRNA molecule. The major spliceosome, consisting of the U1, U2, U4, U5 and U6 snRNP, 
is assembled around the intron to be removed. Splice sites (SSs) are demarcated by conserved sequence 
motifs in the intron, GU and AG for the 5’ and 3’ SSs, respectively (bold). The polypyrimidine tract ((Y)n, 
bold) in between the branchpoint (BP) and 3’ SS is important for binding protein factors that can modulate 
splice site usage. Two sequential transesterification reactions are carried out to remove the intron. (B) Five 
possible modes of alternative splicing. Dotted lines above and below the schematic RNA indicate alternative 
splice events. In the last example the alternative pathway corresponds to no splicing. Inspired by [22,23].
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1surveyed by the NMD quality control mechanism and transcripts harboring a premature stop codon are degraded [31]. Although the majority of premature stop codons in NMD targets have arisen by mistake, for example during pre-mRNA splicing, approximately 10% 
of the NMD targets are normal physiological mRNAs [31]. In that case, NMD functions as 
a post-transcriptional regulation mechanism to promote an appropriate cellular response 
to changes in the environment for which (temporal) abrogation of mRNA production has 
beneficial effects [31].
 Problems arise when interactions between mRNA and RNA-binding proteins are 
disturbed, for example in the case of mutated splicing factors [32]. In amyotrophic lateral 
sclerosis (ALS), mutated FUS proteins interact with minor spliceosome constituent U11 snRNP, 
thereby inhibiting correct splicing of minor introns in mRNAs encoding proteins required for 
motor neuron survival [33]. Likewise, mutant mRNA transcripts with an expanded repeat can 
aberrantly sequester RNA-binding proteins, thereby depleting the cell of available splicing 
factors. Alternatively, RNA-binding proteins only binding to short, endogenous motifs may 
be upregulated [32]. As detailed below, these two mechanisms occur in DM1, where they 
lead to altered levels of muscleblind-like splicing regulator 1 (MBNL1) and CUGBP/Elav-like 
family member 1 (CELF1), causing missplicing of over 30 effector genes [34]. 
1.5  3’-end maturation
The polyadenylation process, consisting of cutting the 3’ end of a pre-mRNA at a defined 
position followed by the addition of a poly(A) tail, may already start while splicing of the pre-
mRNA is not yet finished. Also transcription 3’ from the poly(A) site may still proceed while 
the transcript is being polyadenylated [13]. The two core RNA sequence elements that drive 
polyadenylation are the poly(A) signal, containing the AAUAAA consensus sequence (or a 
variant) and a downstream U- or G/U-rich region [35,36] (Fig. 3A).
 Formation of the 3’ end starts with a multi-protein complex assembling around the 
poly(A) site in the nascent RNA. The cleavage and polyadenylation specificity factor (CPSF) 
binds the poly(A) signal, while the cleavage stimulation factor (CstF) binds the U/GU-rich 
element. Cleavage factors Im and IIm and poly(A) polymerase (PAP) additionally associate 
with the complex [35,36]. After assembly of this core machinery, the RNA is cleaved 10-35 
nucleotides downstream of the poly(A) signal. Then adenosine nucleotides are added by 
PAP in a template-independent manner [13,35]. The newly synthesized poly(A) tail is bound 
by nuclear poly(A)-binding protein (PABPN1) and the interaction between PABPN1, PAP and 
CPSF is critical to establish the processive action of the PAP [36].
 A poly(A) tail of an mRNA was generally believed to contain 150-250 adenosine 
nucleotides, but recent global analyses have revealed that the median tail length is smaller 
(50-100 nt) [39–41]. Furthermore, tail lengths may differ per transcript, for example mRNAs 
encoding ribosomal proteins and transcripts from so-called household genes generally have 
shorter poly(A) tails [41].
16
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 Although transcription may proceed for quite some distance after the poly(A) 
signal has been reached, transcription termination and RNA 3’-end processing are coupled. 
Two general models are put forward to explain this linkage: (i) the anti-terminator model, in 
which extrusion of the poly(A) signal on the mRNA results in a change of factors associated, 
possibly releasing elongation factors or recruiting termination factors, and (ii) the torpedo 
model, in which the new, uncapped 5’-end formed after cleavage at the poly(A) site is a 
substrate for degradation, eventually catching up with and triggering the release of RNAP II 
[13,42].
 Alike alternative transcription initiation and alternative splicing, transcripts can also 
undergo alternative polyadenylation (APA) (also known as alternative 3’ end processing) as a 
result of the presence of multiple potential poly(A) sites (Fig. 3B). Depending on the location 
of alternative poly(A) sites, APA will lead to different 3’ UTR variants or changes in the ORF as 
well as the 3’ UTR [38]. Through altering the coding sequence, APA may function in regulating 
protein function. By changing the 3’ UTR, APA may alter the stability, cellular localization and 
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Figure 3. Polyadenylation. (A) The polyadenylation processing step involves a cleavage event to form 
the 3’ end of an RNA, followed by the addition of adenosine residues. The cleavage and polyadenylation 
specificity factor (CPSF) binds the poly(A) signal (AAUAAA or a variant, bold) and the cleavage stimulation 
factor (CstF) binds the U/GU-rich element (bold (U/GU)n). Also cleavage factors Im and IIm and poly(A) 
polymerase (PAP) associate. The RNA is cut at 10-35 nucleotides downstream of the poly(A) signal and this 
represents the actual poly(A) site where adenosine nucleotides are added by PAP in a template-independent 
manner. The newly synthesized poly(A) tail is bound by nuclear poly(A)-binding protein (PABPN1), important 
for the processive action of PAP. The final poly(A) tail may be 50-250 residues long. (B) Various modes of 
alternative polyadenylation (APA). A gene with multiple poly(A) sites (pA) that potentially can serve in APA is 
drawn (top). APA in the 3’-most exon and in upstream regions is represented in the first two and last three 
transcript isoforms respectively. Inspired by [37,38].
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1translation efficiency of transcripts, since 3’ UTRs function as docking platforms for miRNAs and regulatory RNA-binding proteins [8,43]. Approximately 70% of all human genes contain alternative poly(A) sites, with tandem 3’ UTR APA being the most common form [8] (Fig. 3B). 
APA may be tissue specific and is often coupled to alternative splicing, in particular of the 
last exon [13].
 The poly(A) tail serves several roles. The tail is important for translocation of the 
mRNA to the cytoplasm, plays a key role in translation efficiency and is vital for regulating 
mRNA quality control and degradation [39]. In addition to nuclear polyadenylation, a specific 
sub-population of mRNAs that contain a cytoplasmic polyadenylation element in their 3’ 
UTR may be subject to cytoplasmic polyadenylation [8]. This represents a mechanism of 
gene expression control in early development. In general, poly(A) tail shortening is a key step 
in initiating decay of the mRNA. However, several non-coding RNAs have been described 
which completely lack a poly(A) tail, but these transcripts are stabilized by the formation of 
a terminal triple helix structure [39,44].
 Next to deadenylation, hyperadenylation has been described which represents a 
nuclear RNA quality control mechanism [45]. Hyperadenylation of mRNAs has been linked 
to reduced or inhibited nuclear export, which signals for rapid decay in the nucleus [45–47]. 
Thus, rather than a simple static entity marking the 3’ end of an mRNA, the poly(A) tail is 
dynamic and influences the fate of the mRNA [39].
1.6  RNA epigenetics
Cellular mRNAs carry various chemical modifications, including the N7-methylguanosine 
at the cap. The most abundant internal modification in mRNA is the methylation of the 
N6 position of adenosine (m6A) [48,49]. This RNA modification is the first example of 
reversible RNA methylation [50,51]. m6A is widely distributed in more than 7000 mRNAs 
and is enriched around stop codons, at 3’ UTRs and within long exons [52]. Writer, eraser 
and reader proteins have been identified for this chemical RNA modification [52]. Through 
binding of different reader proteins, the methylation of adenosine may influence various 
aspects of mRNA metabolism [52]. Furthermore, a combination of this m6A modification 
with 2’-O-methylation, which is coined N6, 2’-O-dimethyladenosine (m6Am), in close 
proximity to the 5’ cap was shown to enhance stability of transcripts due to resistance to a 
decapping enzyme [53].
 Another example of a reversible internal mRNA modification is N1-methyladenosine 
(m1A) [54,55]. This modification is present in thousands of transcripts, where modified 
transcripts contain on average one m1A. The previously discussed m6A modification on the 
other hand is generally present on multiple sites on a transcript [48]. The m1A modification is 
enriched around the start codon and although the function remains unclear, it may promote 
translation [54]. Other mRNA modifications include 5-methylcytosine, pseudouridine, and 
2’-O-methylation, but their functions are currently largely unclear [48,49]. 
18
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1 1.7  Nuclear exportDuring the previously described RNA processing steps, the messenger associates with a variety of proteins, forming a messenger RNP particle [5,56]. For example, the exon junction 
complex (EJC) is deposited 20-24 nucleotides upstream of the exon-exon junction late in 
splicing [57]. Also factors involved in nuclear export are recruited during transcription and 
processing, for example the transcription-export complexes (TREX and TREX-2) which are 
recruited in a splicing- and 5’-cap-dependent manner [5,13,58]. 
 Alternatively, RNA processing may occur post-transcriptionally. The nucleus 
contains a variety of compartments to organize its interior and regulate gene expression 
by locally increasing concentrations of molecules involved in transcription initiation or 
repression and RNA processing [59]. These membrane-less nuclear bodies or domains 
form by phase separation primarily driven by proteins which have an intrinsic tendency 
for being conformationally heterogeneous, or intrinsically disordered [60]. An example 
of such a nuclear domain is a so-called nuclear speckle in which many splicing factors, 
TREX components and polyadenylated RNAs are localized [58]. A subset of transcripts are 
processed and matured in these speckles [58].
 After formation of an export-competent mRNP, the complex must move to the 
nuclear periphery followed by translocation of the RNA to the cytoplasm through the 
nuclear pore complex (NPC) [5,58]. The necessary adapter and export factors need to be 
bound for successful mRNA transport, otherwise the mRNA will be retained in the nucleus 
[13,56]. Nuclear RNA export factor 1 (NXF1, also known as TAP) is the major factor that 
bridges the interaction between the mRNP and NPC [61,62]. This bulk export mechanism 
is RanGTP independent. Only specific subsets of mRNAs traverse trough the NPC using the 
RanGTP dependent exportin 1 (XPO1, also known as CRM1) protein export receptor [61,62]. 
After translocation through the NPC, the mRNP is extensively remodeled to remove the 
export factors in order to prevent return of the mRNP to the nucleus [5,58]. Once in the 
cytoplasm, the mRNA, now decorated with other proteins, may be subject to translation. 
 Although most transcripts are transported to the cytoplasm via bulk export 
pathways, selective mRNA export regulates diverse biological processes, including stress 
responses [58]. Some transcripts are selectively retained in the nucleus, for example 
unspliced pre-mRNAs, which are not exported as a result of a quality control mechanism. 
In addition, mRNAs that have been subject to adenosine-to-inosine editing, caused by 
adenosine deaminases acting on RNA (ADARs), can be retained in the nucleus in so-called 
paraspeckles to control gene expression [63]. 
 Nucleocytoplasmic mRNA export can be blocked at various levels. For example, in 
Huntington’s disease (CAG)n-repeat expanded HTT transcripts are retained in the nucleus, 
mediated by splicing factor MBNL1 [64]. Likewise, as outlined in more detail below, in DM1 
DMPK transcripts carrying an expanded (CUG)n repeat are sequestered in the nucleus [65], 
probably caused by aberrant decoration of the mRNA by RNA-binding proteins. Recently, 
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1a novel molecular disease mechanism for the (GGGGCC·GGCCCC)n hexanucleotide repeat expansion in C9orf72 causing ALS and frontotemporal dementia (FTD) was reported, related to defective nucleocytoplasmic transport and dysfunctional nuclear pore complexes [66–68]. 
Neurons, the cell type primarily affected in ALS/FTD, have only limited ability to replace 
damaged nuclear pores. Therefore this cell type is especially vulnerable for expanded 
C9orf72 transcripts, which may explain the neurodegenerative phenotype in ALS/FTD [69].
1.8  Cap-dependent and -independent translation
Once in the cytoplasm, translation of most eukaryotic mRNAs is initiated via a cap-dependent 
scanning mechanism (Fig. 1). The mRNA is circularized and activated by binding of eIF4F to 
the 5’-cap and PABPC to the poly(A) tail [6,70]. The 43S preinitiation complex binds near 
the cap and scans the mRNA in the 3’ direction until it encounters the first AUG codon 
in a Kozak consensus sequence [6,70]. The 60S subunit joins and the mature ribosome 
translates the mRNA into a protein [6,70]. An mRNA can be translated by multiple ribosomes 
simultaneously, forming a structure called a polysome.
 A well-known alternative translation initiation mechanism, independent of the 5’-
cap structure, is based on internal ribosome entry sites (IRESs) [6,70]. The IRES, a highly 
structured RNA sequence, recruits a ribosome internally to an mRNA [6,70]. IRES-initiated 
translation is common for viral RNAs and also some eukaryotic cellular RNAs contain an IRES 
[71]. For example, during mitosis, when global translation is reduced via inhibition at the 
level of 5’-cap-dependent initiation, specific mRNAs, whose protein products are essential 
in the progression of cell division, are translated via IRES-mediated initiation [72].
 Fairly recent, a novel type of translation associated with expansions of short 
sequences (CAG, CUG, CGG and GGGGCC repeat motifs) has been described, called repeat-
associated non-ATG (RAN) translation [73,74]. The RNA structure formed by the repeat 
has been suggested as a possible trigger, but details of how and when RAN translation is 
initiated remain elusive. The RNA repeat structure may be decorated with various proteins, 
resembling a translation initiation unit and thus trigger translation initiation in the absence 
of an AUG start codon [75,76]. Ribosome recruitment may occur via a cap-dependent 
scanning mechanism or via an IRES-like region [75,76]. It may be possible that the 
mechanisms involved differ across repeat types, reading frames and sequence contexts [77]. 
For example, data on RAN translation of the (CGG)n repeat in the 5’ UTR of FMR1 suggests 
a ribosome scanning principle [78], but such a mechanism cannot explain RAN translation 
from the (CAG)n repeat located within the ORF of HTT transcripts. RAN translation may 
occur in all three open reading frames, yielding various homopolymeric or dipeptide repeat 
products which may be toxic to the cell [74–76]. How RAN translation occurs on RNAs that 
are largely retained in the nucleus, as seems to occur in several repeat disorders, is an 
important question for further study, but translation in the nucleus has been described [79].
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1 1.9  Cytoplasmic storage and degradationMembrane-less bodies composed of RNA and proteins are present in the cytoplasm, analogous to the presence of RNP bodies or domains in the nucleus as described above 
[60]. Examples of such bodies are processing bodies (P-bodies) which are enriched for RNA 
degradation factors. Also stress granules, involved in storage of mRNPs stalled in the process 
of translation initiation, belong to this class of cellular structures [60] (Fig. 1). mRNAs 
that are not engaged in translation can aggregate in these cytoplasmic mRNP granules, a 
process that represents another level of gene expression control. Capture of mRNA in these 
bodies or aggregates seems generally a dynamic event, allowing cytoplasmic mRNAs to 
cycle between polysomes (active translation), P-bodies and stress granules, mediated by 
differential association of proteins [80].
 Decay of mRNA eventually follows after its use in translation. Depending on the type 
of transcript and on motifs contained in its primary sequence, RNA degradation may occur 
already after a few minutes upon cytoplasmic entry or be postponed for several days. In 
general, mRNA decay is initiated by shortening of the 3’ poly(A) tail (deadenylation), followed 
by 3’ to 5’ degradation by the exosome or, more commonly, decapping by DCP1/DCP2 and 
subsequent 5’ to 3’ degradation by the XRN1 exonuclease [80]. There are also specialized 
decay pathways to degrade translationally aberrant mRNAs that are produced by defects in 
splicing, 3’ end formation or damage RNA, like the nonsense-mediated decay pathway [80].
1.10  Huge variation in transcript copy number
Distinct types of molecules in the population of mRNAs of the cell do not only differ in 
size and sequence information, they also differ in number. Transcriptome wide studies 
have shown that the copy numbers for particular transcripts range from practically zero 
(low expressed transcripts in only a subset of the cell population and usually considerable 
variation between cells) to several thousand of identical transcripts per cell [81]. So-called 
housekeeping transcripts, like GAPDH and ACTB, are among the most abundantly expressed 
types of transcripts. It is important to note here that transcript number is not a linear related 
and good predictive parameter for biological relevance or pathobiological significance. For 
example C9orf72 transcripts are quite low abundant with ~15 copies per cell, but in ALS/FTD 
patients who carry an expanded hexanucleotide repeat in approximately half of these 
transcripts, this expression level has devastating disease effects [82]. 
 Copy numbers are for most mRNAs closely related to the frequency by which the 
gene is transcribed. Although some genes are transcribed continuously, most genes are 
transcribed in short periods of time, called transcriptional bursts [83–85]. The resulting 
gene expression noise appears to be dampened by mechanisms of nuclear retention, to 
control the number of transcripts entering the cytoplasm [81,86]. In the end, degradation of 
a transcript is also an important factor in maintaining the transcript copy number.
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12  Myotonic dystrophy type 1Myotonic dystrophy (DM), also known as dystrophia myotonica or Steinert’s disease, was 
first described in 1909 [87,88]. It is a progressive disease with a dominant inheritance. Two 
types of DM have been described, type 1 and type 2. DM1 is caused by a (CTG)n repeat 
expansion in the 3’ UTR of the DMPK gene [2–4], while DM2 is characterized by mutant 
lengthening of a (CCTG)n repeat in the first intron of the CCHC-type zinc finger nucleic acid 
binding protein (CNBP or ZNF9) gene [89]. Here I will focus on DM1 only.
2.1  Genetics and clinical phenotype
With an incidence of about 1 in 8000 individuals globally, DM1 is the most common form 
of adult onset muscular dystrophy [1]. Myotonia, the delay in relaxation upon muscle 
contraction, is a hallmark of the disease. Other symptoms include muscle wasting and 
weakening, cardiac arrhythmia, smooth muscle dysfunction, cataract, insulin resistance, 
cognitive abnormalities and hypersomnia [1,34]. The clinical problems are thus highly diverse 
and occur with variable frequency among patients, classifying DM1 as a multisystemic 
neuromuscular disorder.
 Manifestation of disease correlates fairly well with the length of the (CTG)n repeat 
determined in blood DNA [90,91] (Fig. 4). The unaffected population carries between 5 
and 37 CTG triplets, while late-onset DM1 patients carry up to ~150 triplets. Patients with 
adult-onset DM1 carry a repeat consisting of ~100-1000 CTG triplets and the most severely 
affected congenital patients usually carry repeats with over 1000 triplets [1]. A repeat 
>37 CTG triplets is unstable, which results in repeat expansion in somatic tissues and in 
successive generations [92–94]. DM1 is therefore characterized by anticipation, which means 
that severity of the disease increases and symptoms appear earlier in life over successive 
generations [92]. Somatic expansion rate is much higher in skeletal muscle and brain [95], 
indicating that repeat lengths measured in blood are probably an underestimation of the 
actual repeat length in affected tissues. Furthermore, the repeat length is heterogeneous in 
somatic tissues [95].
 Although most DM1 patients carry a pure (CTG)n repeat, DM1 families have been 
described with imperfect expanded alleles [96,97] in which the (CTG)n repeat is interspersed 
with CCG, or - more rarely - GGC and CTC triplets at its 3’ end. Such repeat variations occur 
infrequent, with an estimated prevalence of 3-5% in the DM1 patient population [96,97]. 
Imperfection of the repeat sequence may contribute to the abnormal disease manifestation 
in carriers. 
2.2  DMPK transcripts and proteins
The (CTG·CAG)n repeat segment is located in a gene-dense region on chromosome 19 
(Fig. 4). On the negative DNA strand three (sense) genes are annotated: DMWD (dystrophia 
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1 myotonica WD repeat containing; formerly gene 59), DMPK, and SIX5 (SIX homeobox 5; formerly DM locus-associated homeodomain protein, DMAHP). Furthermore, antisense transcription resulting in the production of antisense RNA was reported to occur across the 
region complementary to SIX5 and DMPK [98], a phenomenon that is obviously shared with 
other genomic loci involved in repeat expansion disorders [99]. Although the discovery of 
antisense transcription in the DM1 locus was already made in 2005, detailed information on 
the structural organization of the RNA products was not available until I started the studies 
as described in Chapter 5 of this thesis. Still not much is known about the biological role of 
the antisense gene.
2.2.1  DMPK splice isoforms
Transcripts from the DMPK gene, composed of 15 exons, are subject to alternative splicing, 
which results in six major RNA isoforms and several minor splice products [100]. The 
proteins encoded by the major isoforms all contain a leucine-rich N-terminus, a Ser/Thr 
protein kinase domain (encoded by exons 2-8), and an α-helical coiled-coil domain (exons 
10-12). The variants differ in the presence (DMPK A, C and E) or absence (DMPK B, D and F) 
of a Val-Ser-Gly-Gly-Gly (VSGGG) motif, by use of a cryptic 5’ splice site in exon 8. The DMPK 
variants also differ in their C-terminus, which depends on splice site usage in exon 12-15. 
The tails of DMPK A-B and DMPK C-D have differential hydrophobicity, while DMPK E and F 
have a truncated tail. The long DMPK isoforms A-D are predominantly expressed in skeletal 
muscle, heart and brain, whereas the short isoforms E and F are mainly found in smooth 
muscle [100,101]. The above described protein domains each contribute to functionality. 
For example, the VSGGG motif regulates DMPK autophosphorylation and folding [102], 
while the coiled-coil domain modulates DMPK multimerization, substrate binding, kinase 
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Figure 4. The DM1 locus and its transcription units. Sense genes transcribed from the negative DNA strand 
(DMWD, DMPK, and SIX5) as annotated by RefSeq. Exons and introns are visualized in dark and light blue 
respectively, with exon numbering depicted below and UTRs as narrow bars compared to wider bars for the 
CDS. Transcription start sites are indicated with arrows and alternative splicing events with an asterisk. An 
antisense gene (DM1-AS) partly overlaps SIX5 and DMPK on the complementary strand and is described in 
more detail in this thesis. The triplet repeat segment (red) is present as (CTG)n in the 3’ UTR in exon 15 of 
DMPK and as (CAG)n in DM1-AS. Disease classification and corresponding (CTG·CAG)n triplet numbers are 
indicated. Repeat sizes are approximations and are known to overlap between the different classifications.
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1activity and subcellular localization [103]. Furthermore, the long C-termini allow anchorage of these DMPK protein isoforms in the mitochondrial outer membrane [102,104]. Short isoforms E and F, however, have a cytosolic location [102].
 Of note, in all major mature DMPK mRNAs, the (CUG)n repeat tract is present in 
the 3’ UTR and does not contribute to the DMPK open reading frame. One minor DMPK 
splice variant was described in which the (CUG)n repeat is located in an intron, by use of a 
cryptic 3’ splice site in exon 15 [105]. The protein encoded by this isoform, designated DMPK 
G, carries a unique C-terminus [102]. Whereas the expanded (CUG)n repeat in the major 
transcript isoforms causes problems in their processing and/or nucleocytoplasmic export 
and results in nuclear retention, the mature RNA that encodes the minor G isoform is not 
retained in the nucleus, because the expanded repeat is spliced out [105]. 
2.2.2  DMPK protein function
DMPK is classified as a Ser/Thr protein kinase belonging to the group of AGC (protein kinase 
A, G and C) kinases [106–108]. Closely related kinases, also known as members of the small 
DMPK family of proteins are myotonic dystrophy kinase-related CDC42-binding kinase 
(MRCK) α, β and γ, rho-associated coiled-coil-containing protein kinase (ROCK) I and II, and 
citron rho-interacting kinase (CRIK). Although the exact function of each of the different 
DMPK isoforms is still not clear, they are thought to be involved in actin cytoskeleton 
dynamics, alike the other DMPK family members, in ion homeostasis [108–111] and in 
maintenance of integrity of the nuclear envelope [112]. For the DMPK E isoform it has been 
demonstrated that its overexpression compromises the functional integrity of the cellular 
actomyosin network, implicating that its expression needs to be tightly controlled [113]. 
Also for the other DMPK isoforms careful regulation of protein dosage is required for proper 
control over skeletal muscle structure and function [108,114]. 
2.3  DM1 disease mechanisms
The molecular pathogenesis of DM1 is complex with potential involvement of several 
factors contributing to the multisystemic phenotype. The toxic RNA gain-of-function theory 
of expanded DMPK transcripts is best accepted and most intensively studied, but the 
contribution of other disease mechanisms cannot be excluded, particularly because the 
toxic RNA hypothesis cannot easily explain why symptoms vary greatly between patients 
(Fig. 5).
2.3.1  Repeat RNA toxicity
A normal unaffected DMPK gene is transcribed and its RNA product is processed and 
exported to the cytoplasm as part of a mature mRNP. This mRNA is reported to be routed 
through nuclear speckles, also known as SC-35 domains or splicing factor compartments 
[116]. Mutant transcripts from an expanded DMPK allele are, however, retained in distinct 
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Figure 5. Molecular pathogenesis of DM1. The main RNA-dependent pathobiological mechanisms in DM1 
shown in one scheme. The expanded (CAG·CTG)n repeat (red vertical bar) is transcribed in both directions, 
yielding DMPK transcripts with an expanded (CUG)n repeat in the 3’ UTR and DM1-AS transcripts with an 
expanded (CAG)n repeat. Knowledge on the exact transcription unit of DM1-AS is limited, and described 
in more detail in this thesis. Mechanisms with potential contribution to DM1 pathology are indicated in 
boxes outlined with dashed lines. (i) The expanded (CUG)n repeat in DMPK transcripts forms alternative 
RNA structures which sequester members of the MBNL family, stabilize CELF1 by hyperphosphorylation and 
leach transcription factors (TF). These events cause missplicing and transcription deregulation. (ii, iii) Double 
stranded RNAs like (ii) hybridized complementary RNAs (DMPK and DM1-AS) and (iii) the (CUG)n hairpin 
activate the RNAi pathway to generate siRNAs. (iv, v) Both (iv) antisense and (v) sense transcripts with 
expanded (CAG)n and (CUG)n triplets, respectively, may be subject to RAN translation in all possible frames 
yielding homopolymeric proteins. (vi) Since mutant DMPK transcripts are retained in the nucleus, DMPK 
protein levels may be decreased in patients. Epigenetic modifications induced by the repeat expansion may 
also influence expression levels of transcripts in the DM1 locus, causing lower SIX5 protein levels. DM1-AS 
transcripts carrying an expanded (CAG)n repeat may also trigger RNA toxicity (i) and activation of the RNAi 
pathway (iii) alike the sense transcript, but these putative effects are not depicted. Inspired by [115].
25
General introduction
1foci (as apparent in RNA FISH) at the periphery of these nuclear speckles [65,116,117]. The process of abnormal foci formation interferes with the role of at least two antagonistic protein families, the muscleblind-like (MBNL) family [118–120] and the CUGBP/Elav-like 
family (CELF) [121], which regulate alternative splicing throughout development. MBNL1 
activity is decreased in DM1 cells due to sequestration in foci [118–120], while CELF1 (or 
CUG-binding protein 1, CUGBP1) activity is increased through protein stabilization mediated 
by hyperphosphorylation [121–123]. The change in activity and subcellular distribution of 
these splicing factors causes MBNL1- and CELF1-regulated transcripts to adopt an aberrant 
embryonic splicing profile in adult tissues [124–126].
 Multiple misregulated splicing events have been described and are likely to play 
a role in DM1 disease manifestation, as reviewed in [127–129]. For example, aberrant 
splicing of the ClC-1 chloride channel in skeletal muscle results in myotonia [130,131] and 
abnormal splicing of the insulin receptor (INSR) will probably contribute to insulin resistance 
[132], although this latter link is currently under debate. However, care should be taken to 
classify splicing changes as true pathobiological effects of presence of the expanded (CUG)n 
repeat, because muscle regeneration defects may also cause similar splicing abnormalities 
[133]. Furthermore, MBNL proteins are also involved in alternative polyadenylation, mRNA 
localization and decay [134–136] and CELF1 regulates translation of certain mRNAs [137,138]. 
Imbalance in MBNL and CELF1 in DM1 cells thus appears to affect cellular processes beyond 
spliceopathy, probably with effects on global ribo- and proteostasis. 
 An important aspect in the RNA toxicity model is the stoichiometry of the 
factors involved. A significant fraction of MBNL proteins, or a particular subset of MBNL 
isoforms with defined cellular function, must be sequestered to explain the downstream 
RNA processing alterations observed. This implies the requirement of a certain dosage of 
expanded (CUG)n RNA, related both by transcript copy number and repeat length of DMPK 
(CUG)n transcripts, or a nucleation event followed by additional aggregation of multiple 
proteins. Indeed, besides MBNL also other transcription factors and RNA-binding proteins 
like DEAD-box helicases and hnRNP proteins are associated in the foci [139,140]. 
 DMPK (CUG)n RNA foci are more dynamic than previously anticipated, and may 
occur in a focal-insoluble state and/or a diffuse-soluble state mediated by protein binding 
[140]. Also during the cell cycle the number and morphology of RNA foci detected per 
nucleus varies, with highest numbers and largest sizes being observed just prior to entering 
mitosis [141]. Foci will escape the nucleus during mitosis, since the nuclear envelope 
dissociates upon start of prometaphase. Accordingly, the number of nuclear foci increases 
upon inhibition of the cell cycle [141]. Also for DM2, in which an expanded (CCUG)n repeat 
in a CNBP intron forms nuclear foci, similar observations have been reported [142]. Non-
dividing cells may thus be more severely affected by the accumulation of nuclear foci if these 
truly are pathogenic. This may partially be reflected in the affected organs in DM patients, 
like the heart and central nervous system. However, also skeletal muscle is heavily affected 
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1 in DM1 patients, despite its greater capability to self-renewal. Additional mechanisms may thus be involved in disease development and progression.
2.3.2  Interference by small RNAs  
Deregulation of several microRNAs (miRNAs) has been observed in tissues of DM1 
patients [143–147]. Processing of one of these miRNAs, pre-miR-1 involved in control of 
gene expression in muscle, was shown to be regulated by MBNL [144,147]. This finding 
thus revealed a causal link between MBNL sequestration, miR-1 level and deregulation of 
miR-1 controlled processes. However, again, this coupling may also be of reciprocal nature 
as miRNA levels are often altered as a consequence of muscular pathology, and are also 
expressed abnormally in other muscular disorders [146,148]. 
 In addition to miRNA-controlled processes, RNA interference (RNAi) mechanisms 
may also be affected in DM1. Because (CUG)n-containing RNAs form imperfect hairpin 
structures they may be processed into small interfering RNAs (siRNAs) [149]. Expanded 
DMPK RNAs may thus be removed from the cell by the Dicer ribonuclease that produces 
siRNA and this may contribute to a reduction in DMPK expression levels. Another possibility 
is that the siRNAs thus formed use the RNAi pathway to silence expression of transcripts 
containing complementary repeat tracts in other transcripts. Combined, these effects may 
contribute to a potentially pathogenic imbalance in gene expression.
 Likewise, simultaneous expression of expanded sense and antisense RNA transcripts 
from the DM1 locus may cause similar effects via RNAi. It has been shown that co-expressed 
(CUG)n- and (CAG)n-tracts in transcripts can anneal and become processed into small 
triplet repeat-derived siRNAs capable of targeting downstream transcripts containing small 
(CUG)n or (CAG)n stretches. When affecting essential RNA functions this may cause toxicity 
[150]. Also the antisense transcript expressed from the DM1 locus, when mutant, may thus 
potentially act through activation of the RNAi pathway by formation of a double stranded 
molecule with part of the sense DMPK transcript.
2.3.3  Homopolymeric proteins generated by RAN translation
Although the expanded (CUG)n repeat in the DMPK mRNA is located in the 3’ UTR, and thus 
not translated via the canonical pathway, homopolymeric proteins may be synthesized via 
RAN translation of the repeat tract. RAN proteins from the sense expanded DMPK transcript 
have not been described yet, but artificial expanded (CUG)n repeat containing transcripts 
have been shown to be subject to RAN translation in vitro [73]. For the antisense transcript 
in the DM1 locus there is in vitro evidence for RAN translation of the (CAG)n repeat in all 
three frames (polyGln, polyAla and polySer) and in vivo evidence from mouse models and 
human samples for production of polyGln peptides [73]. 
 An important question here is where ribosomes and transcripts containing an 
expanded repeat will meet in the cell for the synthesis of RAN proteins. Ribosomes are 
27
General introduction
1generally thought to reside and function in the cytoplasm, although nuclear translation is observed [79], whereas repeat transcripts are often trapped in the nucleus. Interactions resulting in RAN peptides may therefore be rare. In Huntington’s disease, RAN peptides in 
the cell are probably toxic and contribute to pathology [151]. In DM1 cells, the polyGln 
peptide was shown to co-localize with caspase-8, an early indication of polyGln-induced 
apoptosis. DM1 related RAN products thus may have a pathogenic role [73,152] but clearly, 
more work has to be done in this fascinating new area.
2.3.4  Other mechanisms with potential contribution to DM1 pathology
Involvement of additional mechanisms in DM1 pathology cannot be excluded. For example, 
mutant DMPK transcripts induce the formation of stress granules and may cause in trans 
inhibition of translation of certain mRNAs [138]. Repression of translation by cell stress may 
contribute to muscle loss [138]. Alternatively, double stranded RNA, like the hairpin structure 
formed by expanded (CUG)n DMPK RNA, may activate the innate immune response and 
interferon signaling, as observed in patients with DM cataracts [153]. 
 Furthermore, DMPK protein levels may be reduced in DM1 patients since expanded 
DMPK transcripts are largely retained in the nucleus and are thus probably not subjected 
to translation. Published data on cellular DMPK protein levels are however contradictory, 
with some papers describing a decrease in DMPK expression levels [154,155] while others 
describe an increase [156]. In this regard it is important to note that DMPK haploinsufficiency 
may be of only marginal influence in DM1 pathogenesis, since Dmpk knockout mice did 
not suffer from typical multisystemic DM1 features and developed only mild, late-onset 
myopathy [157,158].  Also typical cardiac conduction defects [159] were reported but in 
a more recent study on these mice, no aberrancies in cardiac and muscle function were 
observed [160].
 The (CTG·CAG)n repeat expansion alters the regional chromatin structure and 
gene expression at the DM1 locus [161]. Normally, the region is in a phased nucleosome 
array with a nucleosome positioned over the (CTG·CAG)n repeat and two CTCF-binding sites 
that flank the repeat and form a methylation-sensitive insulator element [162]. The repeat 
is located in a large CpG island, which is disrupted upon expansion of the triplet repeat 
[163] and ultimately the adjacent chromatin structure is altered by establishing a region of 
condensed chromatin [164,165]. 
 Since DMPK is located in a gene dense region (Fig. 4), transcription of the whole 
DM1 locus may thus be affected by an altered chromatin structure. There are controversial 
reports on DMWD expression, with lower [166,167] or unaltered [168,169] levels in DM1 
samples compared to control. Also on SIX5 expression levels, of which the promoter/
enhancer region overlaps the (CTG)n repeat region [170], contradicting reports have been 
published in which expression was claimed to be lower [170–173] or unaltered [167,168] in 
DM1 samples. Six5-deficient mice were generated to determine whether altered expression 
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1 of SIX5 could contribute to DM1 pathology [174,175]. Both homozygous and heterozygous knock-out mice developed cataracts at an early age [174,175], although these cataracts were clinically not identical to those observed in DM1 patients [176]. Six5-deficient mice also 
showed cardiac conduction defects [177] and impaired spermatogenesis [178], but muscle 
contractile properties and histology were normal [179]. Taken together, altered expression 
of neighboring genes may contribute to the multisystemic nature of DM1 pathology, but is 
unlikely to be a major factor.
2.4  Mouse models for DM1
Nearly twenty mouse models have been generated to model disease features of DM1 
[127,180]. Not only have these models contributed to deepening our insight in the 
mechanism of disease, they also provided a valuable resource for preclinical testing of 
various new therapeutic strategies. Here, I will describe the three models that are most 
commonly used in pathomechanistic studies and for assessment of therapeutic strategies: 
DM500 and DMSXL (both descendants from the DM300-328 line), Tg26 and HSALR (Fig. 6). 
More details on these and other DM1 mouse models are reviewed in [127,180].
2.4.1  DM500 and DMSXL mice
DM500 and DMSXL mice are both descendants of the DM300-328 line, which carries the 
complete human DM1 locus, i.e. DMWD, DMPK and SIX5, with an expanded (CTG·CAG)n 
repeat of 330 triplets on a cosmid-based transgenic insert [181]. Because the repeat in this 
strain has undergone intergenerational repeat expansion, sometimes with length increase 
in “big jumps” [182], the DM500 and DMSXL derivative lineages now carry a (CTG·CAG)
n repeat of ~500-600 and ~1300 triplets, respectively (Fig. 6A). In these mice, the DMPK 
transgene is expressed in all DM1-related tissues, including skeletal muscle, heart and 
central nervous system. Since the complete DM1 locus is inserted, the antisense DM1-AS 
transcript that carries the expanded (CAG)n repeat may also be expressed as confirmed by 
RT-PCR identification of transcript segments that lie close to the (CAG)n repeat [183,184]. 
Strikingly, only homozygous DM500 and DMSXL mice show a DM1-like phenotype, which is 
more pronounced in the DMSXL line [127,182]. The phenotype is relatively mild, presumably 
caused by the relatively low transgene expression.
2.4.2  Tg26 mice
The Tg26 mouse model is a DMPK overexpressing mouse, which carries a tandem insert of 
about 25 copies of the complete human DMPK gene with a normal-sized (CTG)11 repeat 
(Fig. 6B) [157,185]. The DMPK transgene is expressed in cardiac, skeletal and smooth muscle 
tissues [185]. Expression of the normal antisense DM1-AS transcript is not possible, since 
the transgene lacks the region in which DM1-AS transcription start sites are located (see 
Chapter 5). Despite the lack of an expanded repeat, the Tg26 mouse exhibits a phenotype 
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with some DM1 features [127,185]. Anomalous effects of RNA and protein overexpression 
may contribute to this phenotype, but it is relevant here to emphasize that DMPK protein 
overexpression is not a characteristic feature of tissues of DM1 patients.
2.4.3  HSALR mice
HSALR mice carry an artificially inserted (CTG)250 repeat in the 3’ UTR of human skeletal 
actin (HSA; also skeletal muscle α-actin, ACTA1) (Fig. 6C) [186]. For a rather long period of 
time this model was considered the most valuable model for DM1 research as it provided 
the first crucial evidence for the toxicity of expanded (CUG)n transcripts per se [127,186]. 
The transgene is under control of the very strong ACTA1 promoter and highly expressed 
in skeletal muscle only, alike endogenous Acta1. Although this model carries a repeat of 
intermediate size, the HSALR mouse has a relatively severe phenotype and suffers from 
several DM1-related skeletal muscle symptoms, including myotonia [186]. The pronounced 
phenotype makes that this mouse is still a widely used model to study potential therapeutic 
modalities in vivo, but since the repeat is expressed at non-endogenous levels and is in a 
non-natural genetic context, care should be taken on interpreting results obtained.
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Figure 6. Transgenes in DM1 mouse models. Schematic representation of transgenes from three DM1 mouse 
models. (A) DM500 and DMSXL mice carry a single insert of a large human genomic DNA segment containing 
the DM1 locus with a (CTG·CAG)n repeat of 500 and 1300 respectively. (B) Tg26 mice carry approximately 
25 copies of the DMPK gene with a repeat of 11 triplets. (C) HSALR mice carry a ACTA1 transgene with a 
(CTG·CAG)n triplet repeat of 250 inserted in its 3’ UTR.
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1 3  Other repeat expansion disordersNearly 30 neurological and neuromuscular disorders are known to be caused by a simple 
repeat expansion in the DNA [187]. Although the repeats involved in these disorders differ 
in nucleotide sequence, the location within the genes (in coding or non-coding regions), 
the range of normal and disease-causing repeat lengths and clinical outcome, their 
disease etiologies do have aspects in common. It is now commonly accepted that the 
mutational expansion of the repeats may cause disease via RNA gain-of-function, protein 
loss-of-function, protein gain-of-function or any combination of these pathobiological 
cascades [188]. Various genomic loci with microsatellite expansions are known to undergo 
bidirectional transcription and produce transcripts with two types of repeats [75,99]. Here 
I describe four repeat expansion diseases with involvement of complex-multifactorial RNA 
toxicity mechanisms in more detail. For a more extensive overview I refer to any of the many 
comprehensive reviews on the topic [189–191]. Knowledge about disease mechanisms 
contributing to other repeat expansion disorders may aid in our understanding of DM1 
pathogenesis. 
3.1  Fragile X-associated tremor/ataxia syndrome (FXTAS)
Fragile X-associated disorders arise from a (CGG)n repeat expansion in the 5’ UTR of FMR1. 
A full mutation, a repeat >200 triplets long, causes fragile X syndrome (FXS) by silencing of 
FMR1 transcription [192]. The premutation, a repeat expansion between 55 and 200 triplets, 
causes fragile X-associated tremor/ataxia syndrome (FXTAS) [192]. In contrast to FXS, the 
expanded FMR1 gene in FXTAS is transcribed, which plays a central role in pathobiology. 
 Several disease mechanisms may contribute to FXTAS. Expanded (CGG)n repeat 
transcripts sequester several protein factors, including MBNL1, which at least partially 
impairs their normal function in the cell [193]. Furthermore, the repeat is bidirectionally 
transcribed and, alike the sense counterpart, the antisense transcript is upregulated in 
premutation carriers and silenced in full mutation individuals [194]. In addition, RAN 
translation of the expanded FMR1 mRNA generates pathogenic polyGly peptides which alter 
the nuclear lamina architecture [195,196]. Evidence has been provided that RAN translation 
of the (CCG)n repeat in the antisense transcripts also plays a pathobiological role [197]. 
Lastly, the expanded repeat also causes more frequent and more structural complex R-loop 
formation [198]. Also this phenomenon may contribute to the cellular problems in FXTAS, as 
excessive R-loop formation can lead to activation of the DNA damage response and result in 
global genomic instability.
3.2  Spinocerebellar ataxia type 8 (SCA8)
Spinocerebellar ataxia type 8 (SCA8) pathogenesis, caused by a (CAG·CTG)n repeat expansion, 
is thought to involve toxic gain-of-function mechanisms at both the RNA and protein level. 
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1The triplet repeat RNA is bidirectionally transcribed, resulting in ataxin 8 (ATXN8) and ataxin 8 opposite strand (ATXN8OS) transcripts with an expanded (CAG)n and (CUG)n repeat respectively [199,200]. The ATXN8 encodes a nearly pure polyGln expansion protein, which 
accumulates in intranuclear inclusions [199]. Furthermore, RAN translation of the expanded 
(CAG)n repeat in ATXN8 transcripts yields polyAla proteins [73]. In contrast, ATXN8OS 
appears to be non-coding and the repeat expansion may contribute to disease via RNA foci 
formation and misregulation of splicing events [200,201]. An additional complication in this 
disease comes from another gene, Kelch-like 1 (KLHL1), which is also transcribed in the 
antisense orientation from ATXN8OS, with the 5’ ends of the genes overlapping in a head-
to-head orientation [202]. Antisense transcription is known to regulate complementary 
transcripts and the ATXN8OS transcript may downregulate KLHL1 expression which - in turn 
- may contribute to the complex manifestation of neuropathogenesis in SCA8 [203].
3.3  Huntington’s disease-like 2 (HDL2)
Huntington’s disease-like 2 (HDL2) is caused by a (CTG)40-59 expansion in the Junctophilin-3 
(JPH3) gene [204]. Dependent on alternative splice site usage, the repeat is located in an 
intron, in a 3’ UTR or in a coding region to produce either a polyAla or a polyLeu polypeptide 
[204]. RNA foci containing MBNL1 are found, implying that an RNA gain-of-function 
mechanism may contribute to disease manifestation [205]. An antisense transcript bearing 
a (CAG)n repeat encoding a polyGln protein may also contribute and may explain the 
similarities between HDL2 and Huntington’s disease, a polyGln disorder with involvement of 
RNA toxicity mechanisms [206,207]. Furthermore, the expanded (CAG)n repeat may also be 
subject to RAN translation [73].
3.4  C9orf72-associated ALS and FTD
A hexanucleotide (GGGGCC)n repeat expansion in C9orf72 is one genetic cause of 
amyotrophic lateral sclerosis (ALS) and can also underlie frontotemporal dementia (FTD) 
[208,209]. The repeat is located upstream of the C9orf72 coding region, either in the 
promoter or first intron, depending on the transcript isoform. The (GGGGCC)n repeat RNA 
may adopt a stable and potentially harmful G-quadruplex structure [210]. Furthermore, the 
repeat is bidirectionally transcribed which also yields transcripts with a (GGCCCC)n repeat 
[211]. Both sense and antisense transcripts form nuclear RNA foci and are subject to RAN 
translation, which results in accumulation of dipeptide repeat proteins [211–214]. 
 In recent studies, defects in nucleocytoplasmic transport were identified to 
contribute to ALS/FTD pathogenesis [66–68]. The hexanucleotide repeat expanded RNA is 
shown to bind target proteins in nuclear pore complexes in the nucleus, thereby disrupting 
nuclear export of RNA [67], and to bind the nuclear import protein RanGAP in the cytoplasm, 
preventing nuclear import [66]. Furthermore, RAN translated dipeptide repeat proteins 
interfere with nuclear import, possibly via interactions with karyopherin proteins [68]. 
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1 Neurons are primarily affected, since they have a limited ability to replace damaged nuclear pore complexes [69]. Whatever the exact pathobiological cascade involved, a recent study has demonstrated that the detrimental effects in this form of ALS/FTD must be caused by a 
very low number of abnormal C9orf72 transcripts per cell [82].
4  Outline and scope of this thesis
The pathobiological mechanisms involved in the progressive multisystemic manifestation 
of DM1 are complex, and may in part be similar to those underlying disease processes in 
other repeat expansion disorders. Since production of mutant RNAs from the DMPK gene 
(with (CUG)n repeat expansion) and most likely also RNAs from the DM1-antisense gene 
(DM1-AS; with (CAG)n expansion) are central events in DM1 disease pathogenesis, I focused 
in my PhD project on the quantification of expression of these transcripts and on the analysis 
of some aspects of their fate during processing and nucleocytoplasmic transport. 
 Studies presented in the first chapters are focused on the sense transcript. Multiple 
animal and cell models are available for DM1 and in Chapter 2 we report on a comparative 
analysis of the levels and timing of expression of transcripts from (CTG)n-repeat containing 
transgenes and from the endogenous Dmpk gene in these models. We also studied how 
these characteristics relate to the human situation, in cells and tissues from DM1-affected 
individuals and controls. In Chapter 3 we provide a description of the nucleocytoplasmic 
distribution of normal and repeat-expanded DMPK RNAs in the cell. We developed a 
method to physically separate normal-sized and mutant DMPK transcripts, which is used in 
Chapter 4 to analyze their polyadenylation state. Chapter 5 is dedicated to the study of RNA 
from the DM1-AS gene. Using a combinatorial approach of experimental and computational 
biology, we characterized expression level and alternative processing steps involved in the 
production and maturation of this RNA in more detail. Chapter 6 summarizes the contents 
of this thesis, by providing a brief discussion of our major findings and a future outlook.
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Abstract
Muscular manifestation of myotonic dystrophy type 1 (DM1), a common inheritable 
degenerative multisystem disorder, is mainly caused by expression of RNA from a 
(CTG·CAG)n-expanded DM1 locus. Here we report on comparative profiling of expression 
of normal and expanded endogenous or transgenic transcripts in skeletal muscle cells and 
biopsies from DM1 mouse models and patients in order to help us in understanding the role 
of this RNA-mediated toxicity. In tissue of HSALR mice, the most intensely used ‘muscle-only’ 
model in the DM1 field, RNA from the α-actin (CTG)250 transgene was at least 1000-fold 
more abundant than that from the Dmpk gene, or the DMPK gene in humans. Conversely, 
the DMPK transgene in another line, DM500/DMSXL mice, was expressed ~10-fold lower 
than the endogenous gene. Temporal regulation of expanded RNA expression differed 
between models. Onset of expression occurred remarkably late in HSALR myoblasts during 
in vitro myogenesis whereas Dmpk or DMPK (trans)genes were expressed throughout 
proliferation and differentiation phases. Importantly, quantification of absolute transcript 
numbers revealed that normal and expanded Dmpk/DMPK transcripts in mouse models and 
DM1 patients are low abundance RNA species. Northern blotting, reverse transcriptase-
quantitative PCR, RNA-sequencing and FISH analyses showed that they occur at an absolute 
number between one and a few dozen molecules per cell. Our findings refine the current 
RNA dominance theory for DM1 pathophysiology, as anomalous factor binding to expanded 
transcripts and formation of soluble or insoluble ribonucleoprotein aggregates must be 
nucleated by only few expanded DMPK transcripts and therefore be a small numbers game.
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Introduction
Myotonic dystrophy type 1 (DM1, OMIM no. 160900) is an autosomal dominant repeat 
expansion disorder, affecting skeletal and smooth muscle as well as the heart, the endocrine 
system, the eye and the central nervous system [1]. The multisystemic manifestation 
and progression of DM1 are caused by expansion of a (CTG·CAG)n repeat, located in the 
3’ untranslated region (3’ UTR) of the dystrophia myotonica protein kinase (DMPK) gene [2] 
and in an overlapping antisense transcription unit in the DM1 locus [3]. In DM1 families the 
expanded repeat is unstable, both somatically and intergenerationally, with a bias towards 
expansion, causing progression of disease symptoms during ageing and over successive 
generations [4].
 Several mechanisms may contribute to the molecular pathogenesis of DM1 [5]. 
Expanded DMPK transcripts are retained in the nucleus, where they form focal complexes 
in insoluble or diffuse-soluble state by abnormal association with transcription factors and 
RNA-binding proteins, like members of the muscleblind-like family (MBNL1-3), DEAD-box 
helicases and hnRNP proteins [1,6,7]. In turn, abnormal phase transitions in RNP complexes 
lead to sequestering of factors needed for processing of other transcripts with in trans 
consequences for faithful alternative splicing and polyadenylation and expression of miRNAs 
[7,8]. Production of proteins by ribosomes that decode the normally untranslated (CUG)n 
repeat tract in DMPK mRNA by a newly discovered process, coined repeat-associated non-
ATG (RAN) translation, is also possible [9,10]. Similar toxic events may occur with antisense 
transcripts originating from the complementary strand of the DM1 locus, overlapping the 
3’ end of the DMPK gene. Abnormal RNAs are thus formed with an expanded (CAG)n repeat, 
potentially leading to the production of homopolymeric peptides by RAN translation of the 
(CAG)n repeat, which may evoke an imbalance in proteostasis [9,10]. Finally, it cannot be 
excluded that problems with DNA replication across the repeat tract or abnormal epigenetic 
modification of the chromatin region containing the DM1 locus also contribute to pathology 
[3,11].
 Together, alterations in the transcriptome, proteome and replisome may 
compromise the physiological integrity of cells and tissues in which the mutant DMPK and 
the DM1-antisense gene are expressed. Throughout development, growth and adulthood 
this imbalance may lead to the loss of function and ultimately to cell degeneration, causing 
the muscle wasting and CNS white matter loss in patients [4,12].
 For study of biological mechanisms underlying DM1 pathology and for testing of 
possible therapeutic strategies in preclinical studies, several animal models are available, 
including Drosophila, zebra fish and mouse [13,14]. Predominant focus is thereby oriented 
towards mechanisms involved in RNA-based disease etiology. Notably, DM1 animal models 
differ profoundly in nature, structural organization and chromatin context of their transgenic 
insert and in the length of the (CTG·CAG)n segment therein. Comparison of pathobiological 
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findings between models and extrapolation to the situation in patients remain therefore 
difficult. Work of others has already demonstrated that the timing of DMPK expression, 
i.e. the onset of potential RNA toxicity, influences phenotypic severity [15]. Expression 
of RNA with an abnormal repeat tract in satellite cells or neuronal progenitor cells may 
affect proper muscle and brain development [16–19] and have serious consequences for 
tissue regenerative capacity in adulthood. The absolute number of expanded RNAs and 
their structure at any given moment may also be crucial, as these ultimately will influence 
the extent of toxicity caused by abnormal RNP binding or abnormal properties of RAN 
translation products [20–22]. The type of gene promoters, whether from endogenous or 
ectopic origin, that drive transcription during development and ageing, and the structure 
of the transcripts that entail the repeat segment are therefore critical parameters in animal 
models and patients.
 Here we report on comparison of expression and measurement of absolute 
numbers of (CUG)n-repeat containing RNAs in muscle cells and tissues of four commonly 
used mouse DM1 models and in cells and biopsies from patients. DM1 mouse models 
express transgenes with different promoters, different structural organization and different 
repeat lengths: DM500, DMSXL, Tg26, and HSALR (Table 1). DM500 and DMSXL mice are 
both descendants of the DM300-328 line, which was subject to intergenerational repeat 
expansion. These mice carry a complete human DM1 locus [23,24]. The DMPK transgene in 
Tg26 mice carries a tandem insert of ~25 copies of the complete human DMPK gene, with 
a normal-sized (CTG)11 repeat [25,26]. In HSALR mice the transgene is under control of the 
ACTA1 promoter and the repeat is embedded in the context of the ACTA1 gene [27]. The 
rationale for quantification of repeat RNA expression in these models is that knowledge 
about toxic RNA concentration will provide us with more insight in pathophysiological 
cascades per se, especially as more and more anatomical, physiological and behavioral 
phenotype data become available, enabling relatively easy cross comparisons. Furthermore, 
some of the DM1 models have already been extensively used for preclinical translational 
studies in the past decade, but translation of findings in these models has been difficult.
 We demonstrate that, in comparison with expression of normal and mutant DMPK 
transcripts in patient cells, considerable variation exists in level and developmental timing of 
transgene expression in DM1 cell and animal models. A remarkable low level of expression 
with absolute numbers of, at most, a few dozen RNA molecules per cell was observed for 
DMPK transcripts in human samples. Our findings highlight the hitherto unrecognized 
involvement of low-abundance RNA molecules in DM1 pathophysiology, altering our current 
view on the RNA gain-of-function theory, which explains the role of repeat RNA in DM1 
manifestation. We discuss the possible implications of our findings for future interpretation 
of data from fundamental and translational studies in which these DM1 models and patient 
cells will be used.
52
Chapter 2
2
Materials and Methods
Human material
Human skeletal muscle samples were obtained from pre-consented post-mortem donors 
for research purposes in accordance with local guidelines in The Netherlands more than 18 
years ago. No additional approval by an ethics committee was required at that time. Muscle 
autopsies were obtained from patients with a confirmed clinical and DNA diagnosis of 
adult-onset DM1 (male DM1-c, 55 years, psoas muscle, (CTG)5/(CTG)exp; female DM1-d, 65 
years, quadriceps muscle, (CTG)16/(CTG)exp) and congenital DM1 (male CDM-e and -f, 14 
days, sternocleidomastoideus and gastrocnemius muscle, (CTG)12/(CTG)1300). All tissues 
were snap frozen immediately after collection and stored at -135 to -80°C until further use. 
As control, skeletal muscle samples from healthy anonymous donors (healthy-a and -b, 
(CTG)11/(CTG)12 and (CTG)5/(CTG)11, respectively) from our own repository were included 
in our study. These samples were collected long before the current guidelines for written 
Mouse 
model
Transgene
Transgene 
copy 
number
Promoter Expression (CTG)n
Genetic 
back-
ground
Refs
DM500 
(DM300-
328 line)
Human DM1 
locus (43 kb 
transgene)
1
Human DMPK 
(~11.5 kb region 
upstream of 
main TSS)
All DM1 related 
tissues (e.g. 
skeletal muscle, 
heart and CNS)
500-600
>90% 
C57BL/6
[23]
DMSXL 
(DM300-
328 line)
Human DM1 
locus (43 kb 
transgene)
1
Human DMPK 
(~11.5 kb region 
upstream of 
main TSS)
All DM1 related 
tissues (e.g. 
skeletal muscle, 
heart and CNS)
~1300
>90% 
C57BL/6
[24]
Tg26
Human DMPK 
gene (14 kb 
transgene)
~25
Human DMPK 
(~1.9 kb region 
upstream of 
main TSS)
All DM1 related 
tissues (e.g. 
skeletal muscle, 
heart and CNS)
11 FVB/n [25]
HSALR 
(LR20b 
line)
Human 
α-actin gene; 
CTG repeat 
inserted in 3’ 
UTR (7.1 kb 
transgene)
2
Human α-actin 
(~2.1 kb region 
upstream of 
TSS)
Skeletal muscle 
only
220-250 FVB/n [27]
WT No transgene n.a. n.a. n.a. n.a.
>90% 
C57BL/6
n.a.
Table 1. Characteristics of DM1 mouse models used in this study
TSS, transcription start site; n.a., not applicable.
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consent were enforced and no detailed information could be traced. 
Mice
Mice were housed and procedures performed with approval of the Animal Ethics Committee 
of Radboud University Nijmegen (Permit number: RU-DEC 2014-099). Characteristics of the 
mouse models are summarized in Table 1. DM500 and DMSXL mice both originated from the 
DM300-328 lineage [23]. Due to intergenerational triplet instability the repeat in the DMPK 
gene grew to 500-600 and ~1300 CTG triplets in DM500 and DMSXL mice, respectively [24]. 
For isolation of immortalized myoblasts, each of the DM1 mouse models was crossed with 
hemizygous H-2Kb-tsA58 transgenic mice (ImmortoMouse®, Charles River Laboratories) 
[28], harboring the gene for thermolabile TAg from SV40. Nine-day old pups carrying one 
DMPK or ACTA1 transgene copy and one H-2Kb-tsA58 transgene copy were selected and 
used for myoblast generation.
Cell culture
Conditionally immortalized myoblasts from the gastrocnemius-plantaris-soleus (GPS) 
muscle of DMSXL, Tg26 and HSALR mice after crossing with H-2Kb-tsA58 mice were derived as 
described [28–30]. Individual myoblast lineages were obtained by ring cloning and selected 
for myotube formation ability. Myoblast populations used in this study were established by 
forming equal mixtures of five cell clones for DMSXL, seven cell clones for Tg26, and four cell 
clones for HSALR. DM500 and WT myoblasts were derived previously [30].
 Myoblasts were grown on 0.1% (w/v) gelatin-coated culture dishes in proliferation 
medium containing Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) supplemented 
with 20% (v/v) fetal bovine serum (PAA Laboratories), 4 mM L-glutamine (Gibco), 1 mM 
pyruvate (Sigma), 50 µg/mL gentamicin (Gibco), 20 units/mL γ-interferon (BD Biosciences) 
and 2% (v/v) chicken embryo extract (Sera Laboratories International) at 7.5% CO2 and 
33°C. Differentiation to myotubes was induced by placing myoblasts, grown to confluency 
on Matrigel (BD Biosciences), in differentiation medium containing DMEM supplemented 
with 5% (v/v) horse serum and 50 µg/mL gentamicin at 7.5% CO2 and 37°C. Differentiation 
conditions were maintained for a maximum of 7 days. Spontaneous contractions started to 
appear around day 3.
 Human myoblast cultures isolated from skeletal muscle of fetuses, one healthy 
control (5/5) and two DM1 affected lines (21/200 with (CCG·CGG)n interruptions in the 3’ 
end of the expanded (CTG·CAG)n repeat; data not shown) and 11/760 were a gift of Dr. 
D. Furling [31]. Myoblasts were maintained on 0.1% (w/v) gelatin-coated culture dishes in 
proliferation medium containing Ham’s F10 medium (Gibco) supplemented with GlutaMAX, 
20% bovine growth serum (Thermo Scientific) and 25 µg/mL gentamicin at 7.5% CO2 and 
37°C. Differentiation to myotubes was induced by placing confluent myoblast cultures in 
differentiation medium containing DMEM supplemented with 4 mM L-glutamine, 1 mM 
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pyruvate, 10 μg/mL insulin (Sigma), 100 μg/mL apo-transferrin (Sigma) and 25 μg/mL 
gentamicin.
 Phase contrast images of cell cultures were taken with a Zeiss Axiovert 35M light 
microscope, 10x/0.30 objective.
FACS 
Immortalized WT mouse myoblasts were detached from the culture surface using trypsin, 
washed in PBS and fixed in 70% (v/v) ethanol in phosphate-buffered saline (PBS) overnight at 
-20°C. After two times PBS wash, cells were stained in 20 µg/mL propidium iodide, 0.2 mg/
mL RNase A, 0.1% Triton X-100 in PBS for 15 min at 37°C. FACS analysis was performed on 
the Beckman Coulter Epics Altra cell sorter. Immortalized DM500 myoblasts were cultured 
in proliferation medium at 37°C for 24 hours, detached and incubated with 3 µg/mL Hoechst 
33342 at 37°C for 30 min and then sorted. Diploid and tetraploid DM500 cells were seeded 
on gelatin-coated glass cover slips, cultured for another 24 h at 37°C and analyzed by FISH. 
RNA isolation 
RNA from cultured cells was isolated using the Aurum Total RNA Mini Kit (Bio-Rad), according 
to the manufacturer’s protocol. RNA from muscle tissue was isolated using TRIzol reagent 
(Invitrogen), according to the manufacturer’s protocol.
Northern blotting
Northern blotting was performed according to standard procedures. RNA was subjected to 
electrophoresis in a 1.2% agarose gel under denaturing conditions. Depending on sample 
availability, 5-12 µg RNA was loaded per lane. RNA was transferred to Hybond-XL nylon 
membrane (Amersham Pharmacia Biotech) by capillary transfer in 10x SSC and hybridized 
with random-primed 32P-labeled cDNA-based probes or 32P-end-labeled oligonucleotides: a 
2.6 kb DMPK cDNA (covering the entire ORF and 3’ UTR) [30] and the complete 1.9 kb human 
18S rRNA cDNA were used as templates in random priming reactions. A (CAG)9 oligo [30], 
a Acta1 oligo (5’-ACCCTGCAACCACAGCACGATTGTCGATTG-3’) [32] and a mixture of three 
oligos complementary to both Acta1 and ACTA1 (5’-GCGGTGGTCTCGTCTTCGTCGCACAT-3’, 
5’-TGGCATACAGGTCCTTCCTGATGTCGATGTC-3’, 5’-GCCTCGTCGTACTCCTGCTTGGTGATCC-3’) 
were 5’-end labeled. The Acta1/ACTA1 oligo mix and the DMPK cDNA probe were used to 
quantify ACTA1 and DMPK mRNA levels, respectively, in human samples. In murine samples, 
the single Acta1 oligo, DMPK cDNA and (CAG)9 oligo probes were used to quantify Acta1, 
Dmpk and transgenic DMPK (DM500 and DMSXL) and transgene (Tg26 and HSALR) mRNA 
levels, respectively. Blots were washed and exposed to X-ray film (Kodak, X-OMAT AR). 
Quantification of signals was performed by phosphor-imager analysis (Molecular Imager FX, 
Bio-Rad) and analyzed with Quantity One (Bio-Rad) and FIJI [33] software. 18S rRNA levels 
were used for normalization.
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 To be able to compare transgene expression in the DM1 mouse models, carrying 
different transgenes (i.e., DMPK- or ACTA1-type), a mix of ACTA1 cDNA probe (1.3 kb, exon 
2-7, 27% G-content) and DMPK cDNA probe (1.3 kb, exon 3-12, 34% G-content) was used. 
Both genes are around 90% identical between mouse and human, so simultaneous detection 
of endogenous and transgenic transcripts was possible. [α-32P]-dCTP label was diluted with 
non-radioactive dCTP for labeling of the ACTA1 probe to obtain comparable signal strengths 
for simultaneous phosphor-imager detection of Acta1/ACTA1 and Dmpk/DMPK on the same 
blot. Signals were corrected for label dilution and G-content in the two probes. Since ACTA1 
and Actb are 84% identical, the ACTA1 probe was also used for detection of Actb. A similar 
method was used to compare DMPK/Dmpk and ACTB/Actb expression. A 1.3 kb ACTB cDNA 
probe was used (exon 1-6, 27% G-content), which has a 90% identical sequence with the 
mouse variant.
In vitro transcription
DNA templates corresponding to DMPK regions exon 1-6 (0.6 kb) 
and exon 11-15 (1.0 kb) were generated by PCR using primers 
5’-GAATTTAATACGACTCACTATAGGGAGAGGCGGCTCCAGCAGC-3’ and 5’-CCGCAGCTTG-
AGGCAAGAG-3’, and 5’-GAATTTAATACGACTCACTATAGGGAGATGGAGGCCATCCG-3’ and 
5’-GTCCTGTAGCCTGTCAGCGA-3’, respectively (T7 promoter underlined). DNA purity 
and sequence identity were confirmed by sequencing. For in vitro transcription, 200 
ng of the templates was used in the MEGAscript T7 Transcription Kit (Ambion) following 
manufacturer’s instructions. RNA products were purified using the Aurum Total RNA Mini Kit 
(Bio-Rad). Transcript length, purity and concentration were verified by gel electrophoresis 
and absorbance at 260/280 nm (NanoVUE spectrophotometer, GE Healthcare Life Sciences). 
Known amounts of RNA fragments DMPK e1-6 and e11-15 were mixed with WT mouse total 
RNA (as carrier RNA) and used as standards in RT-qPCR.
Reverse transcriptase-quantitative PCR
Using 500 ng RNA template per reaction and random hexamers as primers, cDNA synthesis 
was performed with SuperScript™ II Reverse Transcriptase (Invitrogen) or iScript™ cDNA 
Synthesis Kit (Bio-Rad). For RT-qPCR, 3 µL of 10-100-fold diluted cDNA preparation 
was mixed in a final volume of 10 µL containing 5 µl 2x Sybr Green mix (Roche Applied 
Science) or 5 µL iQ™ SYBR® Green Supermix (Bio-Rad) and 4 pmol of each primer: 
DMPK e1-2: 5’-ACTGGCCCAGGACAAGTACG-3’ and 5’-CCTCCTTAAGCCTCACCACG-3’; 
DMPK e15(5’): 5’-AGAACTGTCTTCGACTCCGGG-3’ and 5’-TCGGAGCGGTTGTGAACTG-3’; 
ACTA1: 5’-CACCTCCAGCACGCGACTT-3’ and 5’-CGATGGCAGCAACGGAAGTTGT-3’; Dmpk: 
5’-TTTTGAAGGTGATCGGGCGTG-3’ and 5’-CCTCTCTTCAGCATGTCCCACTTA-3’; 18S rRNA: 
5’-GTAACCCGTTGAACCCCATT-3’ and 5’-CCATCCAATCGGTAGTAGCG-3’. Samples were 
analyzed using the CFX96 Real-time System (Bio-Rad). A melting curve was obtained for each 
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sample in order to confirm single product amplification. cDNA samples from no template 
control (NTC) and no reverse transcriptase control (RT-) were included as negative controls. 
Transgene (DMPK and ACTA1) and endogenous Dmpk mRNA levels were normalized to 18S 
rRNA expression.
Fluorescent in situ hybridization
Human myoblasts (5/5, 21/200, and 11/760) and mouse myoblasts (DM500, Tg26, HSALR, 
and WT) grown on gelatin-coated glass cover slips were washed once with PBS and fixed in 
4% (w/v) formaldehyde, 2 mM MgCl2 in PBS for 10 minutes at room temperature. Cells were 
stored under 70% ethanol at 4°C. After two times PBS wash, cells were prehybridized in 
40% (v/v) deionized formamide in 2x SSC for 20 minutes at room temperature, followed by 
overnight hybridization with a 0.1 ng/μL Cy3-(CAG)7 probe (2’-O-methyl phosphorothioate-
modified) in 40% deionized formamide, 10% (w/v) dextran sulphate, 0.1% Triton X-100, 1 
mg/mL herring sperm DNA, 100 μg/mL yeast tRNA, 0.2% (w/v) BSA, 2 mM VRC, 2x SSC in 
a humidified chamber at 37°C. After two times PBS wash, cells were counterstained with 
0.33 μg/mL DAPI in PBS for 10 minutes at room temperature, followed by a PBS wash, 
dehydration in methanol and mounting in Mowiol. Images were acquired using the Zeiss 
Axiophot2 Fluorescence microscope or Olympus IX-71 wide field fluorescence microscope. 
RNA-sequencing
RNA-sequencing data from healthy and DM1-affected human tissue samples (tibialis 
anterior (TA), quadriceps, and heart) were obtained from www.dmseq.org. RNA-sequencing 
signals of full-length DMPK and GAPDH were used as an independent measure for transcript 
abundance.
Statistical analysis
Endogenous and transgenic mRNA levels were compared between time points and models, 
using a one-way analysis of variance (ANOVA) test, followed by a post-test for linear trend 
or Tukey’s multiple comparison test. All values in graphs are presented as mean ± SEM. 
Foci counts were compared between different myoblast lines with a one-way ANOVA test 
and Tukey’s multiple comparisons post-test. Data are visualized as scatter plot, each dot 
representing one observation, and the mean is shown. Statistical analyses were performed 
with GraphPad Prism version 5.01 for Windows. 
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Results
Derivation of myogenic cell lines from DM1 mouse models
Characteristics of mouse models included in this study are listed in Table 1. For profiling 
of transgene expression at the cellular level, we established conditionally immortalized 
myoblast populations from each model by pooling clones of individual cells derived from 
the calf muscle complex from double hemizygous mice carrying one transgenic DM1 allele 
and one H-2Kb-tsA58 allele [29]. As there is strong evidence that satellite cells from different 
inbred mice behave intrinsically differently [34,35], it is important to note that crossings 
included different genetic backgrounds to generate the double hemizygous animals. The 
cell populations have therefore distinct mixed genetic backgrounds with contributions of 
C57BL6, FVB/n, CBA/Ca and C57BL/10. We do believe, however, that these differences have 
no major impact on transcriptome composition and therefore should not overtly confound 
our comparison.
 An important feature of the immortalized myoblasts is that during prolonged 
passaging in culture under permissive conditions cells have the tendency to undergo 
polyploidization, as an effect of the presence of the temperature-sensitive SV40 large 
T-antigen [36]. This leads to a mix of 2N and 4N cells in populations of the different lineages 
and to variation in the absolute abundance of individual transcripts per cell (Suppl. Fig. S1A). 
Hence, all possible care was taken to compare myoblasts from similar passage numbers.
 DM500, DMSXL, HSALR and WT myoblast populations had normal morphological 
appearance and showed apparently normal proliferative capacity and terminal differentiation 
features upon shift to myogenesis-promoting conditions (Fig. 1). Multinuclear contractile 
myotubes appeared after 3-5 days of differentiation. The Tg26 cell population had normal 
morphological appearance, but showed slightly disordered cell alignment and diminished 
fusion capacity upon induction of differentiation. This may be due to overproduction of 
certain DMPK protein isoforms [26,37,38].
 To quantify gene expression during proliferation and differentiation of the myoblast 
populations, RNA was isolated at various time points and analyzed by northern blotting 
and reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). Progression of 
myogenic differentiation in vitro was accompanied by a clear increase in skeletal muscle 
α-actin (Acta1) mRNA (Fig. 2A), a well-known differentiation marker encoding a major 
constituent of the contractile apparatus [39–41]. The increase was less profound in Tg26 
cultures, in accordance with their diminished fusion capacity. Whereas Acta1 was induced, 
β-actin (Actb) expression decreased during the 7-day differentiation period (Suppl. Fig. S2) 
[42].
 For reference, primary human muscle cells obtained from a healthy individual and 
two DM1 patients were also included in our study. Myoblasts with healthy (CTG)5/(CTG)5 
or disease-specific (CTG)21/(CTG)200 or (CTG)11/(CTG)760 repeat combinations appeared 
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morphologically diverse, which can be explained by their different origin and culture history 
(Fig. 3). Multinucleated myotubes were formed during differentiation, but spontaneous 
contractions were never observed (Fig. 3, data not shown). RNA expression analysis 
corroborated this observation by showing that ACTA1 expression was minimal at all time 
points measured and remained low in comparison with Acta1 levels in DM500 GPS tissue 
(Fig. 4A). We therefore conclude that human cultures did not attain the same endpoint of 
terminal differentiation as mouse myoblasts under our in vitro conditions.
Transgene expression differs between DM1 myoblast models
Transgene expression was assayed in the myoblast populations during proliferation and 
differentiation (Fig. 2B and Suppl. Fig. S3). DMPK transgene expression in differentiating 
DM500 and DMSXL cells transiently increased 3 to 10-fold and then returned to basal levels 
in proliferating myoblasts. A modest increase in transgene expression was also observed in 
WT
DM500
DMSXL
Tg26
HSALR
Proliferation Confluency Differentiation
Day -2 Day 0 Day 1 Day 3 Day 7
Figure 1. Morphology of myoblasts derived from DM1 and control mouse models. Conditionally 
immortalized myoblasts were derived from the GPS muscle complex of DM1 mouse models. Myoblasts 
differentiated into contractile myotubes under low-serum conditions. Representative images of cultures 
during proliferation (Day -2), confluency (Day 0) and differentiation (Day 1, 3 and 7) are shown. Bar 100 µm.
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differentiating Tg26 myoblasts, but this change appeared to be more permanent. In contrast, 
transcript levels from the Dmpk gene hardly varied with differentiation state in any of the 
five myoblast populations (Fig. 2C). The observed differential regulation of endogenous/
transgenic Dmpk/DMPK expression may be caused by (i) species differences between the 
structure and function of Dmpk/DMPK promoters, (ii) differences in the length of the region 
upstream of the TSS in the human transgenes used (Table 1), (iii) differences between 
chromosomal insert sites and the endogenous Dmpk locus or (iv) different epigenetic 
alterations across the transgenic loci. Influence of the (CUG)n repeat length on RNA stability 
is unlikely, because temporal profiles of transgenic RNA expression in DM500 and DMSXL 
cells during myogenic differentiation levels were highly similar. 
 For DMPK expression in human myoblasts, we performed separate quantitative 
analysis of healthy and expanded transcripts, which migrate differentially on northern gels. 
Steady-state levels of normal and expanded DMPK RNA molecules were approximately 
similar for both the 21/200 and the 11/760 patient cell cultures (Fig. 4B). Comparison of total 
DMPK expression levels between healthy 5/5 and patient cell cultures showed variation. 
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Figure 2. Expression profile of proliferating and differentiating myoblasts derived from DM1 and control 
mouse models. Analysis of endogenous Acta1 (A), transgene (B) and endogenous Dmpk (C) mRNA levels by 
northern blotting. Each hybridization signal was normalized to that of 18S rRNA and then compared with the 
normalized value measured for the same (trans)gene in the GPS muscle from that particular DM1 mouse 
model. Data were obtained from two independent culture series per cell line, for which triplicate cultures 
per series were pooled and analyzed; bars represent mean + SEM. For profiling of endogenous Dmpk (C) in 
Tg26 samples RT-qPCR was used, because signals of transgenic DMPK and endogenous Dmpk overlapped on 
northern blot. Bars represent mean + SEM. Timing of differentiation on the x-axis refers to Fig. 1.
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However, temporal profiles had a similar shape with a peak in expression during early 
differentiation, alike expression behavior of DMPK transcripts from the DMPK transgene 
in mouse myoblasts. This supports our idea that species-specific differences in the DMPK/
Dmpk promoter explain the differential expression pattern of DMPK and Dmpk transcripts.
 For better interpretation of in vitro and in vivo findings, we compared DMPK 
transgene expression in myogenic cultures to that in parental GPS muscle in the DM1 models. 
Transgene expression was ~0.6-6 fold higher, 6-to 18-fold higher and 3- to 11-fold lower for 
DM500, DMSXL and Tg26 myoblast/myotube cultures, respectively (Fig. 2B). Of particular 
interest was the expression profile of the expanded ACTA1 transgene in differentiating 
myoblasts from the HSALR model, showing that transcripts were expressed only late in 
differentiation (Fig. 2B). Even in fully differentiated hemizygous HSALR myotubes in vitro, 
expanded ACTA1 transgene expression remained ~200-fold lower than in GPS muscle from 
homozygous HSALR mice.
Transgene expression in distinct DM1 mouse models differs over a 1000-fold range
By extending our analysis to mouse muscle in vivo, using the GPS complex as RNA source and 
18S rRNA for normalization, our comparison revealed that Acta1 expression was remarkably 
similar between models (Fig. 5 and Suppl. Fig. S4A), despite differences in their genetic 
background (Table 1). Also Dmpk expression showed only minor fluctuations. Whereas 
Acta1 and Dmpk expression did not vary >2- to 4-fold between mouse models, the mean 
level of Acta1 RNA was ~2,500-fold higher than that of Dmpk RNA.
5/5
21/200
11/760
Day -2 Day 0 Day 1 Day 3 Day 7
Proliferation Confluency Differentiation
Figure 3. Morphology of primary human DM1 and healthy myogenic cells. Human primary myoblasts 
aligned and fused under low serum conditions. Representative images at different time points during 
proliferation (Day -2), confluency (Day 0), and differentiation (Day 1, 3 and 7) are shown. The number of CTG 
triplets for the two DMPK alleles are indicated for the one healthy (5/5) and two DM1 (21/200 and 11/760) 
cultures. Bar 100 µm.
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 We next compared transgene expression in GPS muscles from DM500, DMSXL 
and Tg26 mice. Quantification was straightforward, since all models expressed differentially 
expanded but otherwise similar and intact DMPK transgenes. Transgenic DMPK RNA 
accumulated in muscle from hemizygous DM500 and DMSXL mice to a 10-fold lower level 
than RNA from the endogenous Dmpk genes (Fig. 5). In contrast, hemizygous Tg26 GPS 
muscle expressed 20- to 25-fold more DMPK mRNA than Dmpk mRNA (assuming that Dmpk 
expression in Tg26 mice (FVB background) was similar to that in DM500 mice (C57BL/6 
background)). Determination of relative levels of transgenic RNA in HSALR muscle appeared 
more challenging. Use of a (CAG)9 probe to detect (CUG)n segments, the only sequence 
shared between transgenic products, proved unreliable to compare RNAs with different 
repeat lengths (data not shown). Therefore a balanced mix of ACTA1 and DMPK probes, 
generated by random-primed labeling on cDNA templates of equal size was used instead 
(see the Materials and Methods section). With this approach we found ACTA1 (CUG)n RNA 
over 1000-fold higher expressed than Dmpk mRNA in homozygous HSALR mice (Fig. 5). This 
means that the concentration of expanded transcripts in HSALR muscle is extraordinarily 
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Figure 4. Expression profile of proliferating and differentiating primary human DM1 myogenic cells. 
Assessment of ACTA1 (A) and DMPK (B) transcript levels by northern blot analysis. Signal strength in each 
sample was normalized to that of 18S rRNA, as outlined in the legend of Fig. 2. To facilitate direct comparison 
with DM1 mouse model-derived myoblasts, ratios were related to Acta1 and Dmpk levels in DM500 GPS 
muscle. Data were obtained from two independent culture series per cell line, for which triplicate cultures 
per series were pooled and analyzed; bars represent mean + SEM. Stacked bar graphs show levels of normal-
sized DMPK (black part) and expanded DMPK (white part) in patient-derived cultures. On average, the 
ratio expanded versus normal-sized DMPK transcripts was 0.63 for 21/200 and 0.84 for 11/760. Timing of 
differentiation on the x-axis refers to Fig. 3.
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high and similar to that of Acta1 mRNA. This finding is perhaps not too surprising as both 
promoter and backbone of the human transgene and the Acta1 gene share strong homology. 
Analysis of DMPK RNA levels in human muscle allows direct interpretation of transgene 
dosage
Skeletal muscle samples from healthy humans and DM1 patients were included in our 
study to extend our comparisons. DMPK mRNA expression in the samples varied, but was 
not >3-fold higher than the level of Dmpk mRNA in mouse GPS tissue (Fig. 6). Expression 
of normal-sized and of expanded DMPK alleles were about equal in each of the patient 
samples. Since DMPK levels in human muscles and Dmpk levels in mouse muscle show high 
similarity, observations about transgene expression dosage effects in DM1 mice may be 
directly translated to relevance for DM1 patients. Any difference in DMPK mRNA content 
between human samples probably represents variation in fiber type and muscle origin or 
must be caused by differentiation or disease state. Note that effects of ageing on repeat 
length heterogeneity were clearly visible on northern blot: in samples from adult DM1 
patients a smear was observed for RNA from the expanded allele, whereas in CDM patient 
material a defined signal was apparent (Fig. 6) [43].
Multi-pronged analysis reveals low copy number of expanded DMPK transcripts
For further stoichiometric and pathomechanistic considerations we decided to determine 
the absolute number of DMPK mRNA copies per cell. Quantification on northern blot, after 
normalization for signal strength and correction for probe length, revealed that DMPK/Dmpk 
expression was 400- to 2000-fold lower than that of ACTB/Actb in proliferating human/
mouse myoblasts (Fig. 7A and Suppl. Fig. S4B). Based on known values for the copy number 
of ACTB/Actb mRNA, which ranges from 350 to 8000 per cell [44–47] (Suppl. Table S1), we 
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Figure 5. Transgene expression in DM1 mouse skeletal muscle. Expression of Acta1, Dmpk and transgenes 
was determined in GPS muscle of each DM1 mouse model. Transcripts were quantified by northern blotting 
using 18S rRNA for normalization (n≥4). Endogenous Dmpk RNA levels in DM500 GPS muscle were used 
as reference (set to one). Mean + SEM are shown. a.u., arbitrary units; n.d., not determined (Dmpk and 
transgenic signals overlap); n.a., not applicable.
63
A  low number of expanded transcripts involved in DM1
2
inferred that the absolute number of DMPK transcripts must be in the range of 1-20 per cell. 
In patient myoblasts, this population consists of approximately equal numbers of normal-
sized and expanded DMPK transcript molecules (Fig. 4 and Fig. 7A).
 To validate this rough estimate, DMPK RNA copy number was quantified using two 
in vitro transcribed DMPK RNAs as standard references in RT-qPCR (Suppl. Fig. S5). We found 
20-25 DMPK transcripts per proliferating 11/760 myoblast and 45-50 DMPK molecules in 
myoblasts just prior to the onset of myogenic differentiation (Fig. 7B). This number includes 
both healthy and expanded DMPK transcripts. On average about four expanded DMPK 
transcripts per cell were detected in DM500 myoblasts.
 Thirdly, we used RNA-sequencing data of healthy and DM1 skeletal muscle 
(available via www.dmseq.org) to estimate DMPK transcript copy number. We calculated 
the DMPK:GAPDH ratio based on RNA-sequencing signal and found that DMPK mRNA 
molecules were 60- to 160-fold less abundant than GAPDH mRNA (Fig. 7C). Based on current 
estimates for the prevalence of GAPDH RNA, which is in the order of 250-2900 molecules 
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Figure 6. DMPK expression in human control and DM1 patient tissue. Northern blot (left) of human control 
and DM1 muscle tissue using a DMPK and a (CAG)9 repeat probe. Healthy DMPK mRNA appeared as a 
defined band in all tissues. Expanded DMPK mRNA appeared as a defined band in congenital DM1 tissue 
(CDM-e and -f) but as a smear (representing somatic mosaicism of repeat size) in adult DM1 tissue (DM1-c 
and -d). As size markers, we indicated the location of DMPK (CUG)700 and (CUG)1300 transcripts. DMPK 
transcript levels, normalized to those of 18S rRNA, were plotted relative to Dmpk transcript levels in DM500 
GPS muscle to allow for comparison with DM1 mouse models (right). Stacked bar graphs show levels of 
normal-sized DMPK (black part) and expanded DMPK (white part) in patient-derived samples. The ratio 
expanded versus normal-sized DMPK transcripts was 0.33 in DM1-c; 0.92 in DM1-d; 0.84 in CDM-e and 1.79 
in CDM-f.
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per cell [44,47–50] (Suppl. Table S2), DMPK transcript copy number must be between 2 and 
50 per cell.
 Finally, we determined the number of FISH-detectable RNP complexes in mouse 
and human myoblasts using a Cy3-labeled (CAG)7 probe. Initial analyses demonstrated that 
the number of FISH signals slightly varied between myoblast pools and experiments and 
was influenced by culture conditions, such as cell density, feeding regime or changes in the 
culture medium (data not shown). This variation in foci number appeared suppressible by 
maintaining a very strict scheme for cell culture. On average, 5-9 foci per cell were detected 
in DM500 myoblasts (Fig. 8A and B). The number of foci differed between diploid and 
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Figure 7. DMPK RNA copy number in human and mouse myoblasts. The absolute number of DMPK 
transcripts per cell was calculated based on experimental data from northern blotting (A), RT-qPCR 
(B) and RNA-sequencing (C). (A) Stacked bar graph showing DMPK/Dmpk : ACTB/Actb transcript ratios 
determined from signal strengths on northern blots for human myoblast lines 5/5, 21/200 and 11/760, and 
mouse myoblasts lines WT and DM500 (Suppl. Fig. S4B). (B) DMPK transcript copy number in 11/760 and 
DM500 myoblasts was determined on the basis of known amounts of synthetic DMPK RNA fragments in 
RT-qPCR (Suppl. Fig. S5). Note that normal-sized and expanded DMPK transcripts could not be measured 
independently. (C) DMPK : GAPDH ratio based on RNA-sequencing signal of healthy and DM1 tibialis anterior 
(TA) and quadriceps (Quad) tissue (www.dmseq.org). Each data point represents a single tissue. Mean + SEM 
(A and B), or mean only (C) are shown. Descriptions d-2 and d0 refer to Fig. 1 and Fig. 3.
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tetraploid DM500 myoblasts, with averages of ~5 and ~9 foci per cell, respectively (Suppl. Fig. 
S1B). For reasons unknown, we also consistently observed signals in WT mouse myoblasts 
(Fig. 8A and B). These signals could not be distinguished from expanded DMPK (CUG)n 
mRNA signals and may also be present in other cell types from mouse. In cells from human 
origin we did not observe overt background signals, so the problem may be species specific. 
To deal with this issue, we decided to apply a correction by defining a background interval 
in Fig. 8. After this correction, an average of two transgenic expanded (CUG)n-specific foci 
per cell remained in DM500 myoblasts. Foci counts in Tg26 and HSALR myoblasts were within 
the background range, as expected, based on the idea that the (CTG)11 repeat in Tg26 RNA 
cannot yield sufficient signal and our finding that the HSALR transgene is barely expressed 
in proliferating myoblasts. In 11/760 patient myoblasts 3-4 foci per nucleus were detected, 
whereas no signal was observed in 21/200 and 5/5 myoblasts (Fig. 8C and D), obviously 
caused by lack of FISH-signal strengths by the limited length of the repeat target.
 All data combined, we conclude that mouse and human myoblasts each contain up 
to half a dozen foci. We have to keep in mind that FISH protocols may detect transcripts with 
an efficiency of only 30-50% [46], for example due to inaccessibility of the transcripts to the 
probe or loss of RNA molecules from the fixed cells during washing. Thus, the actual number 
of RNP complexes that appear as foci may be 2- to 3-fold higher. Given our estimates for the 
absolute number of expanded transcripts, our data suggest that every RNP complex that 
forms a FISH-visible aggregate is nucleated by one or only few expanded (CUG)n transcripts.
Discussion
DM1 is considered a prototypical RNA-dominant disorder, because its neurodegenerative 
and myopathic manifestation is thought to be based on processes wherein repeat-containing 
RNAs play a crucial role. Much of our current knowledge on the presumed toxic role of RNA 
in DM1 pathophysiology originates from direct comparison of findings in mutation carriers 
with findings in transgenic animals or genome edited cells. This is often done with simple 
bypassing of the fact that models may differ profoundly in nature, structural organization 
and chromatin context of the transgene and in length of the contained (CTG·CAG)n repeat 
[13,14]. A major unsolved aspect of DM1 etiology is how repeat length and dose and 
nature of abnormally expanded RNA transcripts affect onset and complexity of disease 
manifestation and its rate of progression and severity. Quantitative studies of transcript 
production could thus help to explain differential experimental findings with distinct DM1 
models and add to conceptual progress. Here, we used gene expression profiling to compare 
relative abundance and absolute copy number of expanded repeat RNAs between muscle 
cells from patients and mouse models that are among the most commonly used in the DM1 
field.
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Figure 8. (CUG)n foci number in DM1 mouse and human myoblasts. Representative RNA FISH images using 
a (CAG)7 oligo probe (A and C) and quantification (B and D) of (CUG)n foci in DM1 mouse and human 
myoblasts. (A and B) RNA FISH signal in WT and DM500 myoblasts. In WT mouse myoblasts foci were 
observed which cannot be specific for the transgenic expanded (CUG)n transcripts. As these signals may 
also be present in cell lines derived from other mouse lineages, including the transgenic models, we defined 
a level of uncertainty, plotted as a shaded area in (B). Thus, an average of two expanded (CUG)n-specific 
foci per cell remained in DM500 myoblasts and no specific foci were identified in Tg26 and HSALR myoblasts. 
(C and D) RNA FISH on human healthy (5/5) and DM1 (21/200 and 11/760) myoblasts. Foci were only 
detected in 11/760 cells. Each data point represents foci number in one nucleus; mean is plotted in graph. 
Bar 20 µm. *** p < 0.001.
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 Our analyses unveiled differences in timing of production during myogenic 
differentiation as well as in the abundance of (CUG)n transcripts between DM1 mouse 
model and patient muscle cells. Expression of DMPK transgenes in DM500, DMSXL and 
Tg26 mice is at a basal level in proliferating myoblasts and peaks early in differentiation 
in a manner similar to the profile of endogenous DMPK expression in human myoblasts. 
Increase in DMPK expression at the start of myogenic differentiation was earlier reported for 
human cells [31] and also seen for C2C12 mouse myoblasts [51]. Our group [25] and others 
[37] have demonstrated that the actual onset of DMPK expression is already seen in somites 
in the developing embryo, well before the actual commitment to specific muscle cell fate 
and the onset of myogenesis.
 DM500/DMSXL- and Tg26-derived myoblasts carry transgenes of different size 
that may lack regulatory elements upstream of the DMPK TSS, but the proximal promoter 
sequence and the enhancer sequence in intron 1 (elements responsive to MyoD via 
conserved E-boxes [52]), are present. Thus, regulatory sequences from the human locus may 
drive ‘near-natural’ behavior of these transgenes and control the peak-shaped upregulation 
with transient increase in transcriptional activity during early differentiation. The ‘human-
like’ regulation of the DMPK transgene renders these mouse myoblasts useful models for 
study of toxic effects of normal or expanded DMPK RNA in early development. Others 
have demonstrated that early-onset expression of repeat-containing RNA may influence 
phenotypic severity by affecting proper tissue development in animals in vivo [16–19].
 In HSALR myoblasts, expression of repeat-containing RNA was hardly detectable until 
late in differentiation in vitro. Conspicuously, the Acta1 gene, whose human counterpart 
served as the recipient body for the transgene with (CTG)250 repeat insertion, showed an 
earlier onset of expression in differentiating mouse cells. The explanation for this differential 
behavior may thus be that the proximal promoter is present in the transgene, but that a cis-
regulatory module in a region that activates transcription in differentiating myoblasts, >20 
kb downstream of the basal promoter [53], is lacking.
 We found pronounced differences in the abundance of (CUG)n-repeat RNAs from 
transgenes and RNA products from the endogenous Dmpk gene and between expanded 
RNAs from cell lineages and the transgenic mouse tissues from which they originate. For 
proliferating cells, comparison was only meaningful for Tg26, DM500 and DMSXL myoblasts, 
as HSALR myoblasts essentially lacked expression of expanded (CUG)n RNA. As explained by 
the presence of multiple copies of the DMPK gene in the transgenic insert in Tg26 cells, DMPK 
levels were relatively high. Transcripts from the DMPK transgene in DM500 and DMSXL cells 
were ~10-fold lower than transcripts from the Dmpk gene in these myoblasts. Even if we take 
into account that these observations reflect the production rate from one DMPK transgene 
versus two Dmpk genes in the DM500 cell model, transgenic RNA production is still ~5-fold 
lower. Intrinsic differences in regulatory capacity of DMPK and Dmpk promoters may partly 
explain this observation, but we cannot exclude involvement of progressive epigenetic 
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alterations, like DNA methylation or heterochromatization of the transgene or the DMPK 
promoter. Brouwer et al [54] observed decreased transgene expression with age in the 
DM300-328 lineage, the ancestral mouse model from which DM500 and DMSXL mice and 
thus DM500 and DMSXL cells originate. Cis effects of repeat presence may have contributed 
to methylation state alterations in the DMPK transgene [54]. Also transient propagation of 
mice in the homozygous state may have triggered partial gene silencing even before the 
myoblasts were derived in vitro [55–57]. Finally, we cannot exclude effects of experimental 
handling, for example, by the use of DMSO during repeated cell freezing, which can affect the 
epigenetic state and is a known modulator of differentiation programming [58]. Although we 
did not systematically study expression levels over time, we have the impression that DMPK 
expression in DM500 cells decreases with increasing passage number (compare data shown 
in [30]). This could point to the influence of epigenetic silencing, explaining also variability 
in observations of different research groups in the DM1 field.
 Also in muscle tissue obtained from hemizygous DM500 and DMSXL mice DMPK 
transcripts were 10-fold less abundant than Dmpk RNAs, confirming the observation by 
Huguet et al. [59]. The overall low level of transgene expression may explain why disease 
manifestation in these models is relatively mild, even in homozygous animals. Conversely, 
however, one can also argue that the presence of these few expanded RNAs is already 
sufficient to cause mild myotonia, slow progressive muscle weakness, nuclear (CUG)n foci 
and splicing abnormalities [1,14,60], for which compelling evidence was provided in various 
studies. 
 Our most conspicuous observation was that ACTA1 (CUG)n expression in GPS 
muscle of homozygous HSALR mice was over 1000-fold higher than that of Dmpk, and 
remarkably similar to Acta1 expression. The high (CUG)n RNA expression may explain why 
the HSALR mouse lineage has by far the most severe DM1-like phenotype of all models, 
including myotonia, extensive splice abnormalities and a conspicuous abnormal density of 
intranuclear foci, all limited to skeletal muscle [1,14,27].
 The use of expression ratios between transgenic and endogenous transcripts (e.g., 
Dmpk, Acta1, Actb and 18S RNA) helped us to compare repeat RNA levels between muscle 
cells and mouse and human tissues, but we reasoned that the knowledge of absolute 
transcript copy numbers in muscle would be mechanistically more informative. Absolute 
numbers of molecules can only be meaningfully assessed if studied on a per cell basis. 
Analysis of DMPK expression in the three human myoblast lineages with no, intermediate 
or long repeat expansions confirmed that transcripts from the wild-type and mutant allele 
are about equally abundant. We found no evidence for an inverse correlation between 
the repeat length and RNA expression level [31,61]. Because endogenous DMPK/Dmpk 
transcripts appeared equally abundant in human and mouse myoblasts, quantitative 
comparison between patients and DM1 models was straightforward. Estimates for RNA 
expression ratios of ACTB and GAPDH, data from northern blot and RNA-sequencing analysis 
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and absolute RT-qPCR experiments all point to the presence of at most 50 DMPK transcripts 
per cell. We thus propose that in patient cells <25 are expanded (CUG)n transcripts. In 
myoblasts from the DM500 and DMSXL mouse models around four RNA molecules per cell 
originate from the DMPK transgene.
 Estimates for DMPK transcript numbers correspond remarkably well with the 
observed foci number in DM500 cell nuclei. Also in patient myoblasts the number of foci per 
nucleus and the number of DMPK transcripts per cell are in the same order of magnitude. 
Other research groups, studying different cell types from DM1 patients, have reported 
similar amounts of foci from their FISH experiments [62–65]. Different and variable amounts 
of foci were observed for MyoD-transduced DM1 fibroblasts, which may be best explained 
by the distinct MyoD induction of DMPK expression, caused by differential vector systems 
or MyoD promoters [63,66]. We therefore predict that RNP complexes that assemble in 
(CUG)n foci contain, on average, one to maximally six expanded transcripts. Along the same 
line of arguments, we propose that RNP aggregate formation is nucleated by one or very 
few expanded RNA molecules, thereby acting as individual entities. Phase transition of 
RNP complexes to insoluble aggregates (which appear as foci after FISH or MBNL antibody 
staining) may therefore not require further fusion with additional naked or RNP-decorated 
RNAs but could be merely a protein-based event.
 Many mechanistic avenues are now awaiting further exploration as our findings 
have important implications for the RNA-gain-of-function hypothesis that is currently in use 
for explaining DM1 features. How low numbers of only 1-25 abnormally folded RNA scaffolds 
can have a negative impact on ribostasis regulation - via titration of protein molecules from 
the total available pools of RNP proteins - is only one of the mechanistic questions that 
must be answered. The extent of loss-of-function of proteins may determine the gain-of-
function toxicity of mutant RNA - and ultimately control the extent of cell stress caused by 
the DM1 mutation. Whether there is a direct relationship with the magnitude of temporal 
or permanent sequestration from the cellular pool of these RNP proteins is still difficult 
to answer. Stochastic events could be involved, as formation of an abnormal type of - 
microscopically visible or invisible diffusive - RNP aggregate on a repeat-containing transcript 
[6,7] might cause temporal or permanent perturbation of a specific nuclear pathway for 
mRNA processing or transport. Dominant effects of low-abundance triplet repeat RNA 
on RNA splicing and polyadenylation may be expected if effects on inhomogeneity and 
compartmentalization of protein factor pools (e.g. MBNL isoforms) in different nuclear 
trajectories for mRNA RNP processing play a decisive role. Finally, amplification of toxic 
effects by rare triplet repeat RNAs may occur otherwise: various studies have demonstrated 
that activation of stress-signaling cascades that involve GSK3β [67], PKC [68], double-
stranded RNA-dependent protein kinase PKR [69] or sensors of foreign RNA that normally 
initiate immune responses [70] is involved in disease manifestation in DM1. Whatever the 
exact course of cellular events in these scenarios, even with low-expressed, abnormally 
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expanded repeat RNAs the probability of exceeding the toxic threshold increases over time 
for any permanently expressing cell in the tissue population. Ultimately, this may result in 
accumulation of stress in an increasing number of cells, and progressive cell loss and loss of 
function of tissue during ageing.
 In a parallel study, we have recently found that expression of another possible 
player, a DM1 antisense transcript carrying a (CAG)n repeat, is even 10-fold lower than levels 
observed for DMPK (Gudde et al. manuscript in preparation). Thus also here the question 
remains how such an extremely rare transcript could contribute to disease manifestation. 
One unifying answer may be that the rare DMPK sense RNA and the even rarer antisense 
transcript both serve as templates for RAN translation [9,10]. Homopolymeric protein 
products thus formed could possibly contribute to disease manifestation via initiation of 
aggregation of metastable proteins, initiating a prion-like cascade of events [71–73]. Again, 
further analysis of steady-state levels of DMPK (CUG)n and antisense transcripts in cycling 
or resting cells and study of the frequency of use of RAN translation on these rare RNAs is 
necessary to better understand this possible distinct aspect of DM1 etiology. 
 Our findings highlight that careful choice of cellular and animal model systems 
that take structural properties of transgenes and transgenic products into account in 
combination with quantitative modeling is imperative for such studies. For this work not only 
knowledge of the ‘per cell’ presence of individual endogenous and mutant RNA molecules 
is important, but also stoichiometric considerations on the binding of MBNL1-3, Staufen, 
DDX, HnRNP or other RNP proteins [7] by one (CUG)n repeat tract are needed to better 
understand nucleation and phase transition events in abnormal aggregates that could form 
around expanded DMPK mRNAs. Whatever the molecular mechanism involved, based on 
our findings we propose that DM1 is caused by anomalous behavior of only very few mutant 
RNA molecules per muscle cell.
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Figure S1. Ploidy of SV40-immortalized myoblasts. (A) FACS analysis of DNA ploidy of WT myoblasts at 
passage 14 and 21 showed a shift from 21% 2N and 65% 4N cells (p=14) to 3% 2N and 67% 4N (p=21). Note 
that the 2N populations are in G1 phase, whereas the 4N population is a mixture of G2 diploid cells and 
G1 tetraploid cells. The 8N population represents G2 tetraploid cells and was not included in the study. (B) 
Number of (CUG)n foci per nucleus detected by FISH in DM500 myoblasts FACS-sorted for DNA ploidy. There 
is a positive correlation (p < 0.001) between number of foci and DNA ploidy. Data points of individual cells 
are plotted and the mean is shown.
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Figure S2. Switch in Act expression during myogenic differentiation. Analysis of Acta1 and Actb expression in 
differentiating HSALR, WT and DM500 myoblasts by Northern blotting (A) normalized to 18S rRNA expression 
(B). The mean value + SEM of the three cell lines is shown. Actb levels decreased during differentiation, while 
Acta1 levels increased. Note that Actb signal in HSALR GPS could not be included in the analysis, because of 
overlap with the transgenic Acta1 signal. Timing of differentiation on the x-axis refers to Fig. 1.
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Figure S3. Transgene expression in proliferating and differentiating myoblasts derived from DM1 mice 
assayed by RT-qPCR. Analysis of transgene mRNA levels by RT-qPCR. 18S rRNA levels were used for 
normalization and values were compared to the value for the parental GPS muscle (set to one). Data 
were obtained from triplicate cultures per cell line. Bars represent mean + SEM. These data confirm those 
obtained by Northern blotting (Fig. 2). Timing of differentiation on the x-axis refers to Fig. 1.
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Figure S4. Simultaneous detection of different transcripts on Northern blot. (A) Raw data belonging to Fig. 
5. Top panel: simultaneous detection of DMPK/Dmpk and ACTA1/Acta1 expression in GPS complexes from 
DM1 mice (n=4 per strain) by Northern blotting using a DMPK/ACTA1 cDNA probe mix (see Materials and 
Methods). Since ACTA1 transgene and Dmpk signal in HSALR samples partly overlapped, the signal for ACTA1 
cDNA probe alone is shown. Middle panel: detection of DMPK/Dmpk with a DMPK cDNA probe. DMPK 
transgene expression in DM500 and DMSXL was weak but detectable above background after long exposure, 
causing the Tg26 transgene signal to be overexposed. Bottom panel: 18S rRNA was used for normalization. 
For quantification, signals were compared after background correction. (B) Raw data belonging to Fig. 7. To 
estimate DMPK transcript copy number, RNA isolates from human and mouse myoblasts were assessed for 
DMPK : ACTB and Dmpk : Actb transcript ratio, respectively, by Northern blotting. Simultaneous detection of 
these transcripts was done using a DMPK/ACTB probe mix. For quantification, signals were compared after 
background correction. Descriptions d-2 and d0 refer to Fig. 1 and Fig. 3.
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Figure S5. DMPK transcript copy number determination by RT-qPCR. (A) Scheme depicting two DNA 
segments used for in vitro transcription to generate DMPK reference RNA for RT-qPCR quantification: e1-e6 
RNA (643 b) and e11-e15 RNA (1030 b). Primer sets e1-2 and e15 (5’) were used to measure DMPK levels 
in RT-qPCR. (B, C) In vitro transcribed RNA visualized by gel electrophoresis to verify product purity and 
identity. The unexpected product >1,000 b in the e1-e6 reaction disappeared upon heating, so represented 
an RNA duplex of the expected 643 b product. (D) DMPK RNA reference curves from RT-qPCR. Known 
concentrations (based on OD260/280) of synthetic DMPK RNA were used in an RT-reaction in presence 
of WT mouse RNA. The resulting cDNA was used in a dilution series in the qPCR. cDNA of pure WT mouse 
RNA (triangles), no template control (diamonds) and RT-minus (squares) were included as negative controls. 
Standard curves (circles) were used to determine the number of DMPK transcripts in DM500 and 11/760 
RNA samples (crosses). All RNA samples were analyzed with both primer sets.
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ACTB copy 
number
Cell type Method Refs
330-370 HeLa Kyoto cells Single molecule FISH [1]
791 Rat hippocampal neurons Single molecule FISH [2]
2,000 GM08402 human fibroblasts RT-qPCR [3]
5,000-8,000 Human naive B lymphocytes Highly parallel qPCR, validated with digital PCR [4]
Table S1. ACTB transcript copy number per cell (literature data)
GAPDH copy 
number
Cell/tissue type Method Refs
250-500 Human naive B lymphocytes Highly parallel qPCR, validated with digital PCR [4]
285-315 HeLa Kyoto cells Single molecule FISH [1]
500 Rat liver RNase protection assay [5]
1,300-1,800
K562 human myeloid leukemia 
cells
RT-qPCR and digital PCR [6]
1,800-2,900 NIH/3T3 mouse fibroblasts RT-qPCR [7]
Table S2. GAPDH transcript copy number per cell (literature data)
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Introduction
Intranuclear RNA foci in DM1 cells are formed when expanded DMPK mRNA molecules 
abnormally bind protein factors and the resulting ribonucleoprotein complexes accumulate 
[1,2]. Based on the data presented in Chapter 2, RNA foci can only be nucleated by one or 
very few expanded DMPK transcripts. MBNL1 is one of the proteins sequestered in RNA foci, 
leading to loss of MBNL1 molecules from the normally available intracellular pool. This loss 
is thought to contribute to the splicing, polyadenylation and miRNA abnormalities observed 
in DM1 patients [3,4].
This addendum is aimed to gain insight in the number of MBNL1 proteins present 
per cell and in the MBNL1 binding capacity of (CUG)n repeats in DM1 cells, in relation to the 
number of expanded DMPK transcripts and their average (CUG)n repeat length.
Results and Discussion
The MBNL1 protein copy number varies in literature between cell lines and tissues. In the 
human osteosarcoma cell line U2OS an estimated number of 9,000 MBNL1 protein molecules 
are present per cell [5] (Fig. A1; grey bar). In mouse cell lines and tissues on average 490,000 
and 52,000 molecules of Mbnl1 are present per cell, respectively [6,7] (Fig. A1; white and 
black bars).
The number of expanded DMPK mRNAs lies between 1 and 25 copies per cell 
(Chapter 2). MBNL1 proteins may bind directly to the (CUG)n repeat with an observed 
packing density of one protein molecule per (CUG)4 repeat [8]. Furthermore, MBNL1 may 
Data from:
- U2OS: Beck et al (2011) The quantitative proteome of a human cell line
- NIH 3T3: Schwanhausser et al (2011) Global quantification of mammalian gene expression control
and
- rest: Wisniewski et al (2014) A “Proteomic Ruler” for Protein Copy Number and Concentration Estimation without Spike-in Standards
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Figure A1. MBNL1 protein copy number from literature in various cell lines and tissues. MBNL1 protein 
copy number differs between cell lines and tissues analyzed. Data from U2OS from [5], NIH 3T3 from [6] 
and other mouse cell lines and tissues from [7].
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bind indirectly to the (CUG)n repeat-MBNL1 complex by self-dimerization [9]. At maximal 
stoichiometric occupancy, this means that approximately 50 MBNL1 molecules may be 
captured per (CUG)100 repeat length.
In individuals with adult onset DM1 and DMPK gene repeat sizes of up to 1000 CTGs, 
and at most 25 expanded DMPK transcripts per muscle cell, this would represent a maximal 
binding capacity for in total (10 x 50 x 25) 12,500 molecules of MBNL1. If the number of 
MBNL1 molecules in muscle cells of patients with classic DM1 is similar to that for U2OS 
cells, this would mean complete sequestration of the entire pool of MBNL1 molecules, but 
only if cells do contain the estimated maximal (CUG)n repeat dosage, i.e. more than 20 
transcripts with repeats of maximal length for classic DM1 (~1000 CUG triplets). In adult- 
and juvenile-onset DM1 the repeat length is in general shorter than 1000 CUG-triplets, with 
variability between muscle cells because of somatic repeat expansion, and binding capacity 
would not be sufficient to segregate all MBNL1 molecules from the cellular pool, certainly 
not if the number of protein molecules is approximately 5-10 fold higher, as found for all 
mouse cell lines and tissues. In congenital DM1 patients, who carry DMPK transcripts with 
very long repeats of up to thousands of CUG triplets, the situation may be different, and all 
MBNL1 molecules may indeed be sequestered from the available pool completely.
Finally, it is of note that the above line of reasoning only holds if the entire pool 
of MBNL1 protein molecules participates in repeat binding. In fact, we know that in most 
tissues a mixture of differentially spliced MBNL1 isoforms is expressed [10]. If only certain 
MBNL1 splice isoforms localize in the nucleus and therefore only a subset of MBNL1 
proteins in the cell can participate in RNA foci formation, pool sizes of pathobiologically 
relevant MBNL1 molecules may be even much smaller than estimated from Fig. A1. In such 
circumstances titration of a fair percentage of distinct types of MBNL1 isoforms away from 
the locales wherein they exert their normal biological role could occur in almost any DM1 
cell that expresses expanded DMPK RNA, independent of repeat length.
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Abstract
Prevailing ideas about intracellular RNA distribution suggest that eukaryotic mRNAs reside 
in the cytoplasm for the majority of their lifetime, at the location where they function as 
template for translation. Recent studies have revealed that transient nuclear accumulation 
may occur and has a role in preventing premature release of mRNAs in the cytoplasm or 
in dampening gene expression bursts. Pathological nuclear retention with obstruction of 
nucleocytoplasmic transport of mRNA may develop in association with disease, for example 
in myotonic dystrophy type 1 (DM1), a neuromuscular degenerative disease. In DM1, caused 
by expansion of a (CTG)n repeat in the DMPK gene, transcripts from the mutant allele with 
a long (CUG)n repeat aggregate in ribonucleoprotein (RNP) complexes and tend to get stuck 
before being exported to the cytoplasm. In this study, we compared the nucleocytoplasmic 
distribution behavior of normal-sized versus expanded DMPK transcripts as occurring 
in cells of patients. In myoblasts, and to a lesser extent also in fibroblasts, we found that 
not only expanded DMPK mRNAs were retained but that also a relatively high percentage 
of normal DMPK mRNAs located in the nucleus, compared to typically cytosolic mRNAs 
ACTB and GAPDH. Like pre-mRNAs, expanded DMPK transcripts were primarily found in 
the non-extractable, chromatin-associated fraction of nuclear RNA. After G0-arrest, both 
normal and mutant DMPK mRNA expression increased in myoblasts and fibroblasts, but 
their nucleocytoplasmic distribution behavior remained unchanged. We speculate in our 
discussion on the role of prolonged nuclear residence of DMPK mRNA. 
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Introduction
The life of eukaryotic mRNAs starts in the nucleus, where - in their nascent state immediately 
after transcription - they are found as precursors. After completion of processing, which 
usually includes capping, splicing, polyadenylation and occasionally RNA epigenetic 
modifications like adenosine methylation, mRNAs are transported to the cytoplasm as 
export-competent mRNPs [1]. There they may be translated or temporarily stored in RNP 
aggregates, before being degraded via specific nucleolytic breakdown at the end of their 
lifecycle [2,3]. 
Under normal steady-state conditions, most mRNAs undergo the different steps in 
their subcellular localization in default, explaining why the majority of mature mRNAs reside 
in the cytoplasm. Up till now, nuclear retention of mRNA, although being a processing step 
with regulatory potential, was considered a relatively rare event. It was only observed for 
hyper-edited or incompletely spliced mRNAs [4–7] and RNA species like long non-coding 
RNAs (lncRNAs) XIST, MALAT1 and NEAT1 [8]. A recent transcriptome-wide study has changed 
this picture, however, as it identified a wide range of spliced, polyadenylated mRNAs that 
were retained in the nucleus for most of their lifetime [9]. According to the newest findings, 
nuclear retention can thus act as a buffer to prevent fluctuations of transcript levels in the 
cytoplasm [9,10], since most genes are transcribed in bursts [11–14].
 RNA synthesis occurs in a compartmentalized nucleus. Various nuclear domains exist, 
including the nucleoli, nuclear speckles, Cajal bodies, polycomb bodies and paraspeckles, 
which are involved in processes that play important roles in the spatiotemporal regulation 
of gene expression, including RNA quality control [15–17]. Nuclear speckles occur near sites 
of transcription and are enriched in pre-mRNA splicing factors [18,19]. Paraspeckles, formed 
by association of proteins and lncRNA NEAT1, are involved in nuclear retention of at least 
one type of edited RNA [5,20]. Whether any of these or perhaps other nuclear bodies are 
specifically implicated in nuclear retention of mRNAs that should not or cannot move to the 
cytoplasm is unclear.
In myotonic dystrophy type 1 (DM1), mutant DMPK mRNAs with an expanded 
(CUG)n repeat in their 3’ untranslated region (UTR) are selectively retained at the periphery 
of nuclear speckles [21–23]. Expanded DMPK RNAs abnormally bind RNA-binding proteins 
(RBPs) like members of the muscleblind-like (MBNL) family, hnRNP and DEAD-box helicases 
[24–27] and, once captured in large RNP complexes or aggregates, undergo altered processing 
associated with long-term nuclear residence near speckles. In turn, the excessive binding 
of RBPs leads to sequestering, causing decrease of MBNL1 activity [25–27]. Conversely, 
also increase in other ribostasis factors like the CELF1 protein is observed, by stabilization 
through hyperphosphorylation by cellular stress signaling [28–30]. As a consequence of 
these alterations in the RNA processing machinery, multiple other transcripts adopt an 
aberrant splicing profile, usually leading to production of embryonic isoforms in adult 
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tissues [31–33]. Similarly, the distortion in the balance of RNA processing factors affects 
alternative polyadenylation of multiple mRNAs [34]. Together, these abnormalities are 
prominent contributors to DM1 manifestation as they have major in trans effects on the 
nucleocytoplasmic partitioning of RNA transcripts and on global cellular ribostasis.
 The cis effects that (CUG)n repeat expansion has on fate specification of DMPK 
mRNA itself, have until now been less well studied. That presence of only the long (CUG)n 
tract proper in RNA is sufficient to trigger abnormal aggregation in RNP complexes, was 
shown by integrating a (CUG)250 repeat in the 3’ UTR of an unrelated mRNA [35]. Repeat 
length may influence the duration or quantity of nuclear residence [36,37], but currently not 
much is known about repeat effects on nuclear dynamics of the mutant DMPK mRNA or its 
capacity to bind miRNAs or regulatory RNPs. Even less knowledge exists about the cellular 
distribution behavior of normal-sized DMPK transcripts. Previous studies from our group 
have revealed that DMPK mRNA copy number is low [38]. Furthermore, overexpression of 
a short cytosolic DMPK protein isoform causes changes in cell shape, motility and viability, 
and a delay in myogenesis [39]. Likewise, ectopic presence of a mitochondrial outer 
membrane-anchored DMPK protein isoform causes abnormal mitochondrial morphology 
associated with physiological changes [40]. We conclude from these observations that 
DMPK expression needs to be carefully orchestrated. 
Stimulated by the still ill-defined picture of DMPK mRNA distribution and 
incomplete appreciation of the role of RNA distribution in regulation of gene expression, we 
started a comparative study of intracellular DMPK mRNA localization. We report here on our 
findings regarding the nucleocytoplasmic DMPK mRNA distribution in myoblasts, one of the 
cell types affected in DM1 patients. Also fibroblasts, which express DMPK mRNA and protein 
at a lower level, were included in our study. Besides confirming that long expanded DMPK 
mRNA was almost fully retained in the nucleus of proliferating myoblasts, we found that 
also normal-sized DMPK mRNA showed a relative high degree of nuclear residence, much 
greater than ACTB and GAPDH mRNAs. The atypical distribution of DMPK mRNA was present 
but less pronounced in fibroblasts. Upregulation of DMPK expression during G0-arrest did 
not associate with a change in partitioning over cytoplasm and nucleus. We speculate on a 
potential role for nuclear retention in expression control of DMPK protein in muscle. 
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Materials and methods
Cell culture 
Immortalized human myogenic cell lines LHCN-M2 (derived from an unaffected individual 
with (CTG)5/(CTG)5 DMPK alleles; 5/5) [41] and C25Cl48 (derived from an unaffected 
individual with ((CTG)5/(CTG)14 DMPK alleles; 5/14) [42] and patient cell line DM11 
((CTG)13/(CTG)2600; 13/2600) [43] were gifts of Dr. V. Mouly and Dr. D. Furling, respectively. 
Myoblasts were grown on 0.1% (w/v) gelatin-coated plastic surfaces in skeletal muscle cell 
basal medium (PromoCell) with Supplement Mix (0.05 mL/mL fetal calf serum, 50 µg/mL 
bovine fetuin, 10 ng/mL recombinant human epidermal growth factor, 1 ng/mL recombinant 
human basic fibroblast growth factor, 10 µg/mL recombinant human insulin, 0.4 µg/mL 
dexamethasone; PromoCell) supplemented with 1% (v/v) GlutaMax (Gibco) and 15% (v/v) 
bovine growth serum (Thermo Scientific) under 7.5% CO2 at 37°C. 
Primary human DM1 myoblasts ((CTG)13/(CTG)800; 13/800), also a gift of Dr. 
D. Furling [44], were grown on 0.1% (w/v) gelatin-coated plastic surfaces in Ham’s F10 
medium (Gibco) supplemented with GlutaMax and 20% (v/v) bovine growth serum (Thermo 
Scientific) under 7.5% CO2 at 37°C. Primary healthy ((CTG)5/(CTG)12; 5/12) and DM1 ((CTG)5/
(CTG)2000; 5/2000) human fibroblasts were grown in DMEM supplemented with 10% fetal 
bovine serum (Gibco), 4 mM L-glutamine, and 1 mM pyruvate under 7.5% CO2 at 37°C.
SV40-TAgts immortalized DM500 mouse myoblasts ([45]; tetraploid cells, carrying 
two identical chromosomes with transgenic inserts that span the human DM1 locus 
with (CTG)530-580 repeats) were grown on 0.1% (w/v) gelatin-coated plastic surfaces in 
proliferation medium containing DMEM (Gibco) supplemented with 20% (v/v) fetal bovine 
serum (PAA), 4 mM L-glutamine (Gibco), 1 mM pyruvate (Sigma), 50 µg/mL gentamicin 
(Gibco), 20 units/mL γ-interferon (BD Biosciences) and 2% (v/v) chicken embryo extract 
(Sera Laboratories International) under 7.5% CO2 at 33°C. 
LHCN-M2 myoblasts were arrested in G0 by loss of substrate attachment as 
described [46,47]. In short, detached cells were brought in suspension culture by transfer 
to semi-solid suspension medium (proliferation medium with 2% (w/v) methylcellulose 
(4000 cP, Sigma) and 50 μg/mL gentamicin (Gibco)) with a density of 1.5x105 cells/mL. 
Suspension cells were harvested by diluting the medium with 4 volumes of PBS, followed by 
centrifugation (30 minutes, 360xg, 4°C).
Subcellular fractionation
Subcellular fractionation was performed as described [48]. In short, cells were harvested 
and cell pellets were washed twice with ice-cold PBS. The cells were resuspended in ice-cold 
cell disruption buffer (10 mM KCl, 1.5 mM MgCl2, 20 mM Tris-Cl (pH 7.5), 1 mM DTT) and 
incubated on ice for 10 minutes. Next, cells were sheared in a chilled Dounce homogenizer 
(Wheaton; 15 strokes), after which Triton X-100 was added to a final concentration of 0.1%. 
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The lysate was spun at 1500xg for 5 min at 4°C and the supernatant (cytoplasmic fraction) 
was separated from the pellet (nuclear fraction). For a subset of samples, the nuclear 
fraction was separated in a chromatin-associated (non-extractable) and nucleoplasmic 
(extracted) fraction as described in [49]. For subsequent RNA isolation, the fractions were 
diluted in lysis buffer (Bio-Rad) and RNA was isolated using the Aurum Total RNA Mini Kit 
(Bio-Rad), according to manufacturer’s protocol. For protein analysis by SDS-PAGE and 
western blotting (see below), the fractions were diluted in 2x sample buffer (4.6% SDS, 127 
mM Tris-Cl (pH 6.8), 20% glycerol, 2% 2-mercaptoethanol, and 0.02% bromophenol blue).
RNA isolation and RT-qPCR
RNA was isolated using the Aurum Total RNA Mini Kit and total RNA yield per sample was 
determined by measuring absorbance at 260/280 nm (NanoVUE spectrophotometer, GE 
Healthcare Life Sciences). RNA was reverse transcribed using the iScript™ cDNA Synthesis 
Kit (Bio-Rad); 200-500 ng cytoplasmic RNA and a cell-equivalent amount of nuclear RNA was 
used per reaction.
For quantitative PCR, 3 µL 10- to 20-fold diluted cDNA preparation was mixed in 
a final volume of 10 µL containing 5 µL iQ™ SYBR® Green Supermix (Bio-Rad) and 4 pmol 
of each primer (sequences in Table 1). Samples were analyzed using the CFX96 Real-time 
System (Bio-Rad). A melting curve was obtained for each sample in order to confirm single 
product amplification. Reactions without template or reverse transcriptase were included 
as negative controls. For MKI67 and DMPK expression quantification in total RNA, combined 
expression of four reference genes (18S rRNA, ACTB, GAPDH and HPRT mRNA) was used 
for normalization. For expression quantification in fractionated RNA samples, the sum of 
nuclear and cytoplasmic expression for each transcript was set to 100%.
SDS-PAGE and western blotting
Proteins in the lysates of subcellular fractions were resolved on 4-15% mini-PROTEAN® 
TGX® stain-free™ precast protein gel (Bio-Rad) and electrotransferred to PVDF membrane 
(Amersham GE Healthcare). Membranes were blocked with 5% non-fat dried milk in TBST 
(10 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.1% Tween-20) and incubated overnight with anti-
Histone H2B rabbit polyclonal antibody (ab1790, Abcam), anti-β-tubulin mouse monoclonal 
antibody (E7, Developmental Studies Hybridoma Bank, University of Iowa, USA) or human 
anti-Topoisomerase I serum (gift from Dept. of Biomolecular Chemistry at Radboud 
University), diluted in the same buffer. After washing in TBST, blots were incubated with 
appropriate fluorescently labeled secondary antibodies and washed in TBST and TBS. Signals 
were detected using the Odyssey® Infrared Imaging System (LI-COR Biosciences).
Ki-67 staining
Detached cells were fixated in 2% paraformaldehyde for 30 minutes followed by three times 
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washing in PBA (PBS with 0.5% BSA and 0.05% NaN3) and stored at 4°C. To bind them to 
poly-L-lysine-coated cover slips, cells were washed twice in PBS and allowed to sink and bind 
to the surface. The cells were fixated in 2% paraformaldehyde for an additional 15 minutes. 
Cover slips were washed three times in PBS, blocked and permeabilized in PBA with 5% 
normal goat serum and 0.1% Triton X-100 for 30 minutes followed by incubation with rabbit-
anti-Ki-67 antiserum (Clone SP6, Thermo Scientific) diluted 1:200 in PBA overnight at 4°C. 
After three times washing in PBS, samples were incubated with goat-anti-rabbit IgG Alexa 
Fluor® 647 (Molecular Probes) and Dapi (Sigma) in PBA for an hour. Samples were washed 
three times in PBS, once in milliQ and mounted in Mowiol. Images were acquired on the 
Leica DMI6000 B inverted microscope using a 20x objective and analyzed in FIJI [50]. Per 
field the total number of nuclei was counted as well as the number of Ki-67 positive nuclei. 
At least 65 nuclei were counted per condition.
Statistical analysis
In both triple-fractionated (chromatin-associated, nucleoplasm and cytoplasm) and nuclear-
cytoplasmic fractionated samples, relative transcript abundances were compared with a 
repeated measures one-way ANOVA, followed by Tukey’s multiple comparison test. MKI67 
Amplicon Forward primer (5’-3’) Reverse primer (5’-3’)
Human
18S rRNA GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
ACTB intron2-exon3 CGTGCTCAGGGCTTCTTGTC CCTCGTCGCCCACATAGGAA
ACTB exon2-exon3 [51] CGGGCCGTCTTCCCCTCCAT TGGGCCTCGTCGCCCACATA
DMPK exon1-exon2 [51] ACTGGCCCAGGACAAGTACG CCTCCTTAAGCCTCACCACG
DMPK exon15 3’ from 
   (CTG)n repeat [51]
TGCCTGCTTACTCGGGAAATT GAGCAGCGCAAGTGAGGAG
GAPDH exon1-exon2 [51] CCCGCTTCGCTCTCTGCTCC CCTTCCCCATGGTGTCTGAGCG
HPRT exon6-exon7 [52] TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT
MALAT1 GAAGGCAGGTCCCCTCTGAC ATAGCAGCACAACTCGTCGC
MKI67 exon11-exon12 GCCTGCTCGACCCTACAGA GCTTGTCAACTGCGGTTGC
Mouse
Actb intron2-exon3 GGTGCTAAGAAGGCTGTTCCCT AGGGTCAGGATACCTCTCTTGC
Actb exon5-exon6 [51] GCTCTGGCTCCTAGCACCAT GCCACCGATCCACACAGAGT
Dmpk exon2-exon3 TTTTGAAGGTGATCGGGCGTG CCTCTCTTCAGCATGTCCCACTTA
Dmpk exon15 3’ from (CTG)n repeat GGATCAGCAAGACCTCTGCCAG TGTGGCTCCGTTGTTAGAGTGC
Gapdh exon2-exon3 [53] GTCGGTGTGAACGGATTTG GAACATGTAGACCATGTAGTTG
Malat1 GCTGTTGGCACGACACCTTC ACTGTGAACCAAAGCCGCAC
Table 1. PCR primers used in this study
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and DMPK mRNA levels in proliferating and G0-arrested cultures were compared using a 
paired t-test. For fractionated RNA samples, the nuclear fraction was used for statistical 
comparison. All values in graphs are presented as mean + standard error of the mean (SEM). 
Statistical analysis was performed with GraphPad Prism version 5.01 for Windows. ns, not 
significant; *, p<0.05; **, p<0.01; ***, p<0.001.
Results
Expanded DMPK mRNA is localized in the nucleus
To examine the cellular distribution of normal-sized and expanded DMPK transcripts under 
steady-state conditions, we prepared nuclear and cytoplasmic fractions from proliferating 
myoblasts. This cell type was chosen because muscle cells are natural DMPK producing cells 
and skeletal muscle is a commonly affected tissue in DM1 patients. The nuclear fraction was 
subsequently differentially extracted to obtain a chromatin-associated (non-extractable) and 
a nucleoplasmic (extracted) fraction. The distribution of DMPK transcripts was examined 
in different cell cultures. We used human primary DM1 myoblasts (13/800) with DMPK 
genes with one normal-sized (CTG)13 and one expanded (CTG)800 repeat and tetraploid 
DM500 mouse myoblasts with two copies of a duplicated DMPK transgene with (CTG)±550 
repeats [45,54] and two parental pairs of endogenous mouse Dmpk genes without a repeat. 
Western blot analysis demonstrated successful cell fractionation [49]: β-tubulin appeared 
exclusively in the cytoplasmic fraction, topoisomerase I was enriched in the nucleoplasmic 
fraction and histone H2B was confined to the chromatin-associated fraction [55] (Fig. 1A).
 For determination of the nucleocytoplasmic distribution behavior in human and 
mouse myoblasts we chose two sets of reference RNAs, with a well-known cellular location. 
As representatives for nuclear RNA we took immature ACTB/Actb pre-mRNA (analyzed with 
a primer pair on an intron-containing segment) and MALAT1/Malat1 lncRNA [56], whereas 
mature ACTB/Actb and mature GAPDH/Gapdh mRNAs served as typical representatives 
for the class of cytoplasmic RNAs. As expected, our RT-qPCR analysis of the distribution 
of ACTB/Actb pre-mRNA and MALAT1/Malat1 lncRNA indeed confirmed that these RNAs 
were primarily nuclear (Fig. 1B). In 13/800 myoblasts, ~90% of the total ACTB pre-mRNA 
was nuclear (60% chromatin-associated, 30% nucleoplasmic). MALAT1 lncRNA resided for 
~70% in the nucleus, equally distributed over chromatin-associated and nucleoplasmic 
fractions. Likewise, in DM500 cells, 90-95% of Actb pre-mRNA and Malat1 RNA were found 
in the nucleus (∼60% chromatin-associated). Conversely, 80-90% of mature ACTB/Actb and 
GAPDH/Gapdh mRNAs were found in the cytoplasm in both cultures. The small fractions 
of these mRNAs that were found in the nucleus resided mainly in the nucleoplasm. These 
results corroborate already known distribution data for these reference RNAs [9,56,57] and 
show the value of our combined simple centrifugation and extraction protocol as a practical 
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and reliable fractionation method for myoblasts.
 To analyze distribution of DMPK transcripts, we used two primer pairs in RT-qPCR: 
one spanning two adjacent exons in the 5’ end, to select for processed mRNAs, and one pair 
close to the (CUG)n repeat in the 3’ UTR (Fig. 1C). Both primer pairs would not discriminate 
between normal and expanded DMPK transcripts and thus provided superimposed analyses 
results for the entire DMPK RNA population. DMPK transcripts with an expanded (CUG)n 
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Figure 1. Subcellular fractionation of DM1 myoblasts. (A) Western blot analysis of chromatin-associated 
(Chrom), nucleoplasmic (Nucpl) and cytoplasmic (Cyto) fractions of DM1 13/800 myoblasts (expressing DMPK 
(CTG)13 and (CTG)800 alleles) and mouse DM500 myoblasts (expressing DMPK (CUG)±550 transgenes). 
Topoisomerase I, β-tubulin and Histone H2B served as marker proteins. Fractionation was performed in 
duplo (two lanes per fraction). Molecular weights are indicated in kDa. (B) RT-qPCR analysis of transcript 
abundance in the three fractions shown in (A). DMPK/Dmpk transcript distribution was analyzed against that 
for nuclear markers (ACTB/Actb intron (a), MALAT1/Malat1 (b)) and cytoplasmic markers (ACTB/Actb (c), 
GAPDH/Gapdh (d)), with significant differences indicated. DM1 13/800 myoblasts: n=2; DM500, n=6. C) For 
expression of DMPK/Dmpk RNA, two amplicons in the 5’ and the 3’ end of each transcript were used (bars 
below the corresponding part of the transcript). Exons are numbered.
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repeat are known to be selectively retained in the nucleus [21,58]. Accordingly, in 13/800 
myoblasts, we found only 40% of its mix of expanded and normal DMPK transcripts in the 
cytoplasmic fraction, a percentage that is significantly different from that of ACTB and GAPDH 
RNAs (Fig. 1B). DMPK mRNAs in the nucleus were equally present in chromatin-associated 
and nucleoplasmic fractions. Species-specific primers allowed us to discriminate between 
expanded transgenic DMPK and endogenous mouse Dmpk transcripts in DM500 myoblasts. 
Surprisingly, also a conspicuously high proportion (~40%) of the endogenous Dmpk mRNAs 
(lacking a (CUG)n repeat) appeared to reside in the nucleus of these cells, equally distributed 
over chromatin-associated and nucleoplasmic fractions. As expected, the large majority 
(~85%) of expanded DMPK mRNAs with (CUG)±550 repeats were exclusively present in the 
nucleus (Fig. 1B), most of them (~60%) being present in the chromatin-associated (non-
extractable) fraction.
A considerable fraction of DMPK transcripts with a normal-sized (CUG)n repeat is in the nucleus
For further study of subcellular DMPK mRNA distribution we simplified our cell fractionation 
protocol. Intranuclear distribution analysis was omitted, because discrimination between 
nuclear and cytoplasmic residence was sufficiently informative for our interest in location 
differences between normal and expanded DMPK mRNAs.
Analysis of (CTG)5/(CTG)5 control LHCN-M2 myoblasts from a non-DM1 affected 
individual, confirmed that >90% of the population of ACTB pre-mRNA molecules and ~60% 
of MALAT1 RNAs were in the nucleus, whereas ~90% of mature ACTB and GAPDH mRNAs 
appeared in the cytoplasm (Fig. 2A). Also for these myoblasts it became apparent that an 
unusual high percentage (30-40%) of mature DMPK RNA molecules had remained in the 
nuclear fraction (Fig. 2A). For another myoblast lineage from a non-affected individual, 
C25Cl48 with (CTG)5/(CTG)14 repeats, the percentages for control RNAs differed somewhat, 
with 80-90% of ACTB pre-mRNA and MALAT1 RNA being in the nucleus and only ~60% of 
mature ACTB and GAPDH mRNAs in the cytoplasm (Fig. 2B). In this cell line even ~65% of the 
DMPK mRNA population with short (CUG)5/14 repeats had a nuclear location. We explain 
the variation in percentages measured by experimental variation, by cell-type or cell-size 
effects on fractionation efficiency. Most relevant is that the fraction of DMPK mRNA in the 
nucleus was consistently higher than that of ACTB and GAPDH mRNA in both cell lines.
Reanalysis of two myoblast cultures from DM1 patients, with (CTG)13/(CTG)800 
and (CTG)13/(CTG)2600 alleles by use of the simplified protocol, confirmed the main 
findings shown in Fig. 1, i.e. that 60-70% of the DMPK transcript population was present 
in the nucleus. Combined, our results suggest that normal and expanded DMPK mRNAs 
behave independently. The high degree of nuclear residence in patient cells, containing a 
mixed mRNA population of normal and expanded DMPK transcripts, reflects the almost 
complete, pathological retention of mutant transcripts [21,58], superimposed on a high 
natural propensity for nuclear residence of normal DMPK mRNAs. Thus, although normal 
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and expanded transcripts cannot be followed independently, our combined findings in 
DM1 and control myoblasts demonstrate the tendency of DMPK mRNA for slow exit of the 
nucleus.
Subcellular distribution of DMPK transcripts is unaffected by G0-arrest
Next, we determined DMPK mRNA localization in myoblasts that have become growth 
arrested. This situation mimics the G0-phase, which poises myoblasts for terminal 
differentiation into multinucleated myofibers, as occurs under special culture conditions in 
vitro or in muscle in vivo [59]. DMPK isoforms might have a special role during this phase in 
the life cycle and there may be need for precise regulation of gene expression [39].
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Figure 2. DMPK mRNA distribution in DM1 and control myoblasts. RT-qPCR analysis of nuclear and 
cytoplasmic fractions of (A) 5/5 and (B) 5/14 myoblasts from healthy individuals and (C) 13/800 and (D) 
13/2600 myoblasts from DM1 patients. ACTB pre-mRNA (ACTB intron, (a)) and MALAT1 RNA (b) served as 
nuclear markers, while ACTB (c) and GAPDH (d) mRNA were included as cytoplasmic markers. Significant 
differences in subcellular distribution between DMPK and the markers are indicated. DMPK mRNA was 
analyzed by two transcript regions as shown in Fig. 1C. n=3.
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To induce transition to G0 but prevent fusion to multinucleated myotubes, which 
would make reliable cell fractionation very difficult, we cultured myoblasts in the presence 
of methylcellulose, thereby avoiding that the cells would attach to the culture dish [46,47]. 
The transition in cell cycle phase was assessed by immunofluorescence for Ki-67, a nuclear 
marker for all active phases of the cell cycle [60]. While ~90% of proliferating LHCN-M2 
myoblasts expressed Ki-67 protein, this was reduced to ~45% after a four day culture in 
suspension medium (Fig. 3A). Analysis of MKI67 mRNA expression, the corresponding 
transcript, confirmed the reduction and showed a ~30% decrease (Fig. 3B). After four days in 
suspension medium, a large proportion of this myoblast population was thus arrested in G0.
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Figure 3. DMPK mRNA distribution in G0-arrested myoblasts. (A) 5/5 myoblasts cultured under proliferating 
conditions (Prol) or for four days in suspension medium (Arr, arrested) were analyzed for Ki-67 protein 
expression in the nucleus (n=2). RT-qPCR analysis of (B) MKI67 and (C) DMPK expression in proliferating and 
arrested 5/5 myoblasts (n=6). (D) Nuclear and cytoplasmic fractions of proliferating and arrested 5/5 cells 
were analyzed by RT-qPCR for expression of DMPK mRNA using nuclear markers (ACTB intron (a), MALAT1 
(b)) and cytoplasmic markers (ACTB (c), GAPDH (d)) as reference (n=6). Significant differences between 
DMPK RNA and marker transcripts in proliferating myoblasts are indicated.
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 In this partially resting cell population we observed a ~2.5-fold increase in DMPK 
expression as compared to a proliferating population (Fig. 3C), a phenomenon which 
mimics the upregulation of DMPK expression during the initial phase of myoblast fusion 
and myotube formation [38]. Concomitantly to this change in expression, DMPK mRNA 
distribution over the nuclear and cytoplasmic fractions did not change. We found ~35% 
of the DMPK mRNA population in the nucleus in both arrested and proliferating cultures 
(Fig. 3D). We consider this tentative evidence that control over timing of nuclear residence 
and subcellular redistribution of DMPK mRNA is not a key factor in regulation of DMPK 
expression upon G0-arrest. For reasons unknown, under the same conditions, nuclear 
localization of MALAT1 RNA shifted from 70% to 90%.
Cellular distribution of DMPK mRNA remains unaltered in G0-arrested fibroblasts
To complete our picture on DMPK mRNA distribution, we extended our analysis to human 
fibroblasts, which express about six-fold lower levels of DMPK than myoblasts (data not 
shown). We used primary fibroblasts from an unaffected individual with DMPK (CTG)5/
(CTG)12 alleles and a DM1 patient with (CTG)5/(CTG)2000 alleles. Cells were either 
cultured under proliferating conditions or induced into quiescence by contact inhibition, 
through the formation of a confluent cell monolayer [61]. ~90% of proliferating fibroblasts 
expressed Ki-67 protein, which was reduced to ~20% in three-day confluent cultures (Fig. 
4A). Analysis of MKI67 mRNA levels confirmed the reduction in Ki-67 staining and showed 
a ~60% reduction (Fig. 4B). After three days of confluence, the majority of fibroblasts in the 
population were thus in G0-arrest. Similar to the situation in cycle-arrested myoblasts, we 
observed a ~1.7-fold increase in DMPK mRNA expression in quiescent fibroblasts compared 
to the proliferating control (Fig. 4C).
Both fibroblast cultures were subjected to subcellular fractionation to examine 
DMPK mRNA distribution. In proliferating fibroblasts, ~80% of nuclear markers ACTB pre-
mRNA and MALAT1 RNA were in the nucleus (Fig. 4D,E), similar to what was observed in 
myoblasts. ~65% of the cytoplasmic markers ACTB and GAPDH mRNA were present in the 
cytoplasm, which is lower than in myoblasts (~80%).  A slightly higher percentage (~50%) of 
DMPK mRNAs in healthy proliferating fibroblasts was found in the nucleus, but the difference 
with ACTB/GAPDH was small. As expected, DM1 fibroblasts showed a higher percentage of 
nuclear residence (~65%) for DMPK mRNAs, caused by the mixed population of normal-
sized and expanded (CUG)n repeat bearing transcripts.
When we analyzed the effect of G0-arrest on RNA distribution, we observed that 
the distribution of DMPK mRNA did not change in control fibroblasts (Fig. 4D). In DM1 
fibroblasts, DMPK mRNA distribution analyzed by the 5’ segment also remained unaltered 
(Fig. 4E). For reasons unknown, DMPK mRNA expression analyzed by the 3’ segment shifted 
significantly from 70% to 85% nuclear localization after growth arrest.
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Figure 4. DMPK mRNA distribution in proliferating and G0-arrested fibroblasts. (A) Human healthy (Control, 
5/12) and DM1 (5/2000) fibroblasts cultured under proliferating (Prol) or contact-inhibited conditions (three 
days of confluence; Arr, arrested) were analyzed for Ki-67 protein expression in the nucleus (n=1-3). Total 
RNA isolated from proliferating and arrested fibroblasts was analyzed for expression of (B) MKI67 and (C) 
DMPK (n=6-9). (D, E) RNA isolated from nuclear and cytoplasmic fractions of control and DM1 fibroblasts 
analyzed for expression of nuclear markers (ACTB intron (a), MALAT1 (b)), cytoplasmic markers (ACTB (c), 
GAPDH (d)) and DMPK mRNA (n=6). Significant differences in subcellular distribution between DMPK and 
the markers in proliferating fibroblasts are indicated.
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Discussion
The majority of mammalian genes are transcribed in bursts [11–14] and cells can buffer 
expression fluctuations by nuclear retention of mRNA to control transcript abundance in 
the cytoplasm [9,10]. Here, we propose that this mechanism is also active in expression 
of the DMPK gene. An unusually high percentage of normal-sized DMPK transcripts, much 
higher than that of cytoplasmic mRNAs ACTB and GAPDH, resides in the nuclei of myoblasts. 
Transcriptome-wide data on mRNA distribution in a mouse pancreatic beta cell line and in 
mouse liver confirm our observations and support the prominent nuclear location of Dmpk 
transcripts (Fig. 5) [9].
Also in unaffected fibroblasts we observed no less than 50% of the DMPK RNA 
population in the nucleus. These findings match those reported in an earlier study on MyoD-
transformed and control fibroblasts [58]. Unexpectedly, however, we identified here that 
this percentage is only slightly higher than that of ACTB and GAPDH mRNAs in these cells. 
The latter two transcripts displayed an atypical nucleocytoplasmic distribution in fibroblasts 
(and also in one of the five myoblast lines tested, Fig. 2B). Subtle differences in cell growth, 
cell density or metabolic state may influence cellular RNA distribution. Besides, our study 
fully relied upon reproducibility of the fractionation procedure. Cell disruption in the 
Dounce homogenizer followed by differential centrifugation of cellular content is a simple 
but delicate procedure, and efficacy of fractionation will probably depend on cell size, 
membrane composition, cytoarchitectural organization and other biological properties. We 
have not yet assessed protein markers for fibroblast-derived cell fractions. Further study is 
therefore needed to find out whether the observations in fibroblasts represent a true cell-
type dependent difference in mRNA distribution or are corrupted by inconsistencies in the 
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fractionation procedure.
Different mechanisms may regulate nuclear RNA accumulation for normal DMPK 
transcripts. (i) A typical example of nuclear RNA retention occurs in paraspeckles, nuclear 
domains formed by association of paraspeckle proteins to lncRNA NEAT1, required as 
a scaffold to maintain integrity [15,20]. RNAs with long 3’ UTR sequences containing 
inverted Alu repeats and adenosine (A) to inosine (I) edited sites are found associated with 
paraspeckles [5,62]. Evidence for involvement of this type of guide motifs in the linear 
DMPK mRNA structure that could serve in its retention is weak, since Alu elements are 
not located in the 3’ UTR (but they are present in introns 8 and 9; unpublished data by 
Smith et al. accessed via RepeatMasker track in UCSC Genome Browser), nor has A-to-I 
editing been reported [63]. (ii) Nuclear transcript retention may also be mediated by the 
expression and nuclear retention element (ENE) [64], exonic splicing enhancer sequences 
[65] or an AGCCC motif [57]. DMPK and Dmpk mRNA contain six and seven AGCCC pentamer 
motifs, respectively, four of which are conserved between human and mouse. The number 
of AGCCC motifs in a transcript correlates with the degree of nuclear localization [57], but 
whether this type of RNA motif actually functions in DMPK mRNA localization remains to 
be determined. (iii) Association of RNA-binding proteins, for example with certain splicing 
factors that form RNP complexes that promote slow or inefficient splicing may directly 
affect RNA nucleocytoplasmic export [66]. In a comparable situation, nuclear retention of 
(CAG)n-repeat expanded HTT RNA is mediated by splicing factors MBNL1 and U2AF65 [67]. 
Finally (iv), also the nuclear mRNA export mechanism itself can in fact be highly selective 
[68]. To discriminate between the abovementioned mechanistic possibilities, single molecule 
mRNA FISH and microscopic imaging techniques for identification of nuclear domains in 
which DMPK mRNAs reside mostly need to be performed. These techniques will require 
improvement of the currently available sets of FISH probes for DMPK immature and mature 
mRNA, specific RNP antibodies and use of sophisticated high resolution microscopy (71).
The here observed striking propensity of normal-sized DMPK mRNA for remaining 
in the nucleus may suggest a mechanism for gene expression control. Previous studies have 
highlighted potential threats of DMPK overexpression, in particular DMPK protein isoforms. 
Mahadevan et al. have shown that overexpression of a normal DMPK 3’ UTR mRNA 
reproduces features of DM1 [69]. Furthermore, own work of our group has revealed that 
a mouse model with high expression of a normal-sized DMPK transgene displays distinct 
muscle traits of DM1 [70]. We also demonstrated in cultured cells that high levels of a 
cytosolic DMPK protein isoform hampers proper cell functioning [39]. There may thus be 
a need for strict control of DMPK expression, but whether nuclear retention plays herein a 
role is unclear.
Nuclear retention of expanded DMPK mRNA with a long (CUG)n tract is presumably 
based on entirely different pathobiological principles, related to the formation of an 
abnormal RNA structure. Swapping experiments whereby the expanded (CTG)n repeat 
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was inserted in an unrelated gene revealed that inclusion in RNP complexes must be 
the overarching mechanism for nuclear presence of repeat-containing RNA [35]. Later 
studies and analogous work in other repeat disorder studies demonstrated that abnormal 
association with factors like MBNL1 and hnRNP H may be the dominant trigger for nuclear 
RNA retention [22,67,71,72].
Triple fractionation experiments provided evidence that the subnuclear 
distribution of expanded DMPK transcripts resembles that of unspliced pre-mRNAs and 
lncRNAs. All these RNAs were enriched in the so-called chromatin-associated fraction, 
a term taken from the original paper by Pandya-Jones and Black [49]. This term may be 
confusing, as the fractionation approach will only distinguish between extractable RNA 
(nucleoplasmic fraction) and RNA in insoluble nuclear material, among which chromatin. 
Microscopy approaches have already demonstrated that expanded DMPK mRNAs locate 
at the periphery of nuclear speckles [21–23]. Our findings are thus fully congruent with 
this location, as RNP complexes near speckles probably behave like chromatin during the 
extraction centrifugation step and may lead the DMPK mRNA in the insoluble fraction if the 
association is strong enough.
Estimates of minimal (CUG)n repeat size for nuclear retention of DMPK RNAs range 
from 80 to 400 triplets [36,37]. These values are loosely based on FISH data with small 
repeat probes, whereby signal strength will be an important limitation for detection. In 
the human DM1 cells a high degree of nuclear residence was found, but exact figures for 
distribution of expanded mRNAs could not be obtained since these could not be examined 
independently. In proliferating DM500 myoblast cultures ~15% of expanded transgenic 
DMPK mRNAs occurred in the cytoplasmic fraction. Expanded DMPK transcripts may escape 
to the cytoplasm after nuclear envelope breakdown during mitosis [73]. We therefore 
propose that escape during cell division or an incomplete block of nucleocytoplasmic export 
of expanded DMPK transcripts explains the less than 100% nuclear retention.
 To assess DMPK mRNA distribution in non-dividing cultures, more closely mimicking 
the in vivo situation, we turned to G0-arrested myoblasts and fibroblasts. Our conditions for 
obtaining a quiescent myoblast culture may have been suboptimal, potentially related to 
the fact that the myoblast lineages used were immortalized by expression of telomerase and 
cdk4, an important cell-cycle regulator involved in G1 to S-phase progression [41,74]. We 
focused on cell populations, with the potential threat of missing delicate processes leveled 
out by cell-to-cell variations. A better approach would therefore be to use synchronized cell 
populations, for example by bringing the G0-arrested suspension myoblasts back to normal 
proliferating conditions [47]. Still, the arrested cell populations displayed an increased DMPK 
mRNA expression. A similar increase was observed during early myogenic differentiation 
[38]. It thus appears that inhibition of cell growth is linked to DMPK upregulation. A higher 
DMPK expression in arrested cultures was not paralleled by a shift in subcellular distribution. 
DMPK upregulation and extended nuclear residence of DMPK mRNA represent different 
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ways of controlling DMPK expression, but our results do not point to a tight interplay 
between the two.
In the future, independent assays with use of live-cell imaging for differential 
tracing of the distribution behavior of normal and expanded DMPK mRNAs will be needed 
to verify the steady-state distribution profiles of total DMPK RNA. Only then we will know 
whether novel regulatory principles for nuclear retention or rather stochastic events are 
dominant in the subcellular RNA distribution for this low abundant mRNA.
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Abstract
In yeast and higher eukaryotes nuclear retention of transcripts may serve in control over 
RNA decay, nucleocytoplasmic transport and premature cytoplasmic appearance of mRNAs. 
Hyperadenylation of RNA is known to be associated with nuclear retention, but the cause-
consequence relationship between hyperadenylation and regulation of RNA nuclear export 
is still unclear. We compared polyadenylation status between normal and expanded DMPK 
transcripts in muscle cells and tissues derived from unaffected individuals and patients with 
myotonic dystrophy type 1 (DM1). DM1 is an autosomal dominant disorder caused by (CTG)n 
repeat expansion in the DMPK gene. DM1 etiology is characterized by an almost complete 
block of nuclear export of DMPK transcripts carrying a long (CUG)n repeat, including aberrant 
sequestration of RNA-binding proteins. We show here by use of cell fractionation, RNA size 
separation and analysis of poly(A) tail length that a considerable fraction of transcripts from 
the normal DMPK allele is also retained in the nucleus (~30%). They carry poly(A) tails with 
an unusually broad length distribution, ranging between a few dozen to >500 adenosine 
residues. Remarkably, expanded DMPK (CUG)n transcripts from the mutant allele, almost 
exclusively nuclear, carry equally long poly(A) tails. Our findings thus suggest that nuclear 
retention may be a common feature of regulation of DMPK RNA expression. The typical 
forced nuclear residence of triplet repeat expanded DMPK transcripts affects this regulation 
in tissues of DM1 patients, but not through hyperadenylation.
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Introduction
Precursors of protein-encoding RNAs (pre-mRNAs) are generally processed to mature 
mRNAs by 5’ capping, splicing, 3’ polyadenylation and sometimes editing and methylation, 
during or shortly after transcription by RNA polymerase II [1–3]. Nuclear export of mature 
mRNA is thereafter the next posttranscriptional step and a pivotal event in the regulation 
of gene expression [2,4]. Proper execution of this entire sequence of events is an important 
aspect of quality and quantity control in the flow of information from DNA to RNA to protein. 
Earlier studies have revealed that a considerable fraction of poly(A) RNA is being retained in 
the nucleus and never reaches the cytoplasm [5]. It took several decades, however, before 
it was recognized that selective nuclear export of poly(A) RNA offers unique possibilities for 
quality control, to prevent mRNA from being prematurely released and translated [6–8].
During successive steps of mRNA maturation, multiple RNA-binding proteins 
variably decorate the (pre-)mRNA and engage the transcript in the formation of 
ribonucleoprotein (RNP) complexes [9]. These RNP complexes can further assemble in 
larger structures, sometimes termed nuclear bodies, that appear as liquid-phase droplets 
that form and dissociate by intracellular phase separation [10,11]. At later moments in the 
maturation process, export adaptors bind to establish a physical bridge between mRNA and 
export receptors, ultimately leading to transport of the mRNA to the cytoplasm through the 
nuclear pore [12,13]. 
 Length of the poly(A) tail is a critical parameter in the nuclear and in the cytoplasmic 
phase of an mRNA’s life cycle. On human mRNAs, tails were assumed to consist of 150-250 
adenosine nucleotides, but new evidence points to a much shorter median tail length of 50-
100 A residues for the majority of mRNAs, lengths of >250 nucleotides being rare [14–16].
Polyadenylation and deadenylation both occur in the nucleus and in the cytoplasm 
[17,18]. Nuclear polyadenylation is functionally and structurally coupled to splicing of the 
terminal intron [19,20]. Poly(A) tails thus formed serve as binding platform for protein factors 
and are involved in nuclear surveillance that controls abundance and nucleocytoplasmic 
export of fully processed mRNAs [21,22]. In the cytoplasm, the poly(A) tail is involved in 
regulation of translation efficiency [23,24] and specification of mRNA fate [25,26]. Elongation 
of poly(A) tails of specific mRNAs may occur in the cytoplasm, for example in neurons when 
localized expression is required and in germ cells and early development when transcription 
is silenced [18].
Deadenylation in both nuclear and cytoplasmic compartments is usually coupled 
to mRNA stability, since the major exonuclease-dependent mRNA decay pathway starts 
with shortening of the poly(A) tail [26]. Short poly(A) tails are not always a signal for decay, 
however, as non-coding RNAs are known in which a terminal triple helix structure is formed 
that uses an oligo(A) tail to provide stability [27]. The converse situation, existence of long 
tails formed by hyperadenylation, has also been observed and is thought to be associated 
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with impaired nucleocytoplasmic export or RNA decay [16]. Whether a long poly(A) tail is 
the cause or the consequence of nuclear retention is still unclear [28–32].
 In myotonic dystrophy type 1 (DM1), disease-related DMPK transcripts are retained 
in the nucleus [33], triggered by the presence of a long (CUG)n triplet repeat expansion in 
their 3’ untranslated region (UTR) [34]. Members of the muscleblind-like family (MBNL1-
3), DEAD-box helicases and hnRNP proteins associate with this expanded (CUG)n repeat 
[35,36]. In turn, this mechanism causes abnormal sequestration of protein factors in RNP 
complexes, with consequences for faithful nuclear maturation steps of other mRNAs, like 
alternative splicing and polyadenylation, and processing of miRNAs [36,37]. Nuclear DMPK 
(CUG)n RNA retention and aberrant binding in RNP complexes in DM1 tissues are thus 
tightly coupled processes, as is also manifested by the formation of ribonuclear inclusions, 
commonly referred to as RNA foci for their appearance in RNA fluorescence in situ 
hybridization using (CAG)n probes or indirect immunofluorescence assays with anti-MBNL 
antibodies [33,38,39].
For the study presented here, we hypothesized that expanded DMPK (CUG)n 
transcripts might be hyperadenylated because of their retention in the cell nucleus. About 
the fate of normal DMPK mRNAs from unaffected individuals we had no biased idea and 
therefore decided to include both types of DMPK mRNAs in a parallel study of poly(A) length 
and nuclear residence. Until now, literature on polyadenylation of (CUG)n-expanded DMPK 
transcripts is scarce and contradictory findings have been published [40–42].
We report here that the nuclear/cytoplasmic distribution ratio of normal DMPK 
transcripts appeared much higher than for RNAs from housekeeping genes like GAPDH and 
ACTB, with ~30% or more of the total population still being in the nucleus. In line with 
earlier observations, the population of mutant DMPK mRNAs with long (CUG)n expansions 
was found almost exclusively in the nucleus (~90%) in our cells with a long mutant DMPK 
allele. Apparently, these differential distribution profiles were not overtly associated with 
differences in length of the poly(A) tails as both normal and expanded DMPK mRNAs 
displayed a similarly broad range of poly(A) tail lengths, ranging between 0 and >500 
nucleotides (between 200 to up to 500 in the nucleus). We therefore conclude that the 
dominant effects that (CTG)n repeat expansion has on residence time have no bearing on 
poly(A) tail lengths of DMPK RNAs. 
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Materials and Methods
Human material
Human tissue material was obtained from preconsented post-mortem donors for research 
purposes in accordance with local guidelines. No additional approval by an ethics committee 
was required at that time (~18 years ago). Heart and psoas muscle autopsies were obtained 
from a congenital DM1 twin with a confirmed clinical and DNA diagnosis related to an 
expanded DMPK (CTG)n repeat of about 1300 triplets (normal alleles contained 5 and 12 
triplets, respectively). Tissues were snap frozen immediately after collection and stored 
between minus 80 and 135°C until further use. A skeletal muscle sample from an unaffected 
anonymous donor ((CTG)11/(CTG)12) from our own repository was included in the study. 
This sample was collected long before the current guidelines for written consent were 
enforced and no detailed information could be traced.
Cell culture
Immortalized human LHCN-M2 myoblasts ((CTG)5/(CTG)5) [43] and DM11 cl5 myoblasts 
((CTG)13/(CTG)2600) [44] were a gift of Drs V. Mouly and D. Furling. Myoblasts were grown 
on 0.1% (w/v) gelatin-coated dishes in skeletal muscle cell basal medium (PromoCell) 
with Supplement Mix (0.05 mL/mL fetal calf serum, 50 µg/mL bovine fetuin, 10 ng/mL 
recombinant human epidermal growth factor, 1 ng/mL recombinant human basic fibroblast 
growth factor, 10 µg/mL recombinant human insulin, 0.4 µg/mL dexamethasone; PromoCell) 
supplemented with 1% (v/v) GlutaMax and 15% (v/v) bovine growth serum (Thermo 
Scientific) at 7.5% CO2 and 37°C. 
Primary DM1 myoblasts ((CTG)13/(CTG)800), also a gift of Dr. D. Furling [45], were 
grown on 0.1% (w/v) gelatin-coated dishes in Ham’s F10 medium (Gibco) supplemented 
with GlutaMax and 20% (v/v) bovine growth serum (Thermo Scientific) at 7.5% CO2 and 
37°C.
RNA isolation and subcellular fractionation
Total RNA from muscle tissue and cultured cells was isolated using TRIzol reagent (Invitrogen) 
and Aurum Total RNA Mini Kit (Bio-Rad), respectively, according to manufacturer’s 
instructions. Ethidium bromide staining of isolated RNA on agarose gel always demonstrated 
distinct 28S and 18S rRNA signals. 28S/18S ratios for RNA isolated from long-frozen psoas 
and heart tissue were 2.2 ± 0.4 (n=6).
For RNA isolation from subcellular fractions, myoblast cultures were grown to 80% 
confluence, collected by trypsinization and pelleted by centrifugation at 1,000 x g for 5 min 
at 4°C. Pellets were washed twice with ice-cold PBS. The cell pellet was resuspended in ice-
cold cell disruption buffer [46] (hypotonic solution with 10 mM KCl, 1.5 mM MgCl2, 20 mM 
Tris-Cl (pH 7.5), 1 mM DTT) and incubated on ice for 10 minutes. Cells were homogenized 
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with a chilled Dounce homogenizer (tight pestle, 0.025-0.076 mm; Wheaton) for 15 strokes 
and then a final concentration of 0.1% Triton X-100 was added. The lysate was spun at 1,500 
x g for 5 min at 4°C. The supernatant (cytoplasmic fraction) and the pellet (nuclear fraction) 
were each diluted in lysis buffer belonging to the Aurum Total RNA Mini Kit and RNA was 
isolated according to manufacturer’s protocol.
SDS-PAGE and western blotting
Proteins in the subcellular fractions were resolved on 10% SDS-PAGE gel and electrotransferred 
to PVDF membrane (Amersham GE Healthcare). Membranes were blocked with 3% bovine 
serum albumin in PBST (PBS with 0.1% Tween-20) and incubated overnight with lamin A+C 
antibody (ab40567, Abcam), β-tubulin monoclonal antibody (E7, Developmental Studies 
Hybridoma Bank, University of Iowa, USA) diluted in the same buffer. After washing in PBST, 
blots were incubated with appropriate fluorescently labeled secondary antibodies and 
washed in PBST and PBS. Signals were detected using the Odyssey® Infrared Imaging System 
(LI-COR Biosciences).
RNA extraction from gel
For size fractionation of RNA via agarose gel electrophoresis, total RNA was denatured at 
70°C for 10 minutes in 50% (v/v) deionized formamide and 1x MOPS, and supplemented to an 
end concentration of 13 ng/μL ethidium bromide, 4.2% (w/v) Ficoll PM 400 and 0.07% (w/v) 
bromophenol blue. RNA was loaded onto a MOPS-buffered 1% agarose gel and run until 28S 
and 18S rRNAs were clearly separated. We had to work without formaldehyde in the gel to 
avoid chemical modification of RNA [47] that would impede downstream applications such 
as RT-PCR. Absence of formaldehyde could leave RNA partially folded during electrophoresis 
and especially expanded DMPK mRNAs might form different topological structures and 
migrate anomalously. For our assay, however, structure effects on DMPK RNA migration 
appeared not to be a confounding problem and RNA migrated at expected positions in 
size ladders (Suppl. Fig. S1). After electrophoresis, the gel was cut across the position of 
28S rRNA and top (RNA size >~5 kb) and bottom (RNA size ~0.1-~5 kb) gel sections were 
collected (illustrated in Fig. 1), from which RNA was extracted using the ZymoClean™ Gel 
RNA Recovery Kit (ZymoResearch) according to manufacturer’s instructions. Briefly, gel 
slices were dissolved in RAD Buffer™ at 55°C and transferred to a silica membrane spin 
column to allow RNA binding. After several washing steps, RNA was eluted from the column 
in water. Successful top-bottom fractionation was verified by running RNA aliquots on a 1% 
MOPS-buffered agarose gel.
RNase H assay
DMPK and GAPDH mRNAs were trimmed at specific locations using RNase H to allow for 
a measurable shift in electrophoretic mobility depending on poly(A) tail length, according 
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to a protocol described by Murray and Schoenberg [48]. Per reaction, an equivalent of 
5-35 µg total RNA was mixed with 5 pmol DMPK primer (5’-GCACTTTGCGAACCAACG-3’), 
5 pmol GAPDH primer (5’- CTGCTTCACCACCTTCTTGATGTCATC-3’) and optionally 5 pmol 
(dT)18 (5’-TTTTTTTTTTTTTTTTTT-3’) in a final volume of 25 µL. Per sample, 10 units RNase 
H (Ambion), 30 units RNaseOUT™ (Invitrogen) and RNase H buffer were added to a final 
concentration of 20 mM HEPES-KOH (pH 8), 50 mM KCl, 4 mM MgCl2 and 1 mM DTT. The 
reaction was incubated at 37°C for 1 hour and terminated via addition of 1 µL 0.5 M EDTA. 
RNA was purified by organic extraction using phenol chloroform (1:1) and precipitated in 
NaAc (pH 5) and ethanol.
Poly(A) RNA selection
Poly(A)-selected RNA was isolated from total RNA using the NucleoTrap® mRNA kit 
(Macherey-Nagel). In short, total RNA was incubated with oligo(dT) latex beads, allowing 
binding of the beads to poly(A) tails of transcripts. After several washing steps using a 
microfilter to trap the latex beads, poly(A)-selected RNAs were eluted from the beads in 
water. Size-fractionated CDM RNA in which DMPK mRNAs were specifically trimmed with 
RNase H was also subjected to poly(A) selection. To minimize the amounts of processed 
CDM RNA required for input in the procedure, mouse total RNA was mixed in and used as 
carrier RNA.
Poly(A) fractionation
Total RNA was fractionated with respect to poly(A) tail length, based on a protocol described 
by Meijer et al [14] and the PolyATtract® mRNA Isolation System (Promega). Total or size-
fractionated RNA (24-30 µg in 185 µL), with DMPK and GAPDH transcripts trimmed using 
the RNase H assay, was denatured at 65°C for 10 minutes. 20x SSC (Promega) was added 
to a concentration of 1x SSC and biotinylated oligo(dT) (Promega) was added to a final 
concentration of 9.4 pmol per µg total RNA. The solution was gently mixed and incubated at 
room temperature until completely cooled. Streptavidin-paramagnetic particles (Promega) 
were washed three times with 0.5x SSC and resuspended in 1x SSC. Each RNA sample was 
added to 600 µL particles and incubated at room temperature while rotating. The unbound 
fraction was collected after 10 minutes. Beads were washed three times in 0.5x SSC, followed 
by elution of poly(A)-selected RNA using buffers containing decreasing concentrations of 
SSC. Beads were kept rotating in between elution steps for at least 5 minutes. All elution 
steps were performed at room temperature. All fractions were saved, stored on ice and 
ultimately precipitated in presence of 10 µg yeast tRNA as carrier in NaAc (pH 5) and ethanol.
Northern blotting
Northern blotting was performed according to standard procedures. Per lane, an 
equivalent of 10 µg total RNA, denatured in 50% (v/v) deionized formamide and 6.7% 
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(w/w) formaldehyde, was subjected to electrophoresis in a 1.2% agarose gel with 6.7% 
(w/w) formaldehyde. RNA was transferred to Hybond-XL nylon membrane (Amersham 
Pharmacia Biotech), by capillary transfer in 10x SSC and then the blot was UV crosslinked 
(Stratalinker® UV Crosslinker, Stratagene). The northern blot was hybridized with random-
primed 32P-labeled probes (2.6 kb DMPK cDNA, covering the entire ORF and 3’ UTR, and the 
complete 1.9 kb 18S rRNA cDNA). Hybridization was carried out in Church-Gilbert buffer 
(0.25 M Na2HPO4 (pH 7.2), 7% (w/v) SDS, 1 mM EDTA (pH 8.0)).
 RNase H-trimmed DMPK and GAPDH RNAs were visualized using an alternative 
northern blotting procedure. Per lane, an equivalent of 5-35 µg total RNA, denatured in 
50% (v/v) deionized formamide, was subjected to electrophoresis in a 1x TBE-buffered 4% 
polyacrylamide gel with 8 M urea. RNA was blotted to Hybond-XL nylon membrane by semi-
dry electrophoretic transfer (Trans-Blot® SD Cell, Bio-Rad). The blot was UV crosslinked and 
hybridized with random-primed 32P- labeled probes (a cDNA fragment representing the 3’ 
terminal 335 nucleotides of DMPK exon 15 and a 1.2 kb GAPDH cDNA, covering the entire 
ORF and parts of the flanking UTRs) or a 32P-end-labeled oligonucleotide complementary to a 
segment in the 3’ UTR of GAPDH (5’-CATGAGGTCCACCACCCTGTTGCTGTAG-3’). Hybridization 
was done in 6x SSC, 10x Denhardt’s reagent [49] (0.2% bovine serum albumin, 0.2% Ficoll 
400, 0.2% polyvinylpyrrolidone), 0.2% SDS and 100 µg/mL herring sperm DNA. Signals from 
both northern blot assays were visualized by Phosphor-Imager analysis (Molecular Imager 
FX, Bio-Rad) and analyzed with Quantity One (Bio-Rad) and FIJI software [50].
RT-PCR
RNA was reverse transcribed using the iScript™ cDNA Synthesis Kit (Bio-Rad). For analysis 
of size-fractionated total and poly(A)-selected RNA, an equivalent of 500 ng total RNA was 
used as input. For analysis of nuclear and cytoplasmic RNA samples, 500 ng cytoplasmic RNA 
and an equivalent of nuclear RNA was used as input. For qPCR, 3 µL 10-50-fold diluted cDNA 
preparation was mixed in a final volume of 10 µL containing 5 µL iQ™ SYBR® Green Supermix 
(Bio-Rad) and 4 pmol of each primer (ACTB ex2-ex3, 5´-CGGGCCGTCTTCCCCTCCAT-3´ 
and 5´-TGGGCCTCGTCGCCCACATA-3´; ACTB in2-ex3, 5’-CGTGCTCAGGGCTTCTTGTC-3’ 
and 5’-CCTCGTCGCCCACATAGGAA-3’; DMPK ex1-ex2, 5´-ACTGGCCCAGGACAAGTACG-3´ 
and 5´-CCTCCTTAAGCCTCACCACG-3´; DMPK ex15 5’ from (CUG)n repeat, 
5’-AGAACTGTCTTCGACTCCGGG-3’ and 5’-TCGGAGCGGTTGTGAACTG-3’; DMPK ex15 3’ from 
(CUG)n repeat, 5’-TGCCTGCTTACTCGGGAAATT-3’ and 5’-GAGCAGCGCAAGTGAGGAG-3’; 
GAPDH ex1-ex2, 5’-CCCGCTTCGCTCTCTGCTCC-3’ and 5’-CCTTCCCCATGGTGTCTGAGCG-3’). 
Samples were analyzed using the CFX96 Real-time System (Bio-Rad). A melting curve was 
obtained for each sample in order to confirm single product amplification. Samples from no-
template and no-reverse transcriptase reactions were included as negative controls.
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PCR on DMPK splice isoforms
For analysis of DMPK isoform abundance, a semi-quantitative PCR using Q5® High-Fidelity 
DNA Polymerase (NEB) was performed on cDNA, including a no-reverse transcriptase 
control. Four regions of DMPK were analyzed: ex1-ex7 (5’-CGAACTGGCCCAGGACAAGTA-3’ 
and 5’-TACACCCAGCGCCCACCAGT-3’) [51], ex7-ex9 (5’-ACGGCGGAGACCTATGGCAA-3’ and 
5’-TCCCGAATGTCCGACAGTGT-3’) [51], ex9-ex12 (5’-CTGTCGGACATTCGGGAAGGT-3’ and 
5’-CAACTCCATCCGCTCCTGCAA-3’) and ex12-ex15 (5’-GAACCGGGACCTAGAGGCACACGT-3’ 
and 5’-TCGGAGCGGTTGTGAACTG-3’). PCR products were visualized after electrophoretic 
separation on a 2-3% agarose gel by staining with ethidium bromide followed by image 
analysis using FIJI software. 
RT reaction and PCR across poly(A) tail
To determine poly(A) tail length using an RT-PCR approach, 10 or 50 pmol (dT)10 adapter 
primer (5’-GGGGATCCGCGGTTTTTTTTTT-3’) [48] was mixed with 500 ng total RNA and 
allowed to anneal. Primers on polyadenylated RNAs were then extended by reverse 
transcription using SuperScript III Reverse Transcriptase (Life Technologies). cDNAs thus 
formed were used as template in a PCR, using Q5® High-Fidelity DNA Polymerase (NEB), with 
a DMPK (5’-TGCCTGCTTACTCGGGAAATT-3’) or GAPDH (5’-CATGTAGACCCCTTGAAG-3’, Bioo 
Scientific) forward primer. No additional reverse primer was added, so the (dT)10 adapter 
primer from the RT reaction functioned as reverse primer. cDNA samples from no-template 
control and no-reverse transcriptase control were included. PCR fragments were separated 
on an ethidium-bromide stained 1.5-3% agarose gel. Additionally, PCR products were 
transferred to Hybond-XL nylon membrane (Amersham Pharmacia Biotech) and hybridized 
with 32P-end-labeled oligonucleotides (DMPK, 5’-TCAGCGAGTCGGAGGACGAGG-3’; (dT)18, 
5’-TTTTTTTTTTTTTTTTTT-3’). Signals were visualized by Phosphor-Imager analysis and 
analyzed with Quantity One (BioRad) and FIJI [50] software.
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Results
Separation of normal and triplet repeat expanded DMPK transcripts
To investigate differential effects of (CTG)n-repeat length on polyadenylation of DMPK 
transcripts, we developed a size fractionation method to independently analyze normal 
and expanded DMPK mRNAs, as they occur in RNA isolated from DM1 cells (Fig. 1). A 
complicating factor in this procedure may seem the length heterogeneity in the population of 
DMPK mRNAs, which is a mix of alternatively spliced transcripts [52,53]. This heterogeneity 
is fortunately not a concern for the analysis of RNA from cells of patients with classical 
or congenital DM1. Their cells carry large (CTG)n repeat expansions, causing the (CUG)n 
repeat tract in mutant DMPK transcripts to contribute more to mRNA length variation than 
alternatively spliced exon sequences. The total mix of DMPK mRNAs in DM1 cells with long 
repeat expansion can thus be broken up into two distinct populations, having either normal 
or expanded repeat tracts and non-overlapping length distributions. We expected DMPK 
mRNAs with repeats >800 triplets to move slower than 28S rRNA (~5 kb), whereas normal 
DMPK mRNAs would migrate between the 18S (~2 kb) and 28S rRNA size markers.
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Figure 1. Size separation of normal and expanded DMPK transcripts. Workflow of the size-fractionation 
method based on differential migration of transcripts in agarose. Heat- and formamide-denatured psoas 
muscle RNA from a CDM patient (input, In) was electrophoresed on agarose gel (1), followed by excision of 
the desired gel fragments guided by migration of 28S rRNA (2). Each lane was sliced in two fractions, one 
containing RNA that migrated slower than 28S rRNA (Top) and the other containing RNA that migrated faster 
than 28S rRNA (Bottom, Bot). RNA was then extracted from the gel slices (3). Recovered RNA from the two 
fractions was analyzed on an ethidium bromide-stained agarose gel using UV exposure to visualize rRNA (4) 
and on northern blot using hybridization with a DMPK probe (5).
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To validate our fractionation method, we subjected RNA from muscle tissue from a 
congenital DM1 (CDM) patient with (CTG)12/1300 alleles to agarose gel electrophoresis. Our 
results confirmed that the migration of 28S rRNA indeed formed a convenient demarcation 
point (Suppl. Fig. S1). Normal and expanded DMPK transcripts were separated and faithfully 
represented among the RNAs that migrated faster (Bottom fraction) or slower (Top fraction) 
than 28S rRNA (Fig. 1). A silica-membrane-based purification method for recovery of RNA 
from the gel slices proved to be highly efficient. The long (CUG)n repeat had no detectable 
influence on RNA yield (unpublished data).
Normal and expanded DMPK transcripts are similarly spliced in DM1 tissues
Nuclear polyadenylation is strongly coupled to splicing of the last intron [19,20]. In fact, 
the 3’ end of DMPK pre-mRNA is subject to developmentally regulated and tissue-specific 
alternative splicing [52,54]. Since this situation might thus be coupled to poly(A) site choice 
or polyadenylation efficiency, we examined whether DMPK mRNA splice modes were 
altered in cis by (CTG)n repeat length. RT-PCR analysis of size-fractionated RNA preparations 
from heart and psoas muscle from a CDM patient revealed that there existed essentially 
no difference between splicing profiles of normal and expanded DMPK transcripts (Fig. 2). 
Furthermore, we found no evidence for alternative poly(A) site choice in DMPK mRNA from 
own experimental data nor bioinformatic analyses in databases (unpublished data). Taken 
together, these data indicate that splice changes do not contribute to 3’ end sequence 
differences or overall size changes in the population of normal and expanded DMPK 
transcripts in DM1 cells.
(CUG)n repeat length influences oligo(dT)-mediated poly(A) RNA selection
To assess whether poly(A) tail length of normal and expanded DMPK mRNAs might 
be different, we subjected RNA from CDM patient heart and psoas muscle to poly(A) 
selection using oligo(dT) beads. Northern blot analysis demonstrated that 18S rRNA was, 
as anticipated, completely absent in the poly(A)-selected RNA fraction (Fig. 3A,B). A DMPK 
probe showed that normal DMPK transcripts (~2.8 kb) were efficiently (75-95%) recovered 
in the poly(A)-selected fraction, in contrast to expanded DMPK transcripts (~7 kb; 40-60%). 
One explanation for this observation would be that only a fraction of expanded DMPK 
mRNAs was polyadenylated. More likely, a considerable portion of the long expanded 
DMPK mRNAs was broken during experimental handling and only poly(A) tail-containing 
3’ fragments of variable size were captured by the beads. Influence of the expanded (CUG)
n repeat on oligo(dT) binding avidity, caused by topological constraints in the expanded 
transcripts, could not be excluded at this point.
In an alternative approach, we started with separation of intact normal and 
expanded DMPK transcripts by size fractionation. Cleavage by RNAse H at a site downstream 
of the (CUG)n repeat was subsequently used to separate the 5’ ends of the transcripts, 
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including the (CUG)n repeat, from the 3’ ends carrying the poly(A) tails under investigation 
(Fig. 3C,D). Poly(A) selection by binding to oligo(dT) beads was subsequently performed 
for each size fraction. DMPK-specific sequences in the bottom and top fractions and in the 
poly(A)-selected cleaved RNA fragments were monitored by RT-qPCR, using amplicons 5’ 
and 3’ of the RNase H-cleavage site (Fig. 3D). The 3’ amplicon indeed gave similar yields for 
normal and expanded DMPK transcripts in poly(A)-selected fractions (Fig. 3E). Signals from 
the 5’ amplicon were completely absent after oligo(dT) selection, as expected. Total yield 
was low for both DMPK RNAs but also for GAPDH mRNA, included as a control. Combined, 
these data indicate that equal fractions of normal and expanded DMPK mRNAs bear a 
poly(A) tail.
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Figure 2. Normal and expanded DMPK transcripts are similarly spliced in DM1 heart and skeletal muscle. 
(A) RT-PCR analysis of the DMPK splice isoform ratios in total RNA (Total) and size-separated fractions (see 
procedure Fig. 1), representing mature expanded DMPK RNA (Top) and mature normal DMPK RNA (Bot) 
from CDM heart and psoas muscle. No-reverse transcriptase (RT-) control was included. Known DMPK splice 
isoforms are indicated with numbered boxes indicating exons. (B) Quantification of signals in (A) for the two 
alternatively spliced regions exon 7 - exon 9 and exon 12 - exon 15. Alternative 5’ and 3’ splice sites related 
to exon 8 (15 nt) and exon 14 (4 nt) are indicated as 8Δ and Δ14, respectively.
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DMPK transcripts have a long residence time in the nucleus
Next, we investigated the relationship between poly(A) tail length and subcellular localization 
of DMPK mRNAs. We used cultured myoblasts, since reliable cell fractionation of nuclear 
and cytoplasmic content is difficult to perform on muscle tissue [46]. Unaffected LHCN 
(CTG)5/5 myoblasts and DM1 myoblasts with (CTG)13/800 or (CTG)13/2600 DMPK alleles 
were separated in nuclear and cytoplasmic fractions, followed by RNA extraction. Western 
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Figure 3. Expanded (CUG)n repeat length negatively influences RNA yield in poly(A)-RNA selection. 
(A) Total and poly(A)-selected (pA+) RNA from heart and psoas muscle from a CDM patient, analyzed by 
northern blotting using probes against DMPK (top panels) and 18S rRNA (bottom panels). * Migration of 
28S rRNA for orientation. (B) Quantification of signals in (A) for normal (white bars) and expanded (black 
bars) DMPK transcripts and 18S rRNA as control (gray bars), visualized as poly(A)+ fraction recovered from 
total RNA. Bars represent mean + SEM (n=2). (C) Workflow to analyze DMPK RNA polyadenylation status 
without (CUG)n-repeat length as a confounding factor in oligo(dT)-mediated poly(A)-selection. (D) Scheme 
representing DMPK exon 15 with positions of the RNase H cutting site and PCR amplicons 5’ and 3’ from 
(CUG)n repeat. (E) RT-qPCR analysis on size-fractionated, RNase H-trimmed, poly(A)-selected CDM psoas 
muscle RNA (bottom fraction, normal DMPK RNA, white bar; top fraction, expanded DMPK RNA, black bar) 
visualized as poly(A)+ fraction recovered from total RNA. GAPDH RNA was included for reference (bottom 
fraction; gray bar).
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blot analysis demonstrated successful cell fractionation: β-tubulin protein was strongly 
enriched in the cytoplasmic fraction (>85%), whereas lamin A and lamin C appeared almost 
exclusively in the nuclear fraction (>95%; Suppl. Fig. S2).
 A relatively large fraction of DMPK (CUG)5 transcripts was localized in the nucleus 
(~30%; Suppl. Fig. S3), compared to the situation for transcripts from regular housekeeping 
genes ACTB and GAPDH (~10%). In DM1 myoblasts, a higher proportion of DMPK mRNA 
molecules was nuclear (~60%; Suppl. Fig. S3). This higher percentage represents the 
superimposed behavior of normal and expanded DMPK RNAs, the latter of which almost 
exclusively reside in the nucleus [40,41]. Combined with the data from LHCN cells, we 
conclude that in patient cells 20-30% of normal and 90-100% of expanded DMPK transcripts 
localize in the nucleus.
Poly(A) tails of DMPK mRNAs in myoblasts show a broad length distribution
To measure poly(A) tail length of DMPK mRNA and draw a comparison with the poly(A) 
tail length of GAPDH mRNA, we used RNAse H cleavage to produce relatively small 3’ end 
fragments of ~400 nt + poly(A) tail. Variation in poly(A) length on such small fragments would 
cause a relatively major shift in mobility, easily detectable on northern blot. For reference, 
a (dT)18 primer was included during cleavage to completely remove the poly(A) tail in some 
samples. Next to the nuclear cytoplasmic fractionation, RNA from DM1 myoblasts was also 
size-fractionated to allow for separate measurement of tails of normal and expanded DMPK 
mRNAs (Fig. 4A).
A smear of fragments representing a broad heterogeneity in poly(A) tail length for 
DMPK RNA was observed for both normal and DM1 samples (Fig. 4B-D). Discrete bands 
matching the expected size of the DMPK RNA 3’ end were only visible after treatment with 
the (dT)18 primer. To our surprise, we observed only a minor difference in poly(A) tail length 
distribution between nuclear and cytoplasmic DMPK transcripts. Nuclear DMPK mRNAs 
primarily carried long poly(A) tails in the 200-500 nt range, whereas the poly(A) tail length 
distribution of cytosolic DMPK mRNAs extended more towards shorter lengths in the 50-500 
nt range. Also in DM1 cells, poly(A) tails on DMPK RNA were long, up to >500 nt, with only 
marginal differences between length profiles of normal and expanded DMPK transcripts 
(Fig. 4C,D). The poly(A) tail length distribution of GAPDH mRNA showed a more restricted 
range around 25-200 nt.
To verify these poly(A) tail length measurements, we also used a dedicated RT-PCR 
approach [48]. Total RNA from unaffected myoblasts was subjected to reverse transcription 
using a (dT)10 adapter primer, which could hybridize anywhere along the poly(A) tail. PCR 
amplification using the same (dT)10 oligonucleotide as reverse primer and a DMPK- or 
GAPDH-specific forward primer produced a smear of products on blot, reflecting the familiar 
length heterogeneity of poly(A) tails (Suppl. Fig. S4). Although this analysis is somewhat 
biased, because shorter poly(A) tails form shorter amplicons and get preferentially amplified, 
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it clearly supports the remarkable length distribution of DMPK mRNA poly(A) tails in actively 
proliferating myoblasts.
DMPK mRNA poly(A) tails in DM1 muscle also show the unusually broad length distribution
We sought to confirm that this atypical broad poly(A) length profile is representative 
for DMPK mRNAs in muscle tissue in vivo, i.e. in noncycling cells in the G0-phase. The 
polyadenylation status of DMPK mRNAs was therefore studied in skeletal muscle from a 
CDM patient. Combined use of RNA size fractionation, RNase-H mediated trimming and 
gel electrophoresis confirmed the broad distribution of poly(A) tail lengths on both normal 
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Figure 4. DMPK transcripts in nucleus and cytoplasm of unaffected and DM1 myoblasts contain a long 
poly(A) tail. (A) Workflow to determine poly(A) tail length of DMPK and GAPDH transcripts in nuclear (Nucl) 
and cytoplasmic (Cyt) fractions of DM1 myoblasts. RNA was subjected to an RNase H assay (see Fig. 3D) 
with (w/) and without (w/o) (dT)18 primer and analyzed on northern blot. (B) Poly(A) tail length analysis of 
DMPK and GAPDH transcripts in unaffected myoblasts as described in (A), except that the size-based RNA 
separation step could be omitted for this cell type. Defined fragments for DMPK (~350 nt) and GAPDH (~430 
nt) transcripts were observed in the presence of (dT)18 primer (i.e., without poly(A) tail, 0 As). A broad 
smear characteristic for poly(A) tail length heterogeneity was observed in absence of (dT)18, illustrated 
with a plot profile on the right (colors correspond with colors above the lanes) and an poly(A) tail length on 
the left. (C,D) Northern blot analysis of the procedure described in (A) for DMPK and GAPDH transcripts in 
13/800 and 13/2600 DM1 myoblasts.
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and expanded DMPK transcripts (Fig. 5). Alike in RNA isolated from proliferating myoblasts, 
poly(A) tail lengths of 0 to >500 nucleotides were identifed, whereas GAPDH RNA from the 
same muscle contained poly(A) tails of 0-200 nucleotides.
To verify these observations we applied poly(A) fractionation based on differential 
binding to oligo(dT) beads, proportional to tail length [14]. Total RNA was RNase-H trimmed, 
mixed with biotinylated (dT)n primer to allow hybridization with poly(A) tails, after which 
streptavidin-coated beads were used to capture oligo(dT)-bound transcripts. Poly(A)+ 
RNA was eluted in fractions using buffers of decreasing salt concentration. Application 
of this procedure to RNA from CDM heart corroborated the broad distribution of poly(A) 
tail lengths of DMPK RNAs, with a range of 0 to >650 nucleotides, whereas tails of <200 
nucleotides were found for GAPDH transcripts (Fig. 5B). In CDM skeletal muscle, similar 
profiles were observed for normal and expanded DMPK transcripts, with the longest poly(A) 
tails appearing on expanded DMPK mRNAs, thus corroborating our findings with the other 
approaches (Fig. 5C).
Discussion
RNA toxicity due to expression of a mutant DMPK allele with an expanded (CTG)n 
trinucleotide repeat is seen as the main trigger for pathobiology in DM1 [55]. To understand 
how this toxicity leads to compromised cell function, detailed study is needed of possible 
differential mechanistic events involved in fate specification of expanded versus normal 
DMPK transcripts. Each type of transcript may follow entirely different routes through the 
nucleus, triggered by RNA topology and decoration with RNA-binding proteins, potentially 
dependent on length of the (CUG)n tract. Previous studies on DMPK mRNA production 
have already made clear that long DMPK transcripts remain predominantly trapped in the 
nucleus, while normal DMPK mRNAs are exported to the cytosol to be translated [33,36,40].
Here we deconvoluted the complexity of DMPK RNA fate, through analysis on 
polyadenylation of expanded and normal DMPK mRNA copies. Based on prior evidence 
on DMPK expression and data on the relationship between polyadenylation and nuclear 
residence of other RNAs [29–31], we aimed to reveal a possible correlation between 
poly(A) tail length and nuclear retention. Moreover, we hoped to learn whether presence 
of a (CUG)n expansion would exert cis effects on polyadenylation of DMPK mRNA. It had 
already been reported that expanded DMPK transcripts do undergo polyadenylation, but 
these findings were not conclusive [40–42]. Besides, data on poly(A) tail length distribution 
of DMPK mRNAs and effects of (CUG)n repeat expansion or intracellular distribution were 
not provided in these reports.
We applied combinations of basic methods to separate normal and expanded 
DMPK transcripts and to isolate nuclear and cytoplasmic RNA. Size fractionation based on 
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differential RNA migration behaviour under partially denaturing conditions enabled us to 
discriminate between mature normal and expanded transcripts in DM1 cells. Any length 
heterogeneity as a result of alternative DMPK splice modes [52,53] were compensated for 
by the long (CUG)n repeat. We estimate that any defined expansion of >300 triplets (i.e. 
~1000 nt length difference) would enable us to perform separation of normal and expanded 
transcripts. This method may therefore also be applicable for separating transcripts in 
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Figure 5. DMPK transcripts in CDM skeletal muscle and heart also contain a long poly(A) tail. (A) Northern 
blot analysis of RNase H assay on DMPK and GAPDH transcripts in size-fractionated RNA from CDM psoas 
tissue. RNase H assay was performed in presence (w/) and absence (w/o) of (dT)18 primer. Normal 
(Bottom, Bot) and expanded (Top) DMPK transcripts were analyzed separately. GAPDH transcripts served 
as reference. A plot profile is indicated on the right (colors correspond with colors above the lanes). (B,C) 
Northern blot analyses of poly(A)-fractionation assays using RNase H-trimmed RNA from CDM heart (B) and 
size-fractionated RNA from CDM psoas (C). RNAs were subjected to oligo(dT)-affinity chromatography and 
eluted with decreasing salt concentrations. Normal (Bottom, Bot) and expanded (Top) DMPK transcripts 
were analyzed separately in (C). Approximate poly(A) tail lengths are indicated on the left. GAPDH transcripts 
served as reference.
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other repeat disorders, provided that the corresponding expansion makes up for other 
heterogeneities in the transcript population, e.g. caused by alternative transcription 
initiation, splicing or polyadenylation.
For our comparative analysis we chose proliferating myoblasts (control and DM1) 
and skeletal and cardiac muscle biopsies from CDM patients with relatively large expansions. 
These cells and tissues are particularly relevant for the muscle and heart problems in DM1 
patients. Also, somatic instability is essentially absent in proliferating myoblasts and cannot 
yet have been very active in young CDM tissues, ensuring DMPK RNA populations with 
relatively defined (CUG)n repeat length (compare expanded DMPK RNA smears from adult 
tissues on blots in [56]).
 Mature mRNAs generally carry poly(A) tails with lengths that range between 
0 and 200 residues [14,57]. This range is in accordance with what we and others [28] 
have determined for the poly(A) tail of GAPDH mRNA. For DMPK mRNAs we observed a 
significantly broader range, between a few and >500 As. Although tails of several hundreds 
of As are unusual for most mRNAs, they have been observed for other RNAs, including 
nuclear long noncoding RNAs NEAT1 and XIST [28]. Since polyadenylation normally occurs 
in the nucleus and deadenylation mainly takes place in the cytoplasm, the distribution of 
poly(A) tail lengths may provide clues on transcript routing and residence in these two 
cellular compartments. Our observation that DMPK mRNA isolated from myoblast nuclei had 
slightly more uniform and longer poly(A) tails than cytoplasmic DMPK mRNA is in keeping 
with the idea that polyadenylation of DMPK transcripts follows the normal processing route.
 A fairly large percentage (~30%) of the pool of normal DMPK transcripts had a 
nuclear location, much more than observed for ACTB and GAPDH transcripts. Either 
rapid cytoplasmic decay or slow nuclear processing and export may explain this unusual 
distribution profile. We consider the first option unlikely, since DMPK mRNAs are rather 
stable with a half-life of 7-24 hours in LHCN-M2 cells (unpublished data) which matches 
data found for other cell types [40,58,59]. The second explanation for the high fractional 
content of DMPK mRNA in the nucleus would be slow nuclear processing, perhaps with a 
role in prevention of premature cytoplasmic release [60]. Earlier we have found that forced 
overproduction of DMPK isoforms has detrimental effects on mitochondrial clustering and 
cell viability [61,62]. Hence, it is tempting to speculate that slow nuclear release of DMPK 
mRNA might regulate timing and level of DMPK protein production. More work is necessary 
to provide any support for this speculation.
Abnormal nuclear retention of transcripts can lead to a process called 
hyperadenylation [29–31]. For example, transcripts produced from a mutant beta-
globin intronless gene are retained in the nucleus, because of inefficient transport to the 
cytoplasm. These beta-globin transcripts subsequently undergo hyperadenylation as a mark 
for rapid decay [28]. Hyperadenylation may also be uncoupled from subsequent decay, 
however, as shown for other transcripts [28]. We feel it is necessary to point out that the 
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term hyperadenylation should be reserved for abnormal elongation of transcripts under 
specific (patho)biological conditions. For the synthesis of the unusually long poly(A) tails on 
normal DMPK mRNAs we do not consider this an appropriate term. 
The situation may be different for expanded DMPK RNAs in cells of DM1 patients. 
We expected to find a link between the block in nuclear export of mutant DMPK transcripts 
captured in abnormal RNP complexes (i.e. formed by aberrant association with MBNL1-
3 and other proteins) and hyperadenylation [28–32]. Surprisingly, analysis of poly(A) tail 
lengths in expanded versus normal DMPK transcripts did not reveal overt differences in 
poly(A) processing: both populations carried poly(A) tails that fall in an exceptional broad 
length range and prolonged nuclear retention obviously is not associated with additional 
hyperadenylation.
Expanded DMPK transcripts may be physically trapped in the nucleus and therefore 
unable to reach nuclear compartments where hyperadenylation occurs. We consider this 
scenario unlikely as others have shown that expanded DMPK mRNAs predominantly locate 
at the periphery of nuclear speckles (SC-35 domains), while normal DMPK transcripts 
traverse through these domains [63,64]. This finding together with our observation that 
expanded DMPK transcripts are normally spliced suggests that export of expanded DMPK 
mRNA is blocked at an early step in intranuclear transport, yet in a phase after completion 
of RNA processing. A more likely explanation thus is that polyadenylation is already largely 
completed before mutant DMPK RNAs get trapped (while normal DMPK RNAs are transported 
further to the nuclear pores). A blockade in transport would thus not result in differential 
effects on poly(A) length. Finally, we cannot exclude the possibility that hyperadenylation 
does not occur in muscle cells or only occurs on mRNAs with specific features or sequences 
absent in DMPK mRNAs.
In conclusion, further study is required regarding the role of nuclear residence and 
the exceptionally long poly(A) tails, which we present here as dominant features in the life 
cyle of normal and expanded DMPK mRNAs in muscle cells. We need to know what the 
exact sequence is of RNA processing steps of normal DMPK mRNAs and the role of different 
RNA-binding proteins therein. These events need to be distinguished from steps involved 
in the selective capturing of long expanded mRNAs in the nucleus. Only then can we better 
understand why (CUG)n repeat length has no differential effect on polyadenylation and 
splicing of mutant and normal DMPK transcripts.
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Figure S1. Agarose gel migration of DMPK transcripts under partially denaturing conditions. (A) 
Conventional northern blot of normal (5/5) and DM1 (13/800 and 13/2600) myoblast RNA, hybridized 
with a DMPK cDNA probe to visualize DMPK transcripts. 1 Expanded DMPK mRNA signals in 13/800 cells. 
2 Expanded DMPK mRNA signal in 13/2600 cells. 3 Unknown signal, unrelated to repeat expansion, also 
visible in normal myoblasts. * 28S rRNA migration for orientation. (B,C) Partially denaturing agarose gel 
(left) and corresponding northern blot (right) loaded with RNA from DM1 13/800 (B) and 13/2600 (C) 
myoblasts. RNA was denatured by formamide and heat and electrophoresed on an agarose gel stained with 
ethidium bromide (EtBr). Normal DMPK transcripts (~2.8 kb) migrated between 18S rRNA (~2 kb) and 28S 
rRNA (~5 kb), while expanded DMPK transcripts all migrated slower than 28S rRNA. Multiple signals were 
visible for expanded DMPK transcripts, presumably due to secondary structure formation under the partially 
denaturing conditions in the agarose gel.
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Figure S2. Subcellular fractionation of myoblasts. Western blot analysis of nuclear (Nucl) and cytoplasmic 
(Cyt) fraction after subcellular fractionation of unaffected 5/5 and DM1 13/2600 myoblasts. Lamin A+C and 
β-tubulin served as nuclear and cytoplasmic marker proteins. Molecular weights are indicated in kDa.
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Figure S3. Fractionation of nuclear and cytoplasmic RNA. Distribution of DMPK mRNA (DMPK ex1-ex2) and 
marker transcripts ACTB pre-mRNA (ACTB in2-ex3, nuclear marker), ACTB mRNA (ACTB ex2-ex3, cytoplasmic 
marker) and GAPDH mRNA (GAPDH ex1-ex2, cytoplasmic marker) was determined in nuclear (black) and 
cytoplasmic (white) RNA fractions by RT-qPCR from unaffected (5/5) and DM1 (13/800 and 13/2600) 
myoblasts. N=6 (5/5), n=9 (13/800) and n=3 (13/2600) from two, three and one independent culture 
period(s), respectively, with triplicate cultures. Bars represent mean + SEM.
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Figure S4. RT-PCR approach to determine poly(A) tail length. Reverse transcription was done on total 
RNA from normal (5/5) myoblasts using a (dT)10 adapter primer complementary to the poly(A) tail (T10-
adap), followed by PCR amplification using DMPK (A) or GAPDH (B) specific forward primers and the same 
(dT)10 adapter primer as reverse primer. No-reverse transcriptase (RT-) and no-template (NT) controls were 
included as negative controls. (A) To enhance the signal for the detection of DMPK amplicons, PCR products 
(left) were transferred to a membrane and hybridized with a DMPK probe (middle) or a (dT)18 probe (right). 
(B) GAPDH PCR products were visualized via staining with ethidium bromide. The smallest amplicons contain 
an (A)10 tail and are 311 bp for DMPK and 105 bp for GAPDH, respectively.
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Introduction
In this addendum we describe an alternative method to separate expanded from normal-
sized DMPK mRNAs. This method is based on the preferential pull-down of expanded (CUG)n 
transcripts using (CAG)7-oligonucleotide coated magnetic beads.
Material and Methods
Human material
Human tissue material was obtained for research purposes from preconsented post-
mortem donors in accordance with local guidelines. No additional approval by an ethics 
committee was required at that time (~18 years ago). A heart muscle autopsy was obtained 
from a congenital DM1 patient with a confirmed clinical and DNA diagnosis ((CTG·CAG)5/
(CTG·CAG)1300). Tissue was snap-frozen immediately after collection and stored between 
-80 and -135°C until further use. A skeletal muscle sample from a healthy anonymous donor 
((CTG·CAG)11/(CTG·CAG)12) from our own repository was included in the study. Also this 
sample was collected long before the current guidelines for written consent were enforced 
and no detailed information could be traced.
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen) according to manufacturer’s 
instructions.
Oligonucleotide-mediated RNA pull-down
Streptavidin-coated magnetic beads (Dynabeads® MyOne™ Streptavidin T1, Invitrogen) were 
washed in the same volume of buffer as the initial volume of Dynabeads® using a Dynal® 
MPC™-S bead separator magnet rack (Invitrogen). Washing steps were as follows: three 
times in binding and washing buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 2 M NaCl), twice 
in solution A (0.1 M NaOH, 0.05 M NaCl) for 2 minutes, once in solution B (0.1 M NaCl), twice 
in solution C (10 mM Tris-HCl (pH 7.5), 0.5% (w/v) SDS, 0.5 M NaCl, 1 mM EDTA), and twice 
in solution D (10 mM Tris-HCl (pH 7.5), 0.5% (w/v) SDS, 0.1 M NaCl, 1 mM EDTA). Per RNA 
sample (12 µg total RNA) an initial volume of 25 µL Dynabeads® was used and the washed 
Dynabeads® were resuspended in a final volume of 100 µL solution D in DNA LoBind Tubes 
(Eppendorf). Per 100 µL resuspended Dynabeads® 2.5 µL 100 µM biotinylated 2’-O-methyl 
phosphorothioate modified RNA oligo ((CAG)7, 5’-CAGCAGCAGCAGCAGCAGCAG-3’ or 
scrambled oligo SCR, 5’-CAGAGGACCACCAGACCAAGG-3’) or biotinylated 2’-O-methyl 
modified RNA oligo (DMPK e2, 5’-AGUCGGACCUCCUUAAGCC-3’ or DMPK e15, 
5’-AGGACGAGGUCAAUAAAUAUCC-3’) was added and incubated at room temperature 
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for 1 hour, with gentle mixing every ~10 minutes. The oligo-coupled beads were washed 
three times in solution 2xC (20 mM Tris-HCl (pH 7.5), 1% (w/v) SDS, 1 M NaCl, 1 mM EDTA) 
and resuspended in a final volume of 35 µL solution 2xC. RNaseOUT (Invitrogen) and DTT 
(Invitrogen) were added to a final concentration of 4 units/µL and 2 µM respectively. Total 
RNA (12 µg in 35 µL Aurum™ total RNA elution solution (BioRad)) was denatured at 70°C 
for 5 minutes, chilled on ice, added to the oligo-coupled beads solution and incubated for 
2 hours at 25°C with gentle mixing every ~10 minutes. To separate bound and unbound 
RNA, the beads were collected and washed twice with 60 µL solution C and twice with 60 
µL solution D. The supernatant and subsequent four washes were collected and pooled per 
condition. RNA bound to the beads was eluted by incubation at 85°C for 6 minutes in 60 
µL solution E (10 mM Tris-HCl (pH 7.5), 0.5% (w/v) SDS, 1 mM EDTA, 0.1 µg/µL yeast tRNA) 
followed by magnetic separation such that the previously oligo-bound RNA was present in 
the supernatant. RNA from both the wash and bead fractions was precipitated in a final 
concentration of 70% ethanol and 0.08 M NaAc (pH 5) at -80°C.
Northern blotting
Northern blotting was performed according to standard procedures. Per lane, an equivalent 
of 10 µg  total RNA, denatured in 50% (v/v) deionized formamide and 6.7% (w/w) 
formaldehyde, was subjected to electrophoresis in a 1.2% agarose gel with 6.7% (w/w) 
formaldehyde. RNA was transferred to Hybond-XL nylon membrane (Amersham Pharmacia 
Biotech), by capillary transfer in 10x SSC and then the blot was UV crosslinked (Stratalinker® 
UV Crosslinker, Stratagene). The northern blot was hybridized with random-primed 
32P-labeled probes (2.6 kb DMPK cDNA, covering the entire ORF and 3’ UTR, and 1.1 kb rat 
Gapdh cDNA). Hybridization was carried out in Church-Gilbert buffer (0.25 M Na2HPO4 (pH 
7.2), 7% (w/v) SDS, 1 mM EDTA (pH 8.0)).
Results and Discussion
To separate DMPK mRNA with an expanded (CUG)n repeat tract from transcripts with a 
normal repeat tract, we used magnetic separation based on discriminative binding of a 
(CAG)7 antisense oligonucleotide to the RNAs. A biotinylated (CAG)7 RNA oligo, modified 
by 2’-O-methyl phosphorothioate modifications to enhance binding and increase stability, 
was coupled to streptavidin-coated magnetic beads. Uncoupled oligo was washed away and 
the oligo-bead complexes were incubated with total RNA from congenital DM1 (CDM) heart 
tissue. Subsequent magnetic separation resulted in two fractions: the bead fraction to which 
transcripts with long (CUG)n tracts were bound, and the wash fraction containing unbound 
transcripts. The fractionated RNA was visualized by Northern blotting (Fig. A1). Expanded 
DMPK mRNA was exclusively present in the beads fraction, while the normal-sized DMPK 
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mRNA was present in the wash fraction. As a negative control, CDM total RNA was pulled-
down with a scrambled oligo, which resulted in both healthy and expanded DMPK mRNAs to 
remain in the wash fraction. As expected, Northern blot hybridization with a probe against 
GAPDH showed that this mRNA, lacking a (CUG)n tract, remained in the wash fraction.
 When total RNA from skeletal muscle from a non-affected ((CUG)11/(CUG)12) 
individual was used for testing in the (CAG)7 oligo pull down assay, only a minor shift of 
DMPK mRNA into the bead fraction occurred. Apparently, presence of a small (CUG)n stretch 
in the DMPK mRNA, sufficient for binding by only one (CAG)7 oligo, enables RNA pull-down 
but not very efficient. The preferential pull-down of the expanded DMPK transcript in the 
CDM sample may be best explained by the numerous binding places available for the (CAG)7 
oligo.  
In Chapter 4 an agarose fractionation method based on RNA size was used for 
selective isolation and discriminative analysis of normal-sized and expanded DMPK mRNAs. 
Here, we present this pull-down approach as an alternative method to separate normal and 
expanded DMPK transcripts.
InWBIn WB WB WB WB WB WB WB WB
CDM Healthy
SCR (CAG)7
Expanded   
DMPK »
Healthy   
DMPK »
GAPDH »
Figure A1. Separation of normal-sized and expanded DMPK transcripts via (CAG)7 oligo-mediated RNA pull-
down. Northern blot of (CAG)7 oligo-mediated RNA pull-down on congenital DM1 (CDM) total heart RNA 
and RNA from an unaffected muscle biopsy. (CAG)7 and scrambled (SCR) biotinylated oligos were coupled 
to streptavidin-coated magnetic beads, unbound oligo was washed away and the oligo-bead complexes 
were incubated with RNA after which bound (bead fraction, B) and unbound (wash fraction, W) RNAs were 
separated on a magnet and analyzed by Northern blotting using a DMPK (top) and GAPDH (bottom) probe. 
The input total CDM RNA and healthy total RNA was included for reference (In).
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Abstract
The unstable (CTG·CAG)n trinucleotide repeat in the myotonic dystrophy type 1 (DM1) locus 
is bidirectionally transcribed from genes with terminal overlap. By transcription in the sense 
direction, the DMPK gene produces various alternatively spliced mRNAs with a (CUG)n repeat 
in their 3’ UTR. Expression in opposite orientation reportedly yields (CAG)n-repeat containing 
RNA, but both structure and biological significance of this antisense gene (DM1-AS) are 
largely unknown. Via a combinatorial approach of computational and experimental analyses 
of RNA from unaffected individuals and DM1 patients we discovered that DM1-AS spans 
>6 kb, contains alternative transcription start sites and uses alternative polyadenylation 
sites up- and downstream of the (CAG)n repeat. Moreover, its primary transcripts undergo 
alternative splicing, whereby the (CAG)n segment is removed as part of an intron. Thus, 
in patients a mixture of DM1-AS RNAs with and without expanded (CAG)n repeat are 
produced. DM1-AS expression appears upregulated in patients, but transcript abundance 
remains very low in all tissues analyzed. Our data suggest that DM1-AS transcripts belong 
to the class of long non-coding RNAs. These and other biologically relevant implications for 
how (CAG)n-expanded transcripts may contribute to DM1 pathology can now be explored 
experimentally.
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Introduction
During the last decade it has become clear that the eukaryotic genome is transcribed in 
a pervasive manner, whereby RNA synthesis occurs from both strands of the DNA for a 
significant number of loci [1,2]. Production of sense and antisense transcript pairs from a 
particular locus is thus a relatively frequent event. The actual expression and structure of 
the RNAs formed may depend on convergent or divergent orientation of the transcribed 
DNA segments, chromatin embedding of the locus, complementary overlap between RNA 
products and ultimately the mode of RNA processing.
As only a minority of all transcripts contain evolutionary conserved open reading 
frames or represent well-characterized structural or catalytic RNAs, most transcripts have a 
still unknown function. Collectively, these RNAs make up what is referred to as pools of stable 
unannotated transcripts (SUTs) or cryptic unstable transcripts (CUTs), for which intergenic, 
intronic and cis-antisense long noncoding RNAs (lncRNAs) are main representatives [3]. 
Based on recent evidence that lncRNAs and other types of non-coding RNAs are not merely 
genomic by-products, but could be key elements of cellular homeostasis [4], attention is now 
increasingly focused on the understanding of how structural alteration and dysregulation 
of production of non-coding RNAs is inherent in development and progression of human 
diseases.
Neurodegenerative diseases that have been associated with transcription across loci 
that contain unstable repeat sequences (usually trinucleotide motifs of variable length [5,6]) 
form particularly interesting cases for non-coding and antisense RNA research. Currently, 
microsatellite instability has been identified as the cause of disease for >30 disorders. Well-
known examples are myotonic dystrophy, Huntington’s disease, Fragile X syndrome, several 
spinocerebellar ataxias (SCAs) and C9orf72-related amyotrophic lateral sclerosis with 
frontotemporal dementia (ALS/FTD). Protein-coding transcripts from repeat-containing 
loci produced in sense orientation were originally considered the only molecular actors in 
disease manifestation. Nowadays, however, it is becoming clear that the pathogenic picture 
is much more complex and involves expression of antisense transcripts from the same locus, 
usually cis-antisense type lncRNAs [7–11]. Specific disease features are usually coupled to 
microsatellite sequences in sense transcripts and can be ribostasis- or proteostasis-related, 
dependent on whether the repeat sequence is located in the 5’ or 3’ UTR region of the 
transcript, in an intron or in the ORF that encodes the final protein product. It cannot be 
excluded, however, that disease features are also, or maybe specifically, associated with the 
complementary repeat element in antisense RNA products from the same locus. Besides, 
pathogenicity may be coupled to the actual bidirectional transcription process through the 
microsatellite tract itself, as transcription is known to enhance repeat instability and thus 
may modulate disease progression [12–14].
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Myotonic dystrophy type 1 (DM1), an autosomal-dominant multisystemic disorder 
caused by expansion of a (CTG·CAG)n repeat in the DMPK gene is the archetypal example 
of a repeat disease with complex RNA-related etiology. In the healthy population, the 
(CTG·CAG)n repeat is polymorphic in length and consists of 5-37 triplets, whereas DM1 
patients carry a DMPK allele with 50 to up to several thousands of triplets. When transcribed 
in the sense direction from the mutant allele, an abnormal DMPK mRNA is produced with a 
long hairpin-forming (CUG)n repeat sequence in its 3’ UTR [15–17]. In the DM field there is 
strong support for this RNA being the primary and dominant cause of toxic gain-of-function 
effects that give the disease its complex and unpredictable character [18,19]. Expanded 
DMPK transcripts are largely retained in the nucleus and form abnormal RNP aggregates 
by sequestration of transcription factors and RNA-binding proteins [20,21]. This leads to 
RNP-related stress that can deregulate transcription and have effects on processing of 
other mRNAs and miRNAs [21,22]. A new potentially toxic mechanism has been recently 
described, by which homopolymeric proteins are formed by repeat-associated non-ATG 
(RAN) translation across the triplet repeat segment in the RNA [23,24].
The picture that posits abnormal, sense DMPK (CUG)n mRNA as the root cause 
of problems in DM1 may not be complete, as also antisense transcription through the 
repeat region in the DM1 locus has been observed [25]. Antisense transcription across 
the (CTG·CAG)n repeat was reported to emanate from the adjacent SIX5 regulatory region 
[25]. The actual unit that is transcribed in antisense direction may thereby extend into a 
chromatin insulator element formed by two CTCF-binding sites that flank the (CTG·CAG)n 
repeat [26]. Based on these findings a role for gene products from the region in regulating the 
surrounding chromatin structure has been proposed [25]. Thus far, however, few dedicated 
analyses were conducted of expression of (CAG)n-repeat segments or flanking regions 
in antisense RNA transcripts [23,27–29]. As a consequence, while detailed knowledge is 
available on sense genes DMWD, DMPK and SIX5 in the DM1 locus, information on the 
antisense gene, here coined DM1-AS, and its products is still scarce.
We investigated DM1-AS transcripts in silico and in vitro using a combinatorial 
approach of bioinformatics analyses of transcriptome-wide data and wet-lab experiments 
based on healthy and DM1 samples. Our data point to the existence of a DM1-AS 
transcription unit that is much larger than originally assumed. Primary DM1-AS transcripts 
occur as very low abundant RNAs of different lengths - with and without the (CAG)n repeat - 
due to alternative polyadenylation. Alternative splicing may remove the (CAG)n repeat from 
the longer DM1-AS RNAs as part of an intron, similar to what happens with the (CCUG)n 
repeat in DM type 2. Thus, DM1 tissues contain a heterogeneous population of DM1-AS 
transcripts with and without expanded (CAG)n repeat. We discuss how our findings may 
help to experimentally explore the normal and pathobiological role of DM1-AS RNA further.
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Materials and methods
Human material
Skeletal muscle samples were collected from pre-consented post-mortem donors. A 14-day-
old male twin had a confirmed clinical and DNA diagnosis of congenital DM1 (CDM) and 
carried a normal-sized repeat of 5 (patient A) and 12 (patient B) triplets, next to expanded 
repeats of around 1300 triplets (5/1300 and 12/1300 in short). Gastrocnemius muscle tissue 
from patient A and psoas muscle tissue from patient B were snap frozen immediately after 
collection and stored at -135 to -80°C.
Cell culture
LHCN-M2 immortalized human satellite cells [30], carrying two (CTG·CAG)5 alleles (5/5 in 
short), were grown on 0.1% (w/v) gelatin-coated plastic surfaces in skeletal muscle cell basal 
medium (PromoCell) with Supplement Mix (0.05 mL/mL fetal calf serum, 50 µg/mL fetuin 
(bovine), 10 ng/mL epidermal growth factor (recombinant human), 1 ng/mL basic fibroblast 
growth factor (recombinant human), 10 µg/mL insulin (recombinant human), 0.4 µg/mL 
dexamethasone), supplemented with 1% (v/v) GlutaMAX and 15% (v/v) bovine growth 
serum (Thermo Scientific) at 7.5% CO2 and 37°C.
 Primary DM1 myoblasts (13/800) [31], were grown on 0.1% (w/v) gelatin-coated 
plastic surfaces in Ham’s F10 medium (Gibco) supplemented with GlutaMAX and 20% (v/v) 
bovine growth serum (Thermo Scientific) at 7.5% CO2 and 37°C.
Immortalized DM500 mouse myoblasts expressing a human DM1 genomic 
fragment carrying a (CTG·CAG)n repeat of approximately 500 triplets [32] were grown on 
0.1% (w/v) gelatin-coated plastic surfaces in proliferation medium containing DMEM (Gibco) 
supplemented with 20% (v/v) fetal bovine serum (PAA, Pasching, Austria), 4 mM L-glutamine 
(Gibco), 1 mM pyruvate (Sigma), 50 µg/mL gentamicin (Gibco), 20 units/mL γ-interferon (BD 
Biosciences) and 2% (v/v) chicken embryo extract (Sera Laboratories International) at 7.5% 
CO2 and 33°C.
RNA isolation and fractionation
Total RNA from muscle tissue and cultured cells was isolated using TRIzol reagent (Invitrogen) 
and Aurum Total RNA Mini Kit (Bio-Rad), respectively, according to manufacturer’s 
instructions.
 For RNA isolation from subcellular fractions, myoblasts were grown to 80% 
confluence, collected via trypsinization and pelleting by centrifugation at 1,000 x g for 5 
min at 4°C. Cell pellets were washed twice with ice-cold PBS. Pellets were resuspended 
in ice-cold cell disruption buffer (10 mM KCl, 1.5 mM MgCl2, 20 mM Tris-Cl (pH 7.5), 1 
mM DTT) and incubated on ice for 10 min [33]. Samples were homogenized in a chilled 
Dounce homogenizer (Wheaton) for 15 strokes and then Triton X-100 was added to a final 
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concentration of 0.1%. The lysate was spun at 1,500 x g for 5 min at 4°C. The supernatant 
(cytoplasmic fraction) and the pellet (nuclear fraction) were mixed with lysis buffer according 
to instructions of the Aurum Total RNA Mini Kit (Bio-Rad) and RNA was isolated.
 Poly(A)-selected RNA was isolated from total RNA using the NucleoTrap® mRNA 
kit (Macherey-Nagel). Total RNA was mixed with oligo(dT) latex beads, allowing binding of 
poly(A) tails of transcripts to the beads, followed by several washing steps using a microfilter 
and ultimately elution of poly(A)-selected RNA. The poly(A)-depleted fraction was obtained 
by isolating RNA from unbound and wash fractions.
 For size-based RNA fractionation, total RNA, denatured in 50% formamide at 70°C 
for 10 min, was electrophoresed in a 1.2% (w/v) MOPS-buffered agarose gel stained with 
ethidium bromide. Gel lanes were sliced in multiple fragments, guided by a ssRNA ladder 
(NEB). RNA was extracted from the gel slices using the Zymoclean™ Gel RNA Recovery Kit 
(Zymo Research), resulting in multiple RNA fractions, each corresponding to a defined range 
of transcript sizes.
RT-PCR analysis
For analysis of expression of specific regions of DM1-AS, an equivalent of 1 μg total RNA was 
subjected to cDNA synthesis using SuperScript III Reverse Transcriptase (Life Technologies) 
and strand-specific primers with a 5’ linker (Table 1) [23,27]. In a subsequent PCR, DM1-
AS regions were amplified from these cDNA samples using Q5® High-Fidelity Polymerase 
(NEB), DM1-AS-specific forward primers (Table 1) and either the RT primer or a reverse 
primer matching the linker attached to each RT primer (5’-GGAGCACGAGGACACTGA-3’). 
PCR conditions were optimized for each reaction and amplicon identity was confirmed by 
sequencing. Amplified products were analyzed via agarose gel electrophoresis followed 
by ethidium bromide staining. A no-reverse transcriptase reaction (RT-) was included as 
negative control. Signals were quantified using FIJI software [34].
 To determine poly(A)-site usage, 500 ng total RNA was subjected to cDNA synthesis. 
To this end 50 pmol of 5’-GGGGATCCGCGGTTTTTTTTTT-3’ adapter [35] was annealed to 
poly(A) containing mRNAs in the mixture, before serving as primer for cDNA synthesis by 
SuperScript III Reverse Transcriptase. Next, the cDNA was used as template for amplification 
by PCR using Q5 polymerase and a DM1-AS-specific forward primer close to predicted poly(A) 
sites (primers in region E, I and J; Table 1). No additional reverse primer was added and the 
5’-GGGGATCCGCGGTTTTTTTTTT-3’ adapter from the RT reaction would function as reverse 
primer. A no reverse transcriptase reaction (RT-) was included as negative control. PCR 
fragments were separated on agarose gel and transferred to Hybond-XL nylon membrane 
(Amersham Pharmacia Biotech). Membranes were incubated with 32P-end-labeled 
oligonucleotides (X: 5’-ACTGTGGAGTCCAGAGCT-3’; Y: 5’-GACCACTTGGCACCTTTCCT-3’; Z: 
5’-GGGGTATGAAGTGGCTGTCC-3’) using conventional methods and signals were quantified 
using a phosphor imager (Molecular Imager FX, Bio-Rad).
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 To examine splicing of primary DM1-AS transcripts, 500 ng total RNA was 
reverse transcribed using SuperScript III Reverse Transcriptase with (dT)18 primer. The 
cDNA preparation was used as template in a PCR, with combinations of forward and 
reverse primers, close to transcription start- and polyadenylation sites respectively, 
using Q5 polymerase. Forward primers were 5’-CAGAAGACGGACCACGCC-3’ and forward 
primers of region C and D (Table 1); reverse primers were 5’-AGCTCTGGACTCCACAGT-3’, 
5’-AGGAAAGGTGCCAAGTGGTC-3’ and 5’-CCAGCTTGATTCTGAACCGC-3’. PCR amplicons 
were visualized on agarose gel, isolated and Sanger sequenced to determine splice modes.
 RT-qPCR was used to analyze size-fractionated RNA (using 1 μg RNA as input for the 
RT reaction) and to analyze nuclear and cytoplasmic RNA fractions (500 ng cytoplasmic RNA 
and an equivalent of nuclear RNA for the RT reaction). RNA was reverse transcribed using 
the iScript™ cDNA Synthesis Kit (Bio-Rad). For qPCR, 3 µL tenfold diluted cDNA preparation 
was mixed in a final volume of 10 µL containing 5 µL iQ™ SYBR® Green Supermix (Bio-Rad) 
and 4 pmol of each primer (MAP3K4 ex3-ex4: 5’-TGCAAAGGGCACGTATAGCATTGG-3’ and 
5’-GCTCCTCCCACGACACAGCA-3’; DMPK ex1-ex2: 5’-ACTGGCCCAGGACAAGTACG-3’ and 
5’-CCTCCTTAAGCCTCACCACG-3’; GAPDH ex1-ex2: 5’-CCCGCTTCGCTCTCTGCTCC-3’ and 
5’-CCTTCCCCATGGTGTCTGAGCG-3’; DMPK ex2-in2: 5´-GAGGGACGACTTCGAGATTCTGAA-3´ 
and 5´-CACCACGAGTCAAGTCAGGC-3´; ACTB ex2-ex3: 5´-CGGGCCGTCTTCCCCTCCAT-3´ 
and 5´-TGGGCCTCGTCGCCCACATA-3´; Actb ex5-ex6: 5’-GCTCTGGCTCCTAGCACCAT-3’ and 
5’-GCCACCGATCCACACAGAGT-3’). Samples were analyzed using the CFX96 Real-time System 
(Bio-Rad). A melting curve was obtained for each sample in order to confirm single product 
amplification. Samples from no template (NTC) and no reverse transcriptase reactions (RT-) 
were included as negative controls.
Region† Primer for RT reaction‡ (5’-3’) Forward primer in PCR (5’-3’)
A AGGCCCTGCCAATGTGCACCTCATCAACTC TCCGAGATGACTGCACCCCT
B CAGCCGAAGTCCTGAGGACCTGGAGAGAGG GCTCCCGTTCACCAGGATGG
C GGGACCAGCTCACAATCTCAGGCGCCCGCG TGGAGCCGCTGGAAGAGG
D TCTTGCAGACTTTGCAGGCGGCCGAGGGTG CTCGGGCGAGAAGCGGAG
E ACCTAGGACCCCCACCCCCGACCCTCGCGA CTCCACACGCCTCCGGATT
F GACCATTTCTTTCTTTCGGCCAGGCTGAGGC TGCGAACCAACGATAG
G CGCCTGCCAGTTCACAACCGCTCCGAGCGT CCTTCGAGCCCCGTTCGC
H CCACAGTCAACTACGCGAGGCAGAGGCTCG ACTCCATCCGCTCCTGCAAC
I AGTGGGGCATTAAGTAAGGGTGTGTGTGTT CTTTGCCCTGGAGGCTCTC
J GGGTTGGAGGGGACAGCCACTTCATACCCC CCTGATGGGGAGACTGCTTG
Table 1. List of primers used to analyze expression of DM1-AS regions by RT-PCR.
† Regions refer to Fig. 3 and Suppl. Fig. S5.
‡ In addition to the sequence listed, each RT primer contained linker sequence 
5’-CGACTGGAGCACGAGGACACTGA-3’ attached to its 5’ end.
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ENCODE RNA-seq 
Processed RNA sequencing data in BAM format was downloaded from ENCODE at 
ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeCshlLongRnaSeq 
[36]. Long RNA-seq reads (101 nt) from Cold Spring Harbor Laboratory (CSHL) were visualized 
in the University of California at Santa Cruz (UCSC) Genome Browser, human genome build 
GRCh37/hg19, as the sum of signals per strand. In total 190 files were used from various 
cell lines, including HeLa-S3, K562, HSMM, and many others. These reads were also used to 
identify splice sites.
 To obtain information on polyadenylation status, ENCODE RNA-seq data by CSHL 
(GSE30567) on poly(A)-selected and poly(A)-depleted RNA from whole cell was included 
from 14 cell lines (A549, AG04450, BJ, GM12878, H1-hESC, HeLa-S3, HepG2, HSMM, 
HUVEC, K562, MCF-7, NHEK, NHLF, and SK-N-SH RA). For analysis on cellular localization 
of transcripts, ENCODE RNA-seq data by CSHL (GSE30567) on nuclear and cytoplasmic-
selected RNA from whole cell poly(A)-selected material was included from 10 cell lines 
(A549, GM12878, H1-hESC, HeLa-S3, HepG2, HUVEC, IMR90, K562, MCF-7, and NHEK).
 Fragments Per Kilobase Of Exon Per Million Fragments Mapped (FPKM) values 
were calculated in Cufflinks (version 2.0.0), using the ENSEMBL GTF file (Homo_sapiens.
GRCh37.75.gtf.gz, accessed on April 2nd, 2014) with the position of the antisense transcript 
(GRCh37/hg19, chr19: 46,270,855-46,276,570) manually included. FPKM values per 
transcript per cell line were calculated for chromosome 19.
 Also for mouse, processed RNA sequencing data from ENCODE by CSHL (GSE36025) 
was available and visualized in the UCSC Genome Browser (mouse genome build 
NCBI37/mm9). Data from the following adult tissues was included: adrenal gland, bladder, 
cerebellum, colon, cortex, duodenum, frontal lobe, genital fat pad, heart, kidney, large 
intestine, liver, lung, mammary gland, ovary, placenta, small intestine, spleen, stomach, 
subcutaneous fat pad, testis, and thymus.
Myotonic Dystrophy Deep Sequencing Data Repository
RNA-seq data from DM1 patients were taken from the Myotonic Dystrophy Deep 
Sequencing Data Repository (www.dmseq.org). RNA originated from biopsies from tibialis 
muscle, provided by Drs Katy Eichinger and Charles Thornton. RNA-seq data from 11 
controls and 45 DM1 patients were included in our study. Samples were aligned to the hg19 
reference genome using the RNA-seq aligner HISAT2. MISO (version 0.4.8) [37] was used 
to estimate isoform frequencies for splicing events using a minimum of 20 reads per event 
and the parameters of burn_in=500, lag=10, num_iters=5000, and num_chains=6. DM1 
patients were classified as mild, moderate or severe by their inferred MBNL concentration, 
described in [38]. DM1 samples were binned as follows: mild, n=19, [MBNL]inferred 
[0.40-0.80]; moderate, n=13, [MBNL]inferred [0.21-0.39]; severe, n=13, [MBNL]inferred 
[0.0-0.20]. Fragments Per Kilobase Of Exon Per Million Fragments Mapped (FPKM) values 
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were calculated in Cufflinks (version 2.0.0), using the ENSEMBL GTF file (Homo_sapiens.
GRCh37.75.gtf.gz, accessed on April 2nd, 2014) with the position of the antisense transcript 
(GRCh37/hg19, chr19: 46268039-46285965) manually included. FPKM values per transcript 
per biopsy sample were calculated for chromosome 19. The sample’s DMPK and DM1-AS 
FPKM values were binned according to the above (mpm) metric (Fig. 5D and E).
 The strand-specific RNA-seq protocols used enable including only reads belonging 
to the original orientation of transcription for the calculation of exon counts. Exon RPKM 
(Reads Per Kilobase of exon model per Million mapped reads) values were calculated 
according to exon hits and normalized against the library size (total MAPQ ≥1 reads) and to 
the merged length of the coding sequence of each gene [39].
Transcription start sites
FANTOM5 mapped transcription start sites (TSSs) and their usage in human and mouse 
primary cells, cell lines and tissues [40]. The TSS profile is based on evidence of read counts 
using cap analysis of gene expression (CAGE) reads. Data was accessed via the FANTOM5 
datahub in the UCSC Genome Browser.
Poly(A) sites
Merck Research Laboratories developed Poly(A)-seq, a strand-specific and quantitative 
method for high-throughput sequencing of 3’ end of polyadenylated transcripts, and 
globally mapped polyadenylation sites in human and mouse tissues (GSE30198) [41]. Data 
is available via the Poly(A)-seq track in the UCSC Genome Browser. 
 The Poly(A) transcript annotation set from GENCODE version 19 was also accessed 
via the UCSC Genome browser [42]. This set contained poly(A) signals and sites manually 
annotated on the genome, based on transcribed evidence (ESTs and cDNAs) of 3’ end of 
transcripts containing at least 3 As not matching the genome.
Histone modification and evolutionary conservation
A comprehensive set of human histone modifications based on ChIP-seq experiments was 
available from ENCODE by the Broad Institute (GSE29611) and the University Washington 
(GSE35583) [36,43]. Occurrence of H3K4me3, a mark of regulatory elements primarily 
associated with promoters and transcription starts, was analyzed.
 Multiple alignments of 100 vertebrate species and measurements of evolutionary 
conservation using phastCons [44] and phyloP [45] were visualized in the conservation track 
(‘Vertebrate Multiz Alignment & Conservation (100 Species)’) in the UCSC Genome Browser.
Exploring protein-coding potential of DM1-AS transcripts
Open reading frames were analyzed via web.expasy.org/translate. Ribo-seq data obtained 
with the ribosome profiling technique was visualized in GWIPS-viz (genome wide information 
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on protein synthesis) genome browser [46,47]. Globplot2 (via globplot.embl.de) was used 
to identify potential domains in DM1-AS ORFs [48].
Statistical analysis
FPKM ratios of poly(A)-depleted : poly(A)-selected RNA and of nucleus : cytoplasm RNA 
were compared between transcripts using multiple Wilcoxon signed rank tests followed by 
a Bonferroni correction. Correlation between expression of DM1-AS, DMWD, DMPK and 
SIX5 (log2 transformed FPKM values) were analyzed using Pearson’s test. Statistical analyses 
were performed in GraphPad Prism version 5.01 for Windows. *, p<0.05.
Results
Antisense transcription in the DM1 locus occurs specifically in the SIX5-DMPK region
The Encyclopedia of DNA Elements (ENCODE) project has systematically mapped regions of 
transcription in a large collection of >35 cell lines, including HeLa-S3, K562, HSMM and many 
others (see Materials and Methods) [36]. We used this data, specifically the cumulative 
scores for RNA-seq signals per strand, to visualize regions in the DM1 locus that are 
transcribed. As expected, RNA-seq signal distribution on one strand (the negative strand) 
was fully in agreement with previously annotated gene structures of DMWD, DMPK and 
SIX5, as indicated by the high signal from known exons (Fig. 1A and B). On the positive 
strand, i.e. the orientation antisense with respect to DMPK and SIX5, RNA-seq signal was 
relatively low but persistent throughout the region complementary to SIX5 intron 1 to DMPK 
intron 9. This signal, which we termed DM1-AS (for DM1 antisense) RNA, was unlikely to 
be noise-related, since similar RNA-seq signals were not observed elsewhere in the DM1 
locus. Even though no absolute exon-intron boundaries could be discerned in the DM1-AS 
RNA-seq signal, the intensity in the mid-region of the presumed transcription unit, where 
the (CAG)n repeat is located, clearly appeared lower.
Since the DM1 locus, comprising DMWD, DMPK and SIX5, is located in a syntenic 
chromosome region well conserved between human and mouse [49], we wanted to learn 
about the degree of evolutionary conservation of DM1-AS, as this is often used as a measure 
for the biological significance of genome elements. Unfortunately, high gene density in this 
chromosome region and inability to separate evolutionary pressure between the 2 DNA 
strands obscured analysis and made it difficult to come to predictive conclusions (Suppl. Fig. 
S1). ENCODE RNA-seq data from mouse tissues learned that, as expected, RNA-seq signal 
of the sense genes was in agreement with previously annotated gene structures (Suppl. 
Fig. S2). In the antisense direction, the signal was low, but started in the same region as 
in humans, complementary to Six5 intron 1. Unlike in human cells, a defined 3’ end of the 
transcription unit could not easily be identified in these mouse samples.
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DM1-AS transcription starts in the region complementary to intron 1-exon 1 of SIX5
To identify potential transcription start sites (TSSs) in DM1-AS, we used data from the 
functional annotation of the mammalian genome 5 (FANTOM5) project [40]. We identified 
multiple TSSs for both the sense genes (DMWD, DMPK, SIX5) and the antisense gene 
(DM1-AS) (Fig. 1C; Suppl. Fig. S3). TSSs for DM1-AS were located in the region complementary 
to SIX5 intron 1 and exon 1, which matches the edge of the previously observed RNA-seq 
signal (Fig. 1B).
To try to clarify TSS usage further, we analyzed ENCODE data regarding positioning 
of histone modification H3K4me3, a regional mark of regulatory elements primarily 
associated with promoters and TSSs [36]. H3K4me3 signal extended into the presumed 
DM1-AS promoter, but appeared difficult to interpret due to overlap with the SIX5 promoter 
in the same area (Suppl. Fig. S4).
 For an interspecies comparison, we analyzed FANTOM5 data on TSSs and their 
usage in mouse primary cells, cell lines and tissues. Multiple TSSs were again identified 
for the sense genes. For the opposite strand, only one TSS was described in the region 
complementary to Six5 intron 1, matching the start of the observed RNA-seq signal for 
Dm1-as (Suppl. Fig. S2) and the location of the human gene. The relevance of this DM1-AS 
TSS is further supported by the evolutionary conservation of a corresponding segment in 
the center of intron 1 of SIX5 (Suppl. Fig. S1).
Multiple poly(A) sites for DM1-AS transcription exist 5’ and 3’ from the (CAG)n repeat
To examine 3’ end formation of DM1-AS transcripts, we focused on polyadenylation and 
potential poly(A) sites. ENCODE RNA-seq data include findings with both poly(A)-depleted 
and poly(A)-selected RNA, which allowed us to determine a signal ratio of poly(A)-depleted 
versus poly(A)-selected RNA for transcripts from the DM1 locus (Fig. 2A). The poly(A)-
depleted : poly(A)-selected ratio in DM1-AS did not significantly differ from those of the 3 
sense transcripts from the DM1 locus, suggesting equal presence of poly(A) tails on DM1-
AS, DMWD, DMPK and SIX5 transcripts.
By using amplicons corresponding to different parts of the presumed DM1-AS gene 
in RT-PCR, we verified polyadenylation of DM1-AS transcripts in healthy human myoblasts 
carrying 2 (CTG·CAG)5 alleles (5/5) and in muscle tissue from a DM1 patient (12/1300) 
(Suppl. Fig. S5). Two RNA fractions were compared: (i) poly(A)-selected RNA, isolated 
through binding to oligo(dT) beads and (ii) poly(A)-depleted RNA representing unbound 
RNA. Most DM1-AS amplicons were detected in both fractions, confirming that a significant 
fraction (30-45%) of DM1-AS transcripts contains a poly(A) tail. Besides, using this assay, 
no obvious differences in polyadenylation status of DM1-AS RNA between unaffected and 
patient samples were detected.
 A subsequent search predicted multiple poly(A) sites in the DM1-AS region, 
according to GENCODE poly(A) transcript annotation [42] and poly(A)-seq results by Merck 
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Research Laboratories [41] (Fig. 1D and E; Suppl. Fig. S3). Sequences flanking these poly(A) 
sites were analyzed for the presence of a poly(A) signal, generally located 10-30 nucleotides 
upstream of the actual poly(A) addition site, which constitutes a CPSF binding site [50,51] 
(Suppl. Table S1). Presence of a GU-rich region downstream of the cleavage site essential for 
binding of CSTF [50–52] was also monitored (Suppl. Table S1). Interestingly, we found a few 
poly(A) sites upstream from the (CAG)n repeat, which indicates that short primary DM1-AS 
transcripts are formed that do not contain a (CAG)n repeat (~10% of molecules in the total 
DM1-AS population; Fig. 2B). Poly(A) sites in the region complementary to DMPK intron 
10 and 9 were most frequently used (85%) in the samples analyzed by Merck Research 
Laboratories.
 Parallel study of poly(A)-seq data from Merck Research Laboratories for mouse 
tissues suggest that the most frequently used poly(A) site for the Dm1-as gene in this species 
is located in the region complementary to Dmpk intron 2 (Suppl. Fig. S2). Thus, although the 
5’ end of Dm1-as matched with that of DM1-AS in humans, its 3’ end probably extends 
much further downstream.
 Poly(A) site usage in human myoblasts was assessed by RT-PCR, where we focused 
on preferred sites, located both 5’ and 3’ of the (CAG)n repeat (Fig. 2B). Total RNA was 
reverse transcribed using an adapter-(dT)10 primer [35], which only allowed cDNA synthesis 
of poly(A)-containing transcripts, followed by a PCR with a DM1-AS specific forward primer 
(see protocol in Fig. 2C). For a sensitive detection, PCR products were transferred to a 
membrane and hybridized with a select set of 32P-labeled oligo probes. In RNA isolated 
from healthy human (5/5) myoblasts, use of poly(A) sites both 5’ and 3’ from the (CAG)n 
repeat was observed (Fig. 2D). In the same analysis, we also used RNA from human DM1 
myoblasts (13/800), CDM psoas muscle (12/1300) and from mouse DM500 myoblasts which 
carry the complete human DM1 locus with a (CTG·CAG)500 repeat [53]. The latter sample 
was included to assess the effect of (CAG)n repeat expansion on DM1-AS poly(A)-site usage 
without confounding products from a healthy human locus. In all these DM1 samples DM1-
AS poly(A) sites 5’ as well as 3’ of the (CAG)n repeat were used (Fig. 2D). Taking the weight 
of our bioinformatics data and RT-PCR findings combined, we conclude that transcripts from 
the DM1-AS gene form a mixture of RNAs with and without a (CAG)n repeat.
specifically at a poly(A) stretch. PCR was subsequently performed using specific forward primers E, I, or J, 
each located upstream of the putative poly(A) addition sites. Successful DNA production from amplicons 
was analyzed on blot using 32P-labeled oligo probes X, Y, and Z. Predicted amplicon lengths, based on 
adapter-(dT)10 primer annealing immediately at the 5’ end of the poly(A) tail, are given (annealing more 
downstream in the poly(A) tail may occur and would result in a slightly larger fragment). (D) The protocol 
illustrated in (C) was applied to five samples: I: healthy human myoblasts (5/5); II: DM1 myoblasts (13/800); 
III: CDM psoas muscle (12/1300); IV: DM500 myoblasts (DM500); V: RT-minus control. Interpretation of the 
signals, taking predicted amplicon lengths (C) into account, is indicated on the right. 1 The 410 bp amplicon 
may arise from an A-stretch in the genome. 2 Signals that cannot be explained with current knowledge.
«
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The (CAG)n repeat is located in an alternatively spliced DM1-AS intron
As judged from differential TSS and poly(A) site usage, primary DM1-AS transcripts vary 
between 1.2 and 6 kb in length (Fig. 1). We next wondered whether these primary gene 
products would be subject to splicing and looked for splice junctions in ENCODE RNA-seq 
data. At least 16 splice donor sites and 15 splice acceptor sites were identified (Fig. 3A; 
Suppl. Tables S2 and S3, and Suppl. Fig. S6). Frequency of splice site usage calculated based 
on the number of reads over a splice junction (exon into exon) and the number of reads 
over an unused splice site (exon into retained intron) was 2-50% (Fig. 3C). A number of 
these DM1-AS splice sites and combinations of splice modes were confirmed by RT-PCR 
using RNA from healthy human and DM500 myoblasts (Suppl. Fig. S6). Identified splice 
sites conformed to consensus sequences MAG|gtragt and yag|RNN at the 5’ and 3’ end 
of the intron respectively (Fig. 3B; Suppl. Tables S2 and S3). Notably, we identified several 
splice modes where the (CAG)n repeat was located in a large intron, indicative of a novel 
pathological cascade in DM1 by which an expanded (CAG)n repeat may end up in a lariat 
structure (Fig. 3A and Suppl. Fig. S6). 
To gain insight in the actual size of primary and processed transcripts in the 
steady-state pool of DM1-AS RNAs, we size fractionated RNA from healthy myoblasts and 
DM1 gastrocnemius muscle and analyzed each fraction for DM1-AS RNA abundance. We 
first confirmed that the fractionation was successful via RT-PCR using known reference 
transcripts of different size (MAP3K4, DMPK and GAPDH) (Suppl. Fig. S7). As anticipated, 
the influence of an expanded (CUG)n repeat on DMPK transcript migration was readily 
visible when comparing healthy and CDM material. Size-fractionated RNA was analyzed for 
relative expression of multiple regions covering the entire DM1-AS gene (Fig. 3D). Healthy 
myoblast RNA showed prominent signals in essentially all fractions between 0.4 and 7 kb, 
corroborating our other findings and suggesting that DM1-AS RNAs exist as a heterogeneous 
population. CDM gastrocnemius RNA in addition showed more prominent signal strength 
in fractions with RNA of >7 kb in length. We take this as evidence for presence of DM1-
AS transcripts containing a (CAG)1300 repeat originating from the expanded allele, which 
renders these RNAs ~4 kb longer than normal-sized transcripts. Broadening of the size 
distribution is similar to that occurring with the population of DMPK transcripts, when 
comparing RNA isolates from unaffected 5/5 and affected 5/1300 muscle (Suppl. Fig. S7).
DM1-AS transcripts are present in the nucleus and in the cytoplasm
ENCODE RNA-seq data was also used to obtain clues about the cellular localization of 
DM1-AS transcripts. Earlier observations made in our lab [54] and by others [55] already 
found a rather high nucleus : cytoplasm distribution ratio for DMPK mRNA. Comparison 
of signal ratio from nuclear and cytoplasmic fractions of transcripts from the DM1 locus 
demonstrated that also a relatively high proportion of DM1-AS transcripts - higher than 
for DMWD and SIX5 RNAs - resided in the nucleus (Fig. 4A). Some care should be taken in 
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interpreting these data, however, since the calculation for DM1-AS was based on transcripts 
from the whole transcription unit, because precise sequence information regarding mature, 
processed DM1-AS RNAs is still unknown. Discrimination between sequences specific for 
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input (size in kb indicated on top) in a series of RT-PCR reactions covering DM1-AS (8 amplicons, locations in 
(A); for approach see Suppl. Fig. S5 and Materials and Methods).
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primary and processed DM1-AS RNA, as was done for sense transcripts from DMWD, SIX5 
and DMPK, was therefore not possible.
 To experimentally validate these bioinformatics data, we analyzed how frequent 
sequences from different regions from the putative DM1-AS gene (for approach see Suppl. 
Fig. S5) were represented in nuclear and cytoplasmic RNA fractions from different types 
of myoblasts. First, efficiency of nuclear-cytoplasmic RNA fractionation was verified by 
monitoring distribution of pre-mRNA DMPK and mature ACTB transcripts, used as reference 
(Suppl. Fig. S8). We observed expression of essentially all DM1-AS regions in healthy (5/5) 
myoblast RNA, with stronger signals for the nuclear samples (Fig. 4B). As anticipated, 2 
control regions upstream from DM1-AS (regions A and B) showed no signal. To analyze 
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whether nuclear retention of DM1-AS transcripts would be more pronounced for RNAs 
carrying an expanded (CAG)n repeat, we analyzed human DM1 (13/800) and DM1 mouse 
model (DM500) myoblast RNAs (Fig. 4B). Again, we observed signal from all segments of 
DM1-AS, with strongest intensities in the nuclear fraction. No stronger nuclear retention 
than for normal-sized DM1-AS transcripts was observed (Fig. 4C), which suggests that 
nuclear retention may be an intrinsic property that is not dominated by presence of an 
expanded (CAG)n repeat. In fact, a fair proportion of DM1-AS transcripts may have lost their 
(CAG)n repeat during splicing, as part of an intron.
Multiple short ORFs are encoded by DM1-AS transcripts
To elaborate on a potential function for DM1-AS transcripts, we analyzed its encoded open 
reading frames (ORFs). In our prediction from sequence analysis, we included regular AUG-
initiated and RAN-initiated ORFs, which can run across the long (CAG)n repeat (Suppl. Fig. 
S9). Among many ORFs identified, the longest one specified a >200 amino acid-long protein, 
while the second longest consisted of 171 amino acids and continued over a splice site. 
These ORFs both used the first AUG codon present in DM1-AS. Only one ORF, starting with 
an AUG codon much more downstream, encompassed the (CAG)n repeat and would encode 
a polypeptide of 78 amino-acids + polySer-stretch (Suppl. Fig. S9).
 Each of the hypothetical peptides longer than 7 amino acids was analyzed with 
Globplot2, an algorithm for predicting intrinsic protein disorder, domains and globularity 
[48]. None showed SMART/Pfam domains and only two showed globular domains (data 
not shown). Furthermore, no region of significant sequence similarity was found for any of 
these hypothetical peptides in the Conserved Domain Database [56].
Finally, we analyzed ribosome profiling (ribo-seq) data provided by genome-wide 
information on protein synthesis (GWIPS), available via a dedicated ribo-seq genome browser 
[46]. Unfortunately, data was not strand-specific and DM1-AS information overlapped with 
those of SIX5 and DMPK (Suppl. Fig. S9). With the information retrieved from these data, we 
can thus neither confirm nor exclude protein-coding potential of DM1-AS.
DM1-AS expression level is very low, but increases with disease severity
Finally, we quantified DM1-AS expression level in more detail. Our analyses were hindered 
by extremely low signal frequencies and by uncertainties regarding splice site choices, 
coupled to the apparent lack of signal variation across putative exon and intron areas (Fig. 
1B) and the possibility of alternative RNA processing (Figs. 2 and 3). We therefore used the 
complete DM1-AS gene for the FPKM (Fragments Per Kilobase Of Exon Per Million Reads 
Mapped) calculation in ENCODE RNA-seq data from 16 cell lines, including SkMC (Fig. 5A). 
The choice for the complete DM1-AS gene may have led to an underestimation of DM1-AS 
expression in comparison to other transcripts. DM1-AS expression varied between cell lines 
and was 4-40-fold lower than that of DMPK (Fig. 5A). Parallel assessment of expression 
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levels using poly(A)-seq data (Merck Research Laboratories) of various tissues revealed that 
DM1-AS expression was lowest in brain and highest in kidney, testis and muscle (Fig. 5B). 
Since expression levels were 10-80-fold lower than that of DMPK, this analysis confirmed 
RNA-seq data. Knowing that DMPK is a low abundant transcript [57], DM1-AS transcripts 
must be very rare. Based on these comparisons, we predict that only one or two molecules 
per cell or even less - one RNA molecule per 5-10 cells – is present in most tissues.
 We also examined a coupling between DM1-AS expression and expression of 
other genes in the DM1 locus. One possibility is that DM1-AS is indeed co-regulated and 
co-expressed with DMWD, DMPK and/or SIX5. Another possibility is that their expression 
is mutually exclusive, because bidirectional convergent transcription is avoided to prevent 
collision of RNA polymerase II molecules [58]. ENCODE RNA-seq data from various cell lines 
were used, with FPKM values calculated against chromosome 19 only. Weak but significant 
positive correlations for DM1-AS expression were found, the highest with expression of 
DMPK and SIX5 (Fig. 5C). 
 Since the (CTG·CAG)n repeat in DMPK and DM1-AS is expanded in DM1 and might 
influence RNA expression from these genes positively or negatively, we used RNA-seq data 
from patients with DM1 (n=45) - classified as either mild, moderate or severe [38] - and 
controls (n=11) to quantify expression in tibialis anterior muscle biopsies. Corroborating the 
results from the ENCODE and Merck data sets, DM1-AS expression was clearly detectable in 
control muscle as well as DM1 samples, but on average 56-fold lower than DMPK expression 
in the same sample (Suppl. Fig. S10; Fig. 5D). Interestingly, no obvious differences in DM1-AS 
read density were observed between DM1 and control samples (Suppl. Fig. S10; data not 
shown). This also holds true for patterns of SIX5, DMPK and DMWD from the opposite 
strand. We observed a weak but significant expression correlation between DM1-AS and 
DMPK (Fig. 5E). Unexpectedly, a much stronger correlation between DM1-AS expression and 
DM1 disease severity was identified (Fig. 5D). DM1-AS expression increased significantly up 
to 3-fold in severely affected DM1 patients (Fig. 5D). 
Discussion
Advances in RNA sequencing technologies have given new insight in the enormous 
complexity of the RNA population that makes up the transcriptome, of which it is now 
known that only ~2% is represented by protein-encoding RNAs and 98% by abundant non-
coding RNAs. Among the latter RNAs, several classes of regulatory RNAs with important 
tasks in biological networks that orchestrate cell growth, homeostasis and communication 
within tissues are being discovered [59]. It is now well established that these tasks go far 
beyond the classical protein-coding role of mRNA or the enzymatic-structural role of rRNAs 
in ribosomes or snRNAs in spliceosomes. For some newer classes of non-coding transcripts, 
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like miRNAs, the functional relevance is already quite well established. For many others, 
in particular members of the heterogeneous group of lncRNAs, relevance is still poorly 
understood [4,59–61]. This situation may rapidly change, as the emerging idea that the 
many thousands of newly discovered RNAs are biologically important for regulation of the 
genome has led to a surge of studies aimed at characterizing the role of abnormal RNA 
expression in disease.
 Here, we report on characteristics and expression of one specific elusive RNA, the 
DM1-AS transcript, which is being produced from the DM1 locus in antisense orientation 
across the (CAG·CTG)n repeat. We anticipated that with improved knowledge on this RNA, 
we would contribute to a better understanding of how bidirectional expression of the 
unstable trinucleotide repeat in the DM1 locus could potentially contribute to the highly 
variable and complex phenotypic manifestation of disease. For many trinucleotide disorders 
it has now been well established that when expanded repeats in RNAs are transcribed in the 
sense orientation they generally cause coding or topological abnormalities (i.e., hairpins, 
G-quadruplexes), which contribute to pathogenesis via in trans effects on cellular ribostasis 
or proteostasis [5,20]. The type of problems depends on whether the repeat tract is in 
the protein-coding or non-coding portion of the RNA. A new phenomenon, called RAN 
(repeat-associated non-ATG) translation, whereby homopolymeric or dipeptide proteins are 
produced, using the repeat as template, may contribute to the complexity [62]. Whether the 
same pathobiological mechanisms apply to antisense transcripts is still an open question for 
a whole series of repeat disorders for which bidirectional transcription has been reported, 
e.g. ALS, DM1, HDL2, FXTAS, FXS, and SCA8 [7–11].
Study of this issue is often hindered by low abundance of antisense transcripts and 
the fact that the regulation of transcription and processing of antisense RNAs often does not 
obey rules that apply for production of mRNAs [7]. There is hope that clues may come from 
structural and functional differences between expanded antisense RNA in patient cells and 
normal-sized antisense RNA in cells from healthy individuals. Concurrent sense transcription 
may blur the picture however, as effects of repeat expansion in antisense RNA can then not 
be easily studied in isolation.
Tapscott and co-workers were the first to describe antisense RNA from the DM1 
locus about ten years ago [25]. In the present study we have been able, using computational 
and experimental methods not available at that time, to considerably refine the structural 
organization of the DM1-AS gene and its RNA products. Bidirectional transcription across 
the (CTG·CAG)n repeat was thought to be locally confined by CTCF binding and antisense 
transcripts were proposed to regulate local chromatin configuration, possibly after being 
converted to 21-nt fragments [25] (see literature summary depicted in Suppl. Fig. S11). We 
provide now data indicating that long DM1-AS RNAs are produced that extent downstream 
from the insulator element formed by the CTCF-binding sites. Another discrepancy with 
previous findings appears in promoter mapping, since the DM1-AS promoter was originally 
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mapped to a region upstream from and overlapping with the hypersensitive-site enhancer, 
a regulatory region located between DMPK and SIX5 [25,63]. This region contains conserved 
E-boxes and it was therefore proposed that DM1-AS expression may be regulated by MyoD 
during cell differentiation [25]. Our analysis of FANTOM5 data identified multiple TSSs for 
DM1-AS in the region complementary to SIX5 intron 1-exon 1, all upstream of the E-box 
area. To explain the differences in findings, we have to keep in mind that entirely different 
methods of TSS analysis (e.g. CAGE and RT-PCR) were used in both studies. In addition, we 
cannot exclude that TSS usage is cell-type specific: while the FANTOM5 promoter atlas is 
based on a variety of primary cells, cell lines and tissues [40], the initial report on DM1-AS 
was primarily based on data from fibroblasts [25]. Recent, detailed epigenome data for the 
DM1 locus [64] also give indication for regulatory histone marks around the newly assigned 
TSS sites proposed here and lend support to our map positions for start of the DM1-AS 
transcript (Suppl. Fig. S4).
Until we started our bioinformatics and experimental analyses only limited data 
was available on the structural organization of the DM1-AS gene, based on use of RT-
qPCR and primers positioned around the (CAG)n repeat [23,27–29] (Suppl. Fig. S11). 
Using RNA-seq information, size-fractionated RNA and tools that covered more extensive 
regions of the putative DM1-AS gene, we found that primary DM1-AS transcripts are 
subjected to alternative polyadenylation, can either be small or conspicuously long, and are 
likely to undergo alternative splicing (graphical summary presented in Fig. 6). Alternative 
transcription and RNA processing thus render a large variety of mature DM1-AS transcripts, 
with some variants being more abundant than others.
Importantly, the (CAG)n repeat is not always present in the primary transcript, 
through use of a poly(A) signal upstream of the (CAG·CTG)n repeat. When transcribed, the 
repeat is removed in approximately 20% of the transcripts, as part of alternative intron 
during splicing. Such a location in a region that can be removed during RNA processing 
creates a situation similar to that for the expanded (CCUG)n repeat in CNBP pre-mRNA 
causing DM2 [65]. Clearly, any DM1-AS RNA gain-of-function toxicity may be triggered at 
all phases in the lifetime of an abnormal DM1-AS RNA and might be caused by processing 
intermediates or by primary or mature transcripts themselves [66,67].
What can be concluded with regard to the quantity and tissue-specificity of DM1-AS 
expression? We did find significant correlations between DM1-AS expression and that of 
other DM1 locus genes, but these correlations were rather weak, indicating that regulation 
of DM1-AS expression occurs largely independently from that of SIX5 and DMPK, like was 
observed for transcripts from other bidirectionally transcribed genome regions [28,29]. Our 
bioinformatics analysis and RT-qPCR approaches have shown that DM1-AS transcripts are 
produced in essentially all cell types and tissues, always in very low abundance. Despite a 
mild increase in DM1-AS expression in patients, our findings indicate that DM1-AS transcripts 
occur roughly 5-50-fold less frequent than DMPK mRNA molecules, with variation in this 
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ratio dependent on cell or tissue type (see also [27,29]). Since we recently determined 
that the absolute number of DMPK transcripts amounts to 1-50 molecules per cell [57], 
we conclude that some cells may contain up to a dozen DM1-AS transcripts, whereas many 
others may completely lack DM1-AS transcripts or contain only one or 2 copies. Only highly 
sophisticated single-molecule single-cell in situ approaches [68,69] can determine whether 
different alternatively processed DM1-AS RNA variants occur as a mixture in one cell (with 
many other cells in the same tissue having no products at all) or whether each cell at a given 
moment contains one unique DM1-AS transcript variant.
The extremely low expression has important implications for the function of 
DM1-AS RNA and for its potential contribution to DM1 pathology. Presence of expanded 
DM1-AS RNA in the nucleus and in the cytoplasm (in a ratio that is atypical for housekeeping 
mRNAs) would allow involvement in the formation of toxic nuclear RNP aggregates and in 
the generation of RAN translation products in the cytoplasm. RNP foci containing expanded 
(CAG)n RNA have indeed been reported for DM1 cells [27,29]. Homopolymeric RAN 
peptides, which could be formed from DM1-AS RNA with expanded (CAG)n tracts, may exert 
proteotoxicity at very low concentration, alike formation of abnormally aggregated protein 
complexes around prion-protein cores in only some cells in a tissue population [70–72]. 
DM1-AS RNAs could, however, also engage in formation of dsRNA molecules by hybridization 
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Figure 6. Model for production of DM1-AS transcripts with and without a (CAG)n repeat. In the model 
the main data presented in this paper are included. The DM1-AS gene is subject to alternative transcription 
initiation (multiple TSSs) and 3’ end formation (multiple poly(A) sites, pA). These events lead to the 
production of short and long primary DM1-AS transcripts, with or without a (CAG)n repeat, presumably 
carrying a poly(A) tail. During further RNA processing, alternative splicing may occur and the (CAG)n repeat 
may be removed as part of an intron. Thus, a variety of primary and processed DM1-AS transcripts can occur, 
with and without a (CAG)n repeat, while the (CAG)n repeat may also be present in the lariat structure of an 
excised intron.
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to complementary sequences in DMPK transcripts. Such an event might trigger toxic dsRNA-
responsive kinase signaling with possible immune effects or abnormal effects of aberrant 
repeat-containing siRNA, formed after DICER processing of the dsRNA [73,74]. More 
speculative, DM1-AS transcripts may play a structural role in local chromatin organization 
in the DM1 locus in the nucleus. Potentially related to that, we identified several possible 
G-quadruplex structures in DM1-AS RNA (Suppl. Fig. S12), which could form a platform for 
protein complex formation and RNA-based guidance to the SIX5-DMPK area, similar to what 
has been described for intronic switch RNAs in immunoglobulin class switch recombination 
[75]. Whatever the (patho)biological function of DM1-AS RNA may be, it is intriguing that 
its abundance positively correlates with disease severity as assessed using functional MBNL 
concentrations [38]. Whether this correlation occurs due to repeat-dependent chromatin 
changes, increased stability of repeat-containing RNA or other mechanisms will be important 
to elucidate. 
Purely based on the expression data for DM1-AS in normal cells and tissues it is 
rather challenging - if not impossible - to properly classify the role of DM1-AS RNA. When 
taking all evidence combined, we tend to conclude that primary and processed DM1-AS 
transcripts belong to the heterogeneous class of lncRNAs [4,59–61], because they share 
many signatures with this type of RNA. LncRNAs, like mRNAs, may be subject to post-
transcriptional processing, including 5’ capping, 3’ polyadenylation and splicing. Despite 
their name-giving, it has now become clear that at least some lncRNAs still do encompass 
an ORF and can undergo translation [76]. We identified multiple AUG-initiated ORFs in 
DM1-AS, with the longest encoding a hypothetical 205-amino acid protein. By a quick 
search in short ORF (sORF) finder, we identified 2 other potential coding regions, but none 
had predicted functionality [77]. Recent studies have demonstrated that any such sORF, 
which is generally smaller than 150 codons, may encode functional peptides [78–81]. 
Gathering evidence for functional sORFs in lncRNAs has so far relied mostly on combining 
computational approaches (for identification of conserved sequences, examination of codon 
content and coding features) with experimental approaches for analyzing transcriptional 
and translational events. Development of specific antibodies and special proteomics tools 
[82] should now be considered as next steps for detection of potential DM1-AS protein 
products, but we consider this work that goes beyond the scope of our present study.
In summary, we provide evidence that DM1-AS transcripts are widely expressed 
as low abundant RNAs and propose that they belong to the functional and structural 
heterogeneous class of lncRNAs. DM1-AS transcripts are formed with different 5’ ends 
from alternative TSSs and different 3’ ends as a result of alternative polyadenylation. RNA 
processing of DM1-AS transcripts involves alternative splicing, whereby the (CAG)n repeat, 
when included in the primary transcript, can be removed in the context of an alternative 
intron, similar to what happens with the (CCUG)n repeat in CNBP intron 1 in DM2. Healthy 
and DM1 tissues thus contain a heterogeneous set of DM1-AS transcripts with and without 
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(CAG)n repeat, which not necessarily are co-expressed with DMPK mRNAs in the same cell. 
These new findings about DM1-AS expression enable us to formulate new hypotheses about 
its possible association with disease and help to refine theories on the etiology of DM1, 
improve prognosis, and facilitate the search for therapeutic targets for disease amelioration.
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Figure S5. Detection of DM1-AS transcripts in poly(A)-selected and -depleted RNA fractions. Expression of 
multiple regions of the putative DM1-AS gene was analyzed by RT-PCR using poly(A)-selected and -depleted 
RNA. (A) Position and length of PCR amplicons (A-J) over a 7 kb region in the DM locus, in the Human 
February 2009 (GRCh37/hg19) genome assembly. RNA-seq signals of both antisense (red) and sense (blue) 
genes are indicated. Vertical blue line, location of (CAG·CTG)n repeat. (B) RT-PCR approach: RNA was reverse 
transcribed using a complementary primer coupled to a linker sequence, followed by a PCR using a DM1-AS 
specific forward primer and the reverse primer on the linker or the complete RT primer. (C) Ethidium 
bromide-stained DNA fragments generated from RT-PCR A-J on agarose gel. Poly(A)-selected RNA (A+), 
poly(A)-depleted RNA (A-) and an RT-minus control (R-) from healthy myoblasts (5/5) and CDM psoas muscle 
(12/1300) were used as input. Signals were present in both the poly(A)-selected and -depleted fractions, 
and signals were entirely missing for regions A and B upstream from the most 5’ TSS, as expected. RT-PCR 
signals in (C) were quantified and relative signal strength (%) in poly(A)-selected (A+) and poly(A)-depleted 
(A-) fractions (total is 100%) was determined for each region (C-J). Average of all eight regions is shown in 
(D). Bars represent mean + SEM.
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Figure S7. Validation of agarose size-fractionation of RNA. Distribution of reference transcripts of known 
size, as determined by APPRIS (annotating principal splice isoforms), across different size-fractions obtained 
after agarose gel electrophoresis of RNA from (A) healthy (5/5) and (B) CDM (5/1300) samples was assessed 
by RT-qPCR. Reference transcripts used are: MAP3K4: 5.3-5.5 kb; DMPK: 2.8 kb; and GAPDH: 1.3 kb and 1.9 
kb. In the middle panels, the effect of presence of an expanded (CUG)n repeat on DMPK transcript migration 
in CDM RNA is apparent.
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Figure S8. Validation of nuclear and cytoplasmic fractionation. Distribution of RNA over nuclear and 
cytoplasmic fractions was monitored by measuring levels of DMPK pre-mRNA (DMPK Ex2-In2; nuclear 
marker) and mature ACTB/Actb (cytoplasmic marker) using RT-qPCR. Nuclear fraction, black; cytoplasmic 
fraction, white. Healthy human myoblasts, 5/5; DM1 myoblasts, 13/800; DM1 mouse model myoblasts, 
DM500. N ≥ 3, bars represent mean + SEM.
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Figure S9. Prediction of open reading frames in DM1-AS. (A) Potential open reading frames (ORFs) longer 
than seven amino acids in RNAs encoded by DM1-AS. AUG-initiated ORFs are indicated per frame. Three 
RAN-initiated ORFs are indicated at the bottom. ORFs up to 200 amino acids are predicted, of which only one 
includes a potential splice junction. (B) Ribo-seq data (from genome-wide information on protein synthesis, 
GWIPS) of the DM1-AS region, in the Human February 2009 (GRCh37/hg19) genome assembly. Four tracks 
describing initiating ribosomes (blue), all ribosomes (red), ribo-seq coverage (red) and mRNA-seq coverage 
(green) are shown. Data is not strand-specific, which obscures the analysis in this gene-dense region. Vertical 
blue bar, (CAG·CTG)n repeat.
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Figure S10. DM1-AS expression in muscle biopsies from DM1 patients and controls. Average RNA-seq read 
density per strand from tibialis muscle tissue from control individuals and three classes of patients with 
DM1 (mild, moderate, severe). Signals from sense transcripts (right, blue) correspond with known exons in 
DMPK and SIX5 (partially shown; gene locations indicated on top for reference). Signals originating from the 
complementary strand (left, red) indicate expression of DM1-AS (gene location based on data from Fig. 1 
indicated on top). Position of the (CAG·CTG)n repeat is indicated.
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# 1
Region 
(hg19, 
Chr19: 
46,27.,...)
Sequence (5’ → 3’) 2
GENCODE 
v19
Poly(A) 
signal
1
3,035-
3,124
CAGACAATAAATACCGAGGAATGTCGGGGTCTCAGTG-
CATCCAAAACGTGGATTGGGGTTGTTGGGGGTCCTG-
TAGCCTGTCAGCGAGTC
Annotated Canonical
2
3,133-
3,222
AGGTCAATAAATATCCAAACCGCCGAAGCGGGCGGAGC-
CGGCTGGGGCTCCGAGAGCAGCGCAAGTGAGGAGGGG-
GGCGCGGGATCCCCG
- Canonical
3
3,218-
3,307
CCCCGAAAAAGCGGGTTTGGCAAAAGCAAATTTCCCGAG-
TAAGCAGGCAGAGATCGCGCCAGACGCTCCCCAGAGCAG-
GGCGTCATGCAC
-
Non-
canonical
4
4,468-
4,557
GGCTGAATAAAGGGCTTCTGCCCTCTAAAGTCGCAAA-
GACGTAGGGTGAGCCCTATATCTGGACGGGGAGACCAG-
GAGCCAGGGAGGGGA
- Canonical
5
5,449-
5,538
TGCTCAAAATCCCTCCAGCTCCCTAATGCCCTCACGA-
CAAAAGGCCTTGCTGGGTTTTGTTTCCTGCTGGCCTCTC-
CAGCCTTCTCAGGA
-
Non-
canonical
6
5,727-
5,816
ACTGTAACTACAGAGACCGTCCCATGTCTGAAG-
TAACCTCGTCTCTCCGTGGTTTCTGTCTGCTTCTGTTCAG-
GAAGTCCCTAGAGGGCT
Annotated
Non-
canonical
7
6,684-
6,773
CCAGTAATAAAAGCTGACTAGAAAACCAACTGTTCTCT-
TAGACAAAGTAGCATGAGGAAGGGGAAAAAAACAAAC-
CAAAAAAACACCTGT
- Canonical
8
6,864-
6,953
ATCTGTATTTTCTAATTTACTTGTGATAAGCAATGCATTAT-
TTGTGTAATTAATACTTTTGTTGAGACCAGGTCTCACT-
TTGTTGCCTAG
-
Non-
canonical
9
7,888-
7,977
TGATTGTAAAAGTCTAAACTTCATATTTTCCAAGTTCTGAA-
GTCCTGTGGCTCTGTGTACTACAGACGTAAAAGTTAATG-
GTTACAAGAT
-
Non-
canonical
10
7,945-
8,034
TACTACAGACGTAAAAGTTAATGGTTACAAGATTCT-
GGGAAGCCCAGTCTGTGACTCTGAGGTTTTAAAAT-
TCAATCTAACATTTTGAAG
-
Non-
canonical
Table S1. Poly(A) signals and sites identified in DM1-AS.
1 Numbers refer to locations shown in Fig. 1 and 3 and Suppl. Fig. S3.
2 Underlined, poly(A) signal annotated in GENCODE v19 or predicted; bold, poly(A) site annotated in 
GENCODE v19 or annotated by poly(A)-seq (Merck Research Laboratories); italics, U-rich and 2GU/U tracts 
downstream of cleavage site.
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# 1 Region (hg19, Chr19: 46,27.,...) Frequent? Sequence (5’ → 3’)
Consensus MAG|gtragt
I 0,918-0,919 Yes (>50) GTGGGGGCGG|gtgggtaaga
II 0,922-0,923 Yes (>50) GGGCGGGTGG|gtaagagtaa
III 1,389-1,390 Yes (>50) CGACAGGCCG|gtgagtgtgg
IV 2,094-2,095 Yes (>50) CGCAGGCAAG|gtagccatgt
V 2,499-2,500 No CGTCTCCAGG|gtcctctgca
VI 2,537-2,538 No CCATCTCGGC|ctgcgctccg
VII 2,551-2,552 No CCCCTCGGAA|ttcccggctc
VIII 3,785-3,786 No CCAGACTGCG|gtgagttggc
IX 3,976-3,977 No ACGCCCATAG|gtgggcccgc
X 4,337-4,338 No GAAGGGACAG|gtgacccgat
XI 4,401-4,402 No GGGAATCGAG|gttggggagg
XII 4,440-4,441 No AGGGAATCTG|gtgaggcctg
XIII 4,933-4,934 Yes (>50) CTGTGGGGAG|gtaaggacgg
XIV 4,942-4,943 Yes (>50) GGTAAGGACG|gtgagtccgt
XV 5,088-5,089 No GCTCTGCCGG|gtgagcacct
XVI 6,161-6,162 No AGAGTCCCAG|gtaggccaat
Table S2. 5’ splice sites in DM1-AS.
1 Roman numerals refer to Fig. 4 and Suppl. Fig. S6.
Capital, exon; lower case, intron; bold, match with consensus. M: A or C; R: G or A.
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# 1
Region 
(hg19, 
Chr19: 
46,27.,...)
Frequent? Sequence (5’→ 3’)
Consensus yag|RNNN
i
1,010-
1,011
Yes (>50)
gagaagggtttgggttAcagggaaaccggagctgggaaaggttcAcgtttcAcaacaaagg-
cagaagacggaccacgccgtccgggcccggagggagtgtgggggcgggtgggtaAgagtaAc-
ggtcAgtgAagaaagggggctgggaggcagcccctacgcggagtggagtggccacaggccct-
gtcctttttcctcag|TCCCTCTAGT
ii
1,745-
1,746
No
tacttgtccactgcgccaagcgcgcggccgcgggcccgctcggcctcAtggtagcgcgcgcgcag-
gtagaggtcctgcaggaaggcgtggtgggcggcggggaaggggcggctctcgagtagccggta-
gagctcggcgtactcgccccgctggaaggccaccagggcccgcgcgcgcaacaccgggtcgctgc-
cacgtag|GCGCTCGGCC
iii
2,372-
2,373
No
cctgtccccccttttcgcccccactccccgctcttctcgatcttctttctggccgaccctgcgccccacgc-
cgggaaggcgagatccagctctccactcgggtctctgtccccttgtgtgtgtccgtccccctcccgtct-
gtctgtgAttctccctttgttttccctccgcctctggccgcgctttctgcctccccccag|CGTGT-
GCTTC
iv
2,390-
2,391
No
ccccactccccgctcttctcgatcttctttctggccgaccctgcgccccacgccgggaaggcgagatc-
cagctctccactcgggtctctgtccccttgtgtgtgtccgtccccctcccgtctgtctgtgAttctc-
cctttgttttccctccgcctctggccgcgctttctgcctccccccagcgtgtgcttctggctcag|GG-
CCTCAGTT
v
2,588-
2,589
No
cctcagtttccccatcgggacaacgcagaaggtaAcgggccgtccaggaggactaAgggcgc-
gaagcctccgccccgagactgAgcttctgcacgcctccgtctccagggtcctctgcaggcccccacat-
tccccatctcggcctgcgctccgcccctcggaattcccggctccgcagggggggcgggtctggccgg-
gag|GAGGGGCGGG
vi
2,597-
2,598
No
cagtttccccatcgggacaacgcagaaggtaAcgggccgtccaggaggactaAgggcgcgaag-
cctccgccccgagactgAgcttctgcacgcctccgtctccagggtcctctgcaggcccccacattc-
cccatctcggcctgcgctccgcccctcggaattcccggctccgcagggggggcgggtctggccgg-
gaggag|GGGCGGGGAA
vii
2,650-
2,651
Yes (>50)
gcgcgaagcctccgccccgagactgAgcttctgcacgcctccgtctccagggtcctctgcaggc-
ccccacattccccatctcggcctgcgctccgcccctcggaattcccggctccgcagggggggcgg-
gtctggccgggaggaggggcggggaacgggctagaaagtttgcagcaacttttctcgagcttgcgtc-
ccag|GAGCGGATGC
viii
2,874-
2,875
No
ggcgcagtggaaggaggatggccgcgcgcgctgccagcccagccccctcttctcgacgctcggt-
ggcacagctgggccacagctgggcgggggcggtgcctccgggtggcccgctcgccctcctattg-
gccggacgccaaagccccgccccgtggcttttcctcccccaaccctgAttcggccgcttcgcatc-
ccgctag|CTCCTCCCAG
ix
3,099-
4,000
No
cacgcctccggattggcccgctgcggagcctccggcccacaacgcaaaccgcggacactgtg-
gagtccagagctttgggcagatggagggccttttAttcgcgagggtcgggggtgggggtcctag-
gtggggacagacaataAataccgaggaatgtcggggtctcAgtgcatccaaaacgtggattggg-
gttgttgggg|GTCCTGTAGC
Table S3. 3’ splice sites in DM1-AS.
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# 1
Region 
(hg19, 
Chr19: 
46,27.,...)
Frequent? Sequence (5’→ 3’)
Consensus yag|RNNN
x
4,747-
4,748
Yes (>50)
agggaggggatctgcagaatgggcagcaggtctgAggcaggggaaagagaggggtcttAcatg-
ggaaggtggatccgtggcccggggactggggacccccgtgAcagctggaaggagaagaaagag-
gcatagggcgcgtggaggggcgaaggagggcggtggcgcggcgtgccccagcgtgggtcccttc-
cctcctccag|GTGTCTATAC
xi
4,847-
4,848
No
gtgacagctggaaggagaagaaagaggcatagggcgcgtggaggggcgaaggagggcggtggc-
gcggcgtgccccagcgtgggtcccttccctcctccaggtgtctatacacgccccgcggagcagacgg-
cccacctcctcccggtcctccggggaaggggacacatgAgggactcAcctgtggctccctctgcctg-
cag|CAACTCCATC
xii
5,563-
5,564
Yes (>50)
ccccatccctgAgtctggtcctctaAatctacacagggaccagagggctggtgctcAaacacta-
AcacaacctatgtccctctgctgctcAaaatccctccagctccctaAtgccctcAcgacaaaag-
gccttgctgggttttgtttcctgctggcctctccagccttctcAggaatgAttcAgccaaac-
tacctttcag|GAACAAATCA
xiii
6,092-
6,093
No
acttactgtttcAtcctgtggggacaccgagggctccaggctgggcgcttgcacgtgtggctcAag-
cagctgctcggcctccagttccatgggtgtggggcctgggacctcActgtccctggggagaggag-
gagggagtggggagggagacagaatgctgAttctctggtggagaaccagaacttctggcctgtggg-
tag|GGGCAGCTGC
xiv
6,253-
6,254
No
ttctctggtggagaaccagaacttctggcctgtgggtaggggcagctgcttccaagacctcctgAttt-
gAggaaggggagcagcagagcgaagagaacagagtcccaggtaggccaatagcccctcctct-
gcttAggaaaagccctgcccctctcctggccttgggcccctgggagctgctctttctaaaccttctg-
cag|GGACTTGGGG
xv
6,322-
6,323
No
aggaaggggagcagcagagcgaagagaacagagtcccaggtaggccaatagcccctcctctgct-
tAggaaaagccctgcccctctcctggccttgggcccctgggagctgctctttctaAaccttctgcag-
ggacttggggtccagacccccatgttctagggtcAgctcAtctcctcccttgAcatgtgaccgctg-
cag|ACCCCTCTTC
1 Roman numerals refer to Fig. 4 and Suppl. Fig. S6.
Capital, exon; lower case, intron; bold, match with consensus; A: Potential branchpoint 
(via http://regulatorygenomics.upf.edu/Software/SVM_BP/). Y: C or T; R: G or A); N, any nucleotide.
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DM1: an archetypal member of the trinucleotide repeat disorder family
Until now more than 30 genetic diseases have been identified that are caused by expansion of 
short tandem repeats in the genomic DNA. Many of these are classified as neuromuscular or 
neurodegenerative disorders [1,2]. Although most of these diseases are rare, together they 
are not that infrequent, affecting about 3-17 in 10,000 individuals in the general population 
[3]. Among the different dynamic events that occur in the repeats in these disorders, the 
trinucleotide or triplet repeat expansions are the most intensely studied type of mutation.
 In repeat expansion disorders various mechanisms of disease manifestation may 
be involved, depending on the location of the repeat segment in a coding or non-coding 
region. For example, when an expanded trinucleotide repeat is present in the coding region 
of a gene, toxic proteins with long polyglutamine or polyalanine stretches may be generated, 
while RNA gain-of-function effects may occur when the repeat is located in a non-coding 
region. Importantly, we know now that repeat tracts may also be translated outside the 
context of the open reading frame of the annotated gene in which they are located, by a 
process called RAN translation [4].
Myotonic dystrophy type 1 (DM1), the focal subject of my PhD study, is caused by 
a (CTG·CAG)n triplet repeat expansion in the q-arm of chromosome 19. It is located in the 
3’ untranslated region (UTR) of the DMPK gene [5–7] and also situated within a gene on the 
opposite DNA strand (DM1-AS) transcribed in antisense direction. In DM1, several different 
pathogenic mechanisms may contribute to disease manifestation in which transcripts with 
expanded (CUG)n and (CAG)n repeats from these genes play a central role [8,9]. So far, 
mainly the consequences of expression of toxic (CUG)n-bearing transcripts from the DMPK 
gene on cellular homeostasis were studied. These studies were carried out by different DM1 
researchers and partly had a joint character. Together, they have had a major impact on our 
current understanding of the DM1 disease mechanism.
In this discussion I will provide a summary of the findings from my PhD study (Fig. 1) 
and explain which approaches were used to broaden our focus, not only for obtaining more 
insight in fate specification of DMPK mRNAs, but also to include new data on the possible 
role of DM1-AS transcripts. I expect that the here provided detailed picture of structure, 
intracellular fate and expression level of normal and mutant transcripts from genes in the 
DM1 locus will aid in a better understanding of DM1 pathobiology.
DMPK mRNA expression in cells, tissues and transgenic models
Because muscle is one of the major tissues affected in DM1, we decided to conduct almost 
all our studies on DMPK mRNA expression in this cell type. In Chapter 2 is described that we 
observed an increase in DMPK transcript levels in confluent myoblast cultures at the start of 
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Upregulation of DMPK RNA expression
Unchanged nucleocytoplasmic distribution
1-25 expanded DMPK RNA copies per cell
Nuclear retention of expanded DMPK RNA
Expanded DMPK poly(A) tail of 0-500 As
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Figure 1. Graphical abstract. Summary of the main findings described in this thesis. Observations in 
proliferating cells are described on the left. Changes seen upon G0-arrest, induced by for example myogenic 
differentiation or contact inhibition, are described on the right. The situation in healthy, non-DM1 cells is 
described on top, and cells containing an expanded (CUG)n repeat are described in the bottom panel.
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myogenic differentiation. A similar increase was seen upon forced G0-arrest (Chapter 4). An 
increase in steady-state expression level was also observed during the transition to contact 
inhibition in fibroblast cultures. Arrest of cell proliferation in vitro thus appears to coincide 
with upregulation of DMPK mRNA expression.
 In vivo, DMPK mRNA is already expressed during the initial stages of myogenic 
differentiation, very early in embryonic development [10,11]. Unfortunately, we could 
not verify, due to the lack of specific antibodies, whether also the level of DMPK protein 
isoforms is similarly controlled. Still, we consider it likely that also DMPK and hence its 
kinase activity undergoes upregulation during cell cycle arrest. DMPK is a serine-threonine 
kinase and closely related to other kinases of the AGC kinase subfamily that interact with 
members of the Rho family of small GTPases [12]. Evidence for involvement in regulation of 
actin cytoskeleton dynamics and ion homeostasis has been reported [12–15], but much is 
still unclear about DMPK’s biological role. It is tempting to speculate that the upregulation of 
DMPK expression serves in the control over shape alterations and intracellular remodeling 
that myoblasts (and several other cell types that express DMPK) undergo during cell cycle 
arrest and onset of terminal differentiation. 
 For combined study of the molecular and integral pathophysiological problems in 
DM1, multiple transgenic animal models have been developed in the past [16]. In Chapter 2 
we compared one central feature of representative mouse models, namely the expression 
behavior of transgenes with a normal or expanded (CTG·CAG)n repeat. Using muscle tissue 
and immortalized, model-derived myoblast lines of four of the most intensely studied DM1 
mice, we measured transcript profiles at different differentiation stages in vitro and in vivo. 
In myoblasts derived from mice with a complete human DMPK transgene, DM500, DMSXL 
and Tg26, the pattern of expression was similar to what is observed in human myoblasts, 
with a peak at the start of differentiation. In HSALR mice, an alternative model with a human 
ACTA1 transgene containing an artificially introduced (CUG)250 repeat in the 3’ UTR, repeat-
containing RNA expression was similar to endogenous Acta1 expression. For myoblasts and 
tissues of this mouse model we observed late onset of transcription start and upregulation 
throughout differentiation.
 Besides differences in expression profiles of the transgenic RNAs during onset of 
differentiation, also copy numbers of (CUG)n-containing RNAs in skeletal muscle showed 
large variation between the models. Transgene expression in the DM500/DMSXL and HSALR 
lines is ~10-fold lower and ~1000-fold higher, respectively, compared to endogenous Dmpk 
mRNA levels in mouse. Furthermore, triplet repeat length varied between the models. 
The other potential player in DM1, DM1-AS RNA, was not studied in this chapter. Based 
on knowledge regarding the structural organization of transcription units in the transgenic 
genomic insert, on advanced insight in DM1-AS transcription and DM1-AS RNA processing 
(Chapter 5) and also on literature data [11,17], we predicted that only DM500 and DMSXL 
cells will express this antisense transcript. 
202
Chapter 6 Summarizing discussion
6
Care should be taken on interpreting and translating findings in the DM1 models to 
the disease symptoms in patients, even though each model has its own benefits in studying 
particular aspects of DM1. For example, the HSALR mouse is used for preclinical trials, since it 
is the only model with a clear phenotype [18], allowing read-out of DM1-typical biomarkers 
as a measure of therapeutic efficacy. The question then remains why this model requires 
such a huge amount of toxic RNA to develop a phenotype, while patients with DM1 suffer 
from severe symptoms when expressing a considerably lower dose of toxic RNA (Chapter 
2). Potentially the sequences surrounding the repeat and the timing of expression during 
development and differentiation are of significant importance.
Repeat RNAs in disease: low copy numbers, large effects
The major pathogenic effects contributing to DM1 manifestation are thought to be caused 
by an RNA gain-of-function mechanism, in which the expanded (CUG)n repeat abnormally 
binds protein factors in the nucleus. Proteins involved are members of the muscleblind-
like (MBNL) family or other protein factors with RNA-binding ability. The diminished or 
altered availability of MBNL proteins, which function in alternative splicing, polyadenylation 
and mRNA transport, results in aberrant expression of embryonic splice isoforms of target 
genes in adult tissue and misregulation of alternative polyadenylation events [19,20]. The 
RNA gain-of-function in DM1 thus largely relies on the sequestration ability of RNAs with 
an abnormal (CUG)n hairpin and therefore on DMPK mRNA copy number. In Chapter 2 I 
described that only 1-50 DMPK mRNA molecules are present per cell, half of which contain 
an expanded (CUG)n repeat in DM1-affected cells. Questions thus arise on how only a few 
expanded transcripts can sequester enough MBNL molecules or other proteins to create a 
disbalance in the available pool of RNA processing factors and abolish proper functioning of 
the cell, especially in cells with (CTG·CAG)n expansions of relatively small size. 
 RNA foci, the expanded DMPK mRNA molecules together with the sequestered 
protein factors, can be visualized in the nucleus by fluorescence in situ hybridization (FISH) 
with (CAG)n probes and by immunofluorescence assays with MBNL antibodies [21,22]. 
Based on the number of visible RNA foci in a typical DM1 cell (mostly ranging between 
1-10 [11,21,23,24]) and our new estimate of (CUG)n RNA copy numbers, we propose that 
each focus must be nucleated by one or only very few expanded DMPK transcripts. Also for 
C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), 
other members of the family of repeat disorders, it is now shown that foci are composed 
of one expanded transcript [25]. But how then can so few foci affect the concentration of 
active MBNL proteins in the cell? MBNL1 protein copy number per cell, which ranges from 
9,000 in a human osteosarcoma cell line [26], 480,000 in a mouse fibroblast cell line [27], 
and on average 52,000 and 490,000 in various mouse tissues and cell lines respectively [28], 
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is much higher than the DMPK mRNA copy number (Addendum to Chapter 2). If all MBNL1 
proteins have to be sequestered in RNA foci in DM1 cells, at least 360 MBNL1 protein copies 
(assuming presence of minimally 9,000 MBNL1 copies and at most 25 expanded DMPK 
copies per cell) must be bound per expanded DMPK transcript. This number is presumably 
an underestimate for many cell types.
 Binding of MBNL1 proteins by the (CUG)n repeat can either be direct, with an 
observed packing density of one protein per (CUG)4 repeat [29], or indirect, through self-
dimerization [30]. For complete MBNL1 sequestration, the required mean repeat length 
must thus at least be 700 triplets, and probably more in most cells. We should also not forget 
that MBNL proteins occur in many splice isoforms and are partitioned at many subcellular 
locations. Our predictive calculations therefore have less value if the effects of factor 
titration affect only the biological role of one or few MBNL1 isoforms or are effectuated only 
in particular locales of the interchromatin space. 
From Mbnl knock-out mice we have learned that many DM1-related splicing defects 
and symptoms are triggered when the last remaining fraction of Mbnl protein is lost [31,32]. 
In congenital DM1 (CDM) patients, the repeat length is in general over thousand triplets 
and thus presumably sufficient for complete sequestration of MBNL protein molecules. 
This ability likely contributes to earlier onset of disease manifestation, and the much higher 
severity of symptoms already around birth. In patients with adult onset DM1 the repeat 
length as determined for blood cells is much shorter, but the repeat is expanded during life 
due to somatic instability, and may show behavior which differs between tissues. This may 
play a role in the variable but overall progressive disease manifestation. Still in this category 
of patients, it remains difficult to explain DM1 pathology solely by the loss of MBNL function, 
since I expect that not all MBNL protein molecules in the available pool can be sequestered. 
Experimental support for this anticipated situation comes from immunofluorescence 
experiments in DM1 cells, which revealed that the amount of freely available MBNL in the 
nucleoplasm is decreased, but not entirely depleted [22].
I therefore assume that also other disease mechanisms are involved in DM1 
pathology. Toxic effects of the repeat RNA may for example be amplified via stress-
signaling cascades. Expression of expanded (CUG)n repeats suppresses Cdk4 signaling 
by increasing the stability and activity of glycogen synthase kinase 3β [33], and results in 
hyperphosphorylation and stabilization of CUGBP1 via PKC activation [34]. Also, (CUG)n RNA 
activates double-stranded RNA-dependent protein kinase R, ultimately leading to inhibition 
of translation of certain mRNAs [35,36]. Over time, accumulation of these forms of stress 
in a number of cells, caused by various cellular events, can easily lead to progressive loss of 
cells and ultimately loss of tissue function. 
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What does DMPK transcript distribution over the cell tell us? 
DMPK transcripts with an expanded (CUG)n repeat are known to be largely retained in the 
nucleus [21,37]. For this behavior presence of the repeat itself is necessary and sufficient, 
since also in the HSALR model artificially expanded ACTA1 transcripts are retained in the 
nucleus [38]. In Chapter 3 we observed that not all expanded DMPK transcripts were 
retained in the nucleus in proliferating DM1 myoblasts. This may be explained by escape of 
nuclear transcripts during cell division, when the nuclear envelope breaks down [24]. Some 
studies have shown that the extent of nuclear retention correlates with repeat length [39], 
so transcripts carrying a repeat with intermediate length may not be completely blocked in 
nucleocytoplasmic transport.
 We also analyzed nucleocytoplasmic distribution of normal-sized DMPK mRNA and 
found in myoblasts a higher nuclear abundance than for housekeeping mRNAs ACTB and 
GAPDH. This deviant subcellular localization may be indicative for a specific mechanism of 
gene expression regulation. It has been described that mammalian transcription occurs in 
bursts and levels of cytoplasmic mRNA are regulated by nuclear retention to reduce gene 
expression noise [40,41]. To see whether such a mechanism would also underlie DMPK 
mRNA retention, we compared the DMPK nucleocytoplasmic distribution in proliferating 
and G0-arrested myoblasts and fibroblasts. In the G0-arrested cells we observed an increase 
in DMPK mRNA expression, however, this was not associated with a clear shift in subcellular 
localization of the transcript. Apparently, there is no urgent reason for the cell to smoothen 
the increased and perhaps fluctuating bursts of DMPK by a regulatory mechanism that 
involves nuclear retention of the mRNA, but further study of this is needed. At this point it is 
also difficult to speculate about the biological significance of DMPK mRNA - and presumably 
DMPK protein - upregulation upon growth arrest and alteration of differentiation state. From 
the work presented here and from already available literature data on RNP aggregation, we 
may conclude that during all phases of cell state differential pathways for nuclear retention 
must be involved for normal-sized and expanded transcripts. A pathological cascade is only 
triggered if transcripts with expansions are involved. To obtain more in depth insight in the 
coupling between cell state and DMPK expression modes and levels for normal and mutant 
gene products, future experiments should focus on single-molecule transcript and protein 
imaging techniques with high-resolution microscopy. 
In our transcript distribution analyses we focused on cell populations, thus 
assessing average values and potentially missing delicate changes or differences between 
cells. In the future, DMPK mRNA expression and distribution should be studied in single 
cells. Since a DMPK transcript with an expanded (CUG)n repeat contains a multitude of 
binding places for a fluorescent (CAG)n oligo, thus allowing a good signal-to-noise ratio, 
RNA foci were already studied in single cells with FISH in Chapter 2. Single molecule FISH 
approaches [42–45], some of which employ a signal amplification step, are now available 
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to study also normal-sized DMPK mRNA. Unfortunately, all these methods require sample 
fixation, while we would ideally like to visualize DMPK mRNA in living cells, to study the 
molecule from cradle to grave.
The MS2-GFP system, based on the presence of multiple MS2 stem loop structures 
in the transcript to which GFP-tagged MS2 proteins can bind [46], and the Spinach RNA 
aptamer, which binds and activates a small fluorophore [47], represent methods to visualize 
transcripts in living cells. Employing such imaging techniques is not without challenges. For 
example, the Spinach RNA aptamer proved to be salt sensitive and improved versions are 
still being published [48,49]. Despite our attempts to optimize experimental conditions, we 
were not able to successfully use the early versions of the Spinach aptamer in our research 
(unpublished data). Moreover, these approaches require genetic encoding of the tag and 
are often used in transfected, artificial constructs. Recent advances in the CRISPR/Cas9 
technology provide a tool for targeted insertion of MS2 stem loop or Spinach aptamer 
sequences in the genome [50]. However, in that case, despite endogenous expression, the 
transcript would contain multiple versions of a tag which may influence cellular localization 
and RNA-protein interactions. The ultimate goal is to track unaltered endogenous DMPK 
mRNA molecules in living cell. This may be achieved using a recently described method 
based on a catalytically inactive Cas9 protein with a fluorescent tag which is loaded onto a 
specific mRNA sequence by a guide RNA [51]. But again, although the transcript targeted 
by this approach is endogenous, being bound by a non-endogenous protein may alter its 
intracellular routing.
Long poly(A) tails independent of repeat expansion
Since also normal-sized DMPK mRNAs have a rather high nucleocytoplasmic distribution, we 
extended our research into RNA fate specification to polyadenylation, an important aspect 
of transcript processing in the nucleus. In Chapter 4 we reported that we observed lengths 
for DMPK poly(A) tails that ranged from almost 0 to up to 500 A-residues. This size range 
appeared abnormally broad compared to poly(A) tail lengths reported in literature of few to 
250 As [52]. Poly(A) tail length may impact several processes, including mRNA localization, 
translation efficiency and stability [53], but whether the tail plays a role in DMPK mRNA’s 
destiny remains to be determined.
 A delay in nucleocytoplasmic transport has been associated with hyperadenylation 
of mRNAs [54,55]. This idea primed us to also assess poly(A) tail length distribution of 
expanded DMPK transcripts retained in the nucleus. For separate analysis of normal and 
expanded DMPK transcripts in DM1 samples, we developed a method to independently 
isolate and analyze both transcripts based on differential migration speed in agarose gel, 
caused by the length difference of the (CUG)n repeat. This approach is simple and effective, 
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and may also be useful for separate analysis of normal-sized and expanded transcripts 
involved in other repeat expansion diseases, provided that the mutational increase in repeat 
length causes an adequate shift in migration.
 We also tested an alternative strategy for separating normal-sized and long DMPK 
transcripts, based on preferential binding of transcripts with an expanded (CUG)n repeat 
to magnetic beads coated with a (CAG)7 oligonucleotide (Addendum to Chapter 4). Initial 
results were very promising, but recovery of intact expanded DMPK transcript was not 
always successful or reproducible. Similar approaches have been established in literature, 
for example for pull down of microRNA targets using biotinylated microRNA mimics [56]. 
We attribute the difficulties encountered while using this method to the length of the 
expanded DMPK transcripts (~8,500 nt). RNAs of that size are vulnerable to breakage during 
experimental manipulation and may therefore not appear entirely equally in the enriched 
fraction.
 Using the migration speed dependent separation method, we analyzed the poly(A) 
tail length of expanded DMPK transcripts. Despite their uniform behavior with clear nuclear 
retention, we did not observe a significantly longer poly(A) tail length than in normal-sized 
DMPK mRNA. Thus, hyperadenylation of expanded DMPK RNAs had not occurred. Moreover, 
we and others have found no evidence for alterations in alternative splicing of expanded 
DMPK transcripts [37,57,58]. Major aspects of processing of expanded DMPK mRNA thus 
seem to occur normal and cannot provide a rational explanation for the observed nuclear 
retention. Rather, aberrant protein binding of for example MBNL1 and hnRNP H is likely the 
major cause of DM1-related nuclear retention, as supported by nuclear release of expanded 
DMPK mRNA upon MBNL1 knockdown [58–60] and restoration of cytoplasmic expression 
upon hnRNP H knockdown [61].
Antisense (CAG)n transcripts from the DM1 locus
Advances in transcriptome sequencing have revealed that the genome is pervasively 
transcribed at most genomic loci in a bidirectional fashion [62]. The first clues on bidirectional 
transcription of the triplet repeat region in DMPK date already from a decade ago [63]. 
In Chapter 5, we described how combined use of bioinformatics and wet-experimental 
molecular approaches enabled us to analyze the structural and functional organization of the 
region that produces the antisense transcripts from the DM1 locus (DM1-AS) in more detail. 
We identified transcription start sites in the region complementary to intron 1 and exon 1 
of SIX5, upstream from the (CAG)n repeat from the antisense perspective. DM1-AS RNAs 
thus initiated are heterogeneous in length, not only because of alternative transcription 
initiation, but also due to alternative splicing and poly(A) site usage.
 Of special interest is of course the question whether the expanded (CTG·CAG)n 
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repeat segment is always transcribed in opposite direction in patients, forming RNAs with 
(CAG)n repeats that may contribute to pathogenesis. Unfortunately, this question cannot 
be unequivocally answered as we found alternative polyadenylation signals upstream and 
downstream of the (CAG)n repeat. Therefore the repeat region is not always included in 
primary antisense transcripts of the DM1-AS gene. We further observed that the DM1-AS 
primary transcript undergoes extensive alternative splicing, in which the (CAG)n repeat is 
located in an alternative intron. In DM1, the expanded (CAG)n repeat may thus potentially 
exert toxic effects as part of a mature RNA or as integral part of an intron, alike in DM2, 
caused by an expanded (CCTG)n repeat in an intron of the CNBP gene. 
 Bidirectional transcription of a trinucleotide repeat has been reported for multiple 
unstable microsatellite diseases, like Huntington’s disease (HD), Huntington’s disease-like 
2 (HDL2), fragile X-associated tremor/ataxia syndrome (FXTAS), fragile X syndrome (FXS) 
and spinocerebellar ataxia 8 (SCA8) [64–68]. Complete characterization of the antisense 
transcripts and the extent to which they contribute to disease will be difficult to assess, 
since copy numbers are usually low and multiple mechanisms of disease may be involved 
depending on the location of the repeat in the transcript. 
Like other expanded RNAs in expansion disorders, expanded DM1-AS transcripts 
may abnormally bind proteins, like MBNL1, leading to aggregation in RNA foci. Indeed, 
(CAG)n-based foci have been observed in human DM1 material [11]. Expansion of (CAG)n 
stretches may thus also lead to sequestering of factors like MBNL1 [69], but this has not 
been shown for expanded DM1-AS RNAs yet [11]. Furthermore, if both sense and antisense 
transcripts co-exist in one and the same cell, double-stranded RNA structures may form 
between parts of DM1-AS and DMPK RNA, especially across the expanded repeat region. 
DICER may process these double-stranded RNAs into siRNAs, which may trigger downstream 
silencing of genes containing short (CAG) repeats, for example of the TATA binding protein 
and Ataxin-2 genes [70]. 
Toxic homopolymeric proteins may be produced from the expanded DM1-AS RNAs. 
We identified a few ORFs of >50 amino acids in the transcript, one of which runs across 
the repeat region and specifies a polyserine stretch. When engaged in non-conventional 
repeat-associated non-ATG (RAN) initiated translation the repeat in DM1-AS RNA may 
produce polyalanine, -glutamine and -serine proteins. At this point it is important to note 
that polyglutamine-containing proteins have actually been found in DM1 cells [71]. Such 
homopolymeric proteins may be toxic at very low copy number since low-complexity 
regions in proteins may have an amyloidogenic propensity to trigger protein aggregation in 
vulnerable cells and potentially have the ability to spread to neighboring cells in a prion-like 
manner [72–75]. In multinucleated cells, like myotubes, the cytoplasm is shared between 
multiple nuclei and proteins may spread between intracellular sites of fused myoblasts in 
one myotube, while shuttling through their common cytoplasmic space [76]. Such spreading 
mechanisms may contribute to toxicity. 
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To accurately determine if and how DM1-AS contributes to DM1 disease 
manifestation, additional experiments are required. DM1-AS RNA expression is very 
low: our current estimates range between 1 transcript per 1 to 10 cells. Therefore, to 
trigger pathogenicity to measurable levels in short term experiments in vitro, boosting 
expanded DM1-AS expression levels may aid in deciphering its potential harmful role. Such 
experiments have now become possible by use of the CRISPR-Cas9 system, whereby a 
catalytically inactive dCas9 protein can be fused to a transcriptional activation domain. Upon 
expression of this chimeric factor in target cells, frequently an increase of transcription can 
be achieved by the use of proper guide RNAs that recognize transcriptional control motifs 
within the desired locus [77–79]. Since the promoter regions of SIX5 and DM1-AS are in 
close proximity, it is possible that this system will lead to upregulation of expression of both 
genes simultaneously. Care should thus be taken in attributing cellular effects to DM1-AS 
expression, since increased SIX5 expression may also contribute, for example by altering 
levels of target genes [80]. To specifically study the effect of DM1-AS RNA, cell- or animal 
models should be generated that express an artificial DM1-AS construct with an expanded 
(CAG)n repeat. This would give an opportunity to study the effect of an expanded (CAG)n 
repeat in DM1-AS RNA, in absence of an active expanded DMPK gene (provided that its 
promoter is lacking). Analysis of these models at both RNA and protein level will indicate 
whether (CAG)n RNA foci are formed that sequester proteins and whether homopolymeric 
proteins are produced.
Apart from a potential role in DM1 pathology, the regular function of DM1-AS in 
healthy tissue remains elusive. With characteristics like an extremely low copy number (~10 
fold lower than DMPK), predominant nuclear localization and no evident major ORF, DM1-AS 
may be classified as a lncRNA. Many antisense lncRNAs are thought to function in gene 
expression regulation. This may occur at various stages, from transcription and translation 
to RNA degradation [81]. Knowledge on subcellular localization of a lncRNA may provide 
additional clues on functionality [82]. For example, a lncRNA primarily located near a site of 
transcription may be involved in transcriptional regulation of that gene or a neighbouring 
locus [83–85]. In future efforts sensitive single molecule FISH methods, as described above, 
will be needed to analyze the DM1-AS intracellular transcript distribution to contribute to 
our understanding of its functionality.
Our study of DM1-AS transcripts has greatly benefitted from publicly available 
(epi-)genome and transcriptome datasets from consortia like ENCODE and FANTOM. This 
underscores the potential value of such data for other research projects, beyond the original 
purpose of the data. When asking the relevant questions, large datasets can be successfully 
mined. Furthermore, the availability of open access data is of great importance [86]. Only 
by sharing knowledge we can build on previous findings and together contribute to improve 
understanding.
209
Summarizing discussion
6
Translational impact and future directions
Throughout this thesis, we mainly focused on skeletal muscle tissue and the study of muscle 
cells. Myoblasts - whether as primary or immortalized cells - can easily be propagated in 
culture in vitro and be kept in a stage of differentiation that is reminiscent, but not identical, 
to that of satellite (muscle progenitor) cells in vivo. Muscle was chosen because it is the 
principal affected tissue in DM1 patients. DM1 is not simply a muscular disorder, however, 
but rather a multisystemic disease, with for example devastating neurological and cardiac 
symptoms [8]. Expanding our analyses, based on the methodology now developed, to other 
cell types, like neurons or astrocytes and cardiomyocytes, would thus almost certainly 
contribute to a more complete understanding of DM1.
By expanding our knowledge of players involved in DM1 pathology, the work 
described in this thesis forms a foundation for more translational studies in the near 
future. For example, we have provided a detailed description of the DM1-AS gene and 
transcript(s) in Chapter 5, whereby our analysis of sites for transcription initiation, 
alternative polyadenylation, splice processing and ORFs open up various new possibilities 
for involvement of DM1-AS transcripts in clinical problems in DM1 patients. Possible 
contribution of DM1-AS RNA to DM1 pathobiology via RNA gain-of-function toxicity or RAN 
production of homopolymeric proteins [71] is thereby shared with the mechanisms that 
involve mutant DMPK gene and DMPK transcripts.
Merely based on the copy number estimates presented, one may conclude that 
production of mutant DM1-AS RNA and protein should be regarded less important for disease 
development. But does this line of reasoning make sense, given the limited knowledge that 
we now have? The identification of DM1-AS as a lncRNA may in fact imply that DM1-AS 
transcripts have truly novel biological significance, without overlap with the conventional 
pathobiological nature of mutant DMPK gene products. We consider it therefore necessary 
to examine if such possible hypothetical significance may have implications for disease 
manifestation and/or progression. Once that insight has been acquired it will certainly help 
in future decision making regarding the development and improvement of therapeutic 
modalities for DM1.
Ideally, future therapeutic approaches in DM1 should focus on the development 
of procedures aimed at blocking the toxic effects of repeat expansion, while leaving the 
normal biological role of the unaffected DMPK or DM1-AS gene and gene products 
intact. One commonly accepted strategy that is already in pre-clinical use is based on the 
development and use of antisense oligonucleotides or small organic drug compounds to 
selectively degrade the expanded DMPK (CUG)n mRNA or block the factor binding ability of 
the (CUG)n repeat [18,87,88]. In fact, besides the absence or presence of the repeat tract 
my PhD studies did not directly yield additional properties that could be straightforwardly 
employed to differentially target transcripts from the normal and mutant DM1 locus. No 
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obvious differences were found in polyA tail length distribution and - although complete 
nuclear aggregation is a special feature of mutant transcripts - prolonged nuclear residence 
time was also found for DMPK mRNA. Potentially other steps in the processing and 
metabolism of both DMPK and DM1-AS RNAs could be employed. One alternative approach 
for eliminating the toxic (CUG)n repeat from DMPK pre-mRNA would perhaps be to stimulate 
alternative cryptic splicing around the (CUG)n repeat in DMPK mRNA, or of the (CAG)n repeat 
in DM1-AS RNA once we know more about the splicing events involved in production of this 
presumed lncRNA. Own unpublished data supported by data from Dr. Eric Wang (Univ. of 
Florida, Gainesville, FL, USA; Poster at IDMC-6, Milan, Italy, 2007) have shown that the (CUG)
n repeat in DMPK pre-mRNA is located in a cryptic intron. Antisense blocking or stimulating 
oligonucleotides might thus be used for altering splice site choices and promoting removal 
of the (CUG)n-containing intron from DMPK pre-mRNA, similar to therapeutic strategies 
aiming at upregulation of an infrequent splice mode in spinal muscular atrophy (SMA) 
[89,90] or forcing exon skipping in Duchenne muscular dystrophy [91]. Clearly, for intron 
removal to be effective as a DM1 therapeutic approach, the (CUG)n-containing intron must 
be degraded after being spliced out, as a repeat located in an intron may still cause disease 
like in DM2. Also the consequences of such forced splice alteration for transcripts from 
the unaffected DMPK gene are still not sufficiently clear and require more work. Whether 
DM1-AS (CAG)n RNA could be included in similar strategies as a second molecular target for 
antisense therapy also awaits further study.
Finally, an almost ideal therapeutic approach would be to delete the complete 
repeat region from the DNA. The use of the CRISPR/Cas9 genome editing tool has grown 
tremendously in the last years and is currently employed in countless cell and animal models 
[92]. Our group has shown that precise excision of the (CTG·CAG)n repeat is possible using 
dual CRISPR/Cas9-cleavage at either site of the repeat [93]. Importantly, this restores normal 
cell functioning. Whether such a therapeutic approach may successfully be employed in the 
future remains to be seen because of the requirement for appropriate and effective delivery 
systems to target specific tissues, potential off-target effects and ethical concerns.
Concluding remarks
With the fundamental work described in this thesis, I have contributed to more profound 
understanding of RNA products from the DM1 locus. Improved knowledge about central 
players in DM1 pathology is important for gaining more insight in the molecular mechanisms 
involved. Ultimately, knowledge about the disease will hopefully help the scientific 
community in its efforts to generate a successful therapy. 
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Er bestaan meer dan 30 genetische ziekten die veroorzaakt worden door abnormale 
expansie (mutatie) van korte DNA-herhalingen in het genoom, meestal met neuromusculaire 
of neurodegeneratieve symptomen tot gevolg. De meeste van deze ziekten zijn zeldzaam, 
maar tezamen komen ze toch voor met een incidentie van 3-17 aangedane individuen per 
10.000 personen. Expansie van een korte DNA-herhaling van drie nucleotiden, een triplet, 
werd het eerst beschreven en is ook het meest intensief bestudeerd.
Verschillende moleculaire en cellulaire mechanismen kunnen betrokken zijn bij de 
manier waarop DNA-herhalingsziekten zich uiten. Dit hangt af van de locatie van de DNA-
herhaling in het genoom. Als deze in een stuk genoom ligt dat alleen wordt overgeschreven 
in RNA, dan kan dit verlengde RNA zich afwijkend gedragen door bijvoorbeeld abnormaal 
eiwitten te binden zodat het RNA zelf (maar ook RNA’s van andere genen die door de 
abnormaal gebonden eiwitten gereguleerd worden) zijn oorspronkelijke functie niet meer 
kan uitoefenen. Als de DNA-herhaling zich in een eiwitcoderend stuk van het RNA bevindt, 
zullen de resulterende eiwitproducten een serie identieke aminozuren bevatten die toxisch 
kan zijn voor de cel. Verstoring van nog complexere cellulaire processen, of combinaties van 
genoemde problemen, kunnen ook optreden. 
 In dit proefschrift beschrijf ik mijn studie naar moleculaire ziektemechanismen in 
myotone dystrofie type 1 (DM1). DM1 wordt veroorzaakt door een verlengde herhaling van 
een (CTG·CAG)n DNA-tripletvolgorde gelegen op de lange arm van chromosoom 19. Binnen 
dit deel van het genoom liggen, gecodeerd op de twee complementaire DNA-strengen, 
twee genen tegenover elkaar. De verlengde DNA-herhaling is daardoor aanwezig als (CTG)n 
in het 3’ onvertaalde deel van het ene gen, het DMPK gen voor het dystrophia myotonica 
protein kinase eiwit, maar tevens als (CAG)n-herhaling in het DM1-AS (DM1 locus antisense) 
gen. In DM1 dragen verschillende mechanismen bij aan de manifestatie van de ziekte. 
Algemeen wordt aangenomen dat transcripten van de genoemde genen met een verlengde 
(CUG)n- of (CAG)n-herhaling hierbij een belangrijke rol spelen. Tot nu toe zijn echter vrijwel 
alleen de gevolgen van de aanwezigheid van verlengde (CUG)n-transcripten op de RNA- en 
eiwit-homeostase van de cel intensief bestudeerd. Deze studies hebben een grote bijdrage 
geleverd aan onze huidige kennis over de primaire ziektemechanismen en mogelijke opties 
voor moleculaire therapie voor DM1. In deze samenvatting beschrijf ik nieuwe bevindingen 
verkregen tijdens mijn promotieonderzoek dat vooral was gericht op de aanmaak en rijping 
van RNA’s van de DMPK en DM1-AS genen zoals deze voorkomen bij gezonde en DM1-
aangedane patiënten.
Hoofdstuk 1 geeft een algemene introductie op het onderwerp. Hierin worden 
alle “levensstadia” die een RNA doorloopt in detail beschreven. Een prematuur RNA wordt 
afgeschreven van het DNA en ondergaat vervolgens verschillende modificaties, zoals het 
verwijderen van niet-coderende delen (intronen) en het aanzetten van een poly(A)-staart. 
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Daarna wordt het RNA vanuit de kern naar het cytoplasma getransporteerd, waar het 
gebruikt wordt als matrijs voor het synthetiseren van eiwitten, mits het een zogenaamde 
boodschapper RNA (mRNA) betreft. Uiteindelijk zal het RNA worden afgebroken. In 
Hoofdstuk 1 staat ook een uitgebreide introductie over het variabele verloop en de complexe 
uiting van myotone dystrofie type 1 waarbij de verschillende betrokken ziektemechanismen 
beschreven worden. Het RNA-toxiciteitsmechanisme, waarbij het verlengde RNA-molecuul 
eiwitten bindt, waardoor die niet meer hun normale functie in de cel kunnen uitvoeren en 
complexen vormt die kunnen aggregeren in zogenaamde foci, is het meest onderzochte 
ziektemechanisme. Naast de mechanismen betrokken bij RNA-toxiciteit worden ook andere 
ziektemechanismen die betrokken zijn bij DM1 manifestatie beschreven.
 Er zijn verschillende transgene muismodellen beschikbaar om DM1 te bestuderen. 
Vier van de modellen die gebruikt worden in preklinische studies worden geïntroduceerd in 
Hoofdstuk 1, te weten DM500, DMSXL, Tg26 en HSALR. De belangrijkste verschillen tussen deze 
muismodellen worden veroorzaakt door de karakteristieke eigenschappen van het menselijke 
transgen dat is ingebracht. DM500- en DMSXL-muizen hebben een groot transgen bestaande 
uit humaan genomisch DNA dat DMPK en de omliggende genen omvat, met daarin een DNA-
herhaling van respectievelijk 550 en 1300 tripletten. Tg26 heeft een veel kleiner transgen 
met alleen het DMPK gen met een korte DNA-herhaling van 11 tripletten, zoals dat ook 
voorkomt bij gezonde personen. Het HSALR model heeft een artificieel transgen, opgebouwd 
uit een DNA-herhaling van 250 tripletten in het ongerelateerde gen ACTA1. In Hoofdstuk 
2 kijken we naar expressie van de transgenen in myoblastcellijnen afgeleid van deze vier 
muismodellen en vergelijken we dit met endogene DMPK expressie in DM1-patiëntencellen. 
In de muizenmyoblasten met een compleet humaan DMPK transgen (DM500, DMSXL en 
Tg26) zien we dat de timing van de expressie gelijk is aan die in humane myoblasten, met 
een piek aan het begin van differentiatie. In de HSALR-myoblasten zien we daarentegen een 
latere start van transcriptie-inductie en een verhoging van de expressie relatief laat tijdens 
de spierceldifferentiatie. Dit expressiepatroon lijkt veel op het expressiepatroon van het 
originele transgen, ACTA1, waarin de DNA-herhaling is geïntroduceerd. De expressie van het 
DM1-AS gen is in dit hoofdstuk nog niet bestudeerd, maar kan op basis van kennis over de 
bekende transgengrootte en de bestaande wetenschappelijke literatuur naar verwachting 
alleen tot expressie komen in de DM500- en DMSXL-modellen.
Daarnaast laten we in Hoofdstuk 2 zien dat ook het aantal kopieën (moleculen) van 
de (CUG)n-bevattende transcripten grote verschillen vertoont tussen de modellen. In de 
DM500- en DMSXL-muizen is de transgenexpressie ongeveer 10x lager dan het niveau van 
expressie van het endogene Dmpk gen, maar in de HSALR-muis is het daarentegen wel 1000x 
hoger. Het expressieniveau van DMPK mRNA in humane cellen en Dmpk mRNA in muizencellen 
is ongeveer gelijk. Met behulp van verschillende methoden hebben we uiteindelijk bepaald 
dat er slechts een opvallend klein aantal van 1-50 DMPK mRNA-transcripten aanwezig is per 
cel, waarvan ongeveer de helft een verlengde DNA-herhaling heeft in DM1 patiënten. Dat 
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betekent dat elke focus, het fluorescente RNA-signaal gedetecteerd via FISH in celkernen 
van DM1 patiënten, slechts gevormd wordt door één of hooguit enkele verlengde DMPK 
transcripten.
 In de literatuur was redelijk goed omschreven dat DMPK transcripten met een 
lange geëxpandeerde tripletherhaling na vorming grotendeels achterblijven in de kern, en 
gehinderd worden in de nucleocytoplasmatische export, vermoedelijk door ingevangen te 
worden in ribonucleoproteïne complexen. In Hoofdstuk 3 hebben we onze aandacht ook 
gericht op de verdeling van normale DMPK transcripten over kern en cytoplasma. Onverwacht 
bleek normaal DMPK RNA ook relatief veel in de kernen van prolifererende myoblasten voor 
te komen. Om te onderzoeken of deze verdeling wellicht een regulatiemechanisme vormt 
om te voorkomen dat een grote hoeveelheid DMPK transcripten te snel en gelijktijdig in het 
cytoplasma komt en daar parallel vertaald wordt, hebben we gekeken naar myoblasten en 
fibroblasten die in hun groei gearresteerd waren en waarin de DMPK-expressie licht verhoogd 
was. De verdeling van DMPK transcripten tussen kern en cytoplasma bleek onafhankelijk 
van de expressieverandering en onveranderd met een relatief sterke accumulatie in de 
kern. De verhoging in expressie van DMPK RNA wordt dus niet gereguleerd via additionele 
nucleaire retentie. De relatief grote hoeveelheid normale DMPK transcripten in de kern blijft 
opmerkelijk, maar het mechanisme hierachter is zeer waarschijnlijk geheel onafhankelijk 
van het pathogene mechanisme dat DMPK transcripten met een verlengde triplet herhaling 
ophoudt in de kern.
 We hebben vervolgens ons onderzoek uitgebreid naar een andere stap in de 
levensloop van DMPK mRNA, de polyadenylering; een belangrijk aspect in de vorming van 
mature en stabiele transcripten in de kern. Voor normale DMPK transcripten zagen we 
dat de poly(A)-staart varieert in lengte en bestaat uit 0 tot wel 500 adenosineresiduen. 
Deze lengteverdeling bleek erg breed in vergelijking met de gegevens in de literatuur waar 
doorgaans een opbouw van 0 tot 250 nucleotiden werd gerapporteerd. Omdat DMPK 
transcripten met een verlengde tripletherhaling in hoge mate in de kern verblijven en 
daardoor wellicht onderhevig zijn aan hyperadenylering, wilden we ook graag de poly(A)-
staartlengtes van deze transcripten analyseren. Daarvoor was het eerst noodzakelijk 
een methode te ontwikkelen om normale en verlengde DMPK transcripten van elkaar te 
scheiden. Door electroforetische scheiding van deze transcripten in een agarose gel, op 
basis van het verschil in lengte, werd dit doel bereikt. Zodanig verkregen afzonderlijke 
transcriptpopulaties werden uit gel geëxtraheerd en separaat geanalyseerd. Ondanks de 
sterke kernretentie van DMPK transcripten met een verlengde tripletherhaling bleek hun 
poly(A)-staart vergelijkbaar met die van normale DMPK transcripten. We concluderen dus 
dat de abnormale kernaccumulatie niet van invloed is op het (de)adenylatieproces dat 
(CUG)n-verlengde transcripten ondergaan en dat deze zich op dit punt niet onderscheiden 
van normale DMPK transcripten.
 In het laatste experimentele hoofdstuk karakteriseren we het antisense 
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transcript van het DM1 locus in meer detail. Door te zoeken in openbare genoom- en 
transcriptoomdatasets en onze vindingen vervolgens experimenteel te verifiëren hebben 
we verschillende transcriptiestartplaatsen geïdentificeerd welke complementair zijn aan 
sequenties uit intron 1 en exon 1 van het SIX5 gen. Natuurlijk is het voor DM1-gerelateerd 
onderzoek van groot belang om te weten of de tripletherhaling ook in RNA getranscribeerd 
wordt, omdat een verlengde (CAG)n-herhaling wellicht ook voor toxische effecten in 
de cel kan zorgen. In de DM1-AS transcriptieunit hebben we zowel voor als achter de 
tripletherhaling polyadenyleringsplaatsen gevonden, waardoor de tripletregio niet altijd 
wordt getranscribeerd. Daarnaast vindt er ook alternatieve splicing plaats waarbij de 
(CAG)n triplet mogelijk verwijderd wordt als onderdeel van een intron en daardoor geen 
deel meer uitmaakt van het mature DM1-AS RNA. We voorspellen dat de resulterende 
DM1-AS transcriptpopulatie erg heterogeen is, doordat processing kan plaatsvinden op 
veel verschillende manieren. Op grond van analogie met andere transcripten speculeren 
we dat DM1-AS behoort tot de categorie van lange niet-coderende RNAs (lncRNAs), een 
recent ontdekte klasse van RNA-producten met dezelfde complexe en uiteenlopende 
karakteristieke eigenschappen. Ook voor het mengsel van DM1-AS transcripten hebben we 
de kopie-aantallen bepaald. Deze zijn opvallend laag: naar schatting is er slechts ongeveer 
één DM1-AS RNA-molecuul aanwezig per 1 tot 10 cellen. Het is daarmee volstrekt onduidelijk 
wat de functie van deze DM1-AS transcripten is. Verder onderzoek zal moeten uitwijzen 
of de aanwezigheid van DM1-AS RNAs daadwerkelijk bijdraagt aan de pathobiologische 
manifestatie van DM1.
 Tot slot geef ik in Hoofdstuk 6 een samenvattende beschrijving van onze 
belangrijkste bevindingen en bediscussiëer ik hun relevantie voor toekomstig fundamenteel 
en translationeel werk aan DM1. Het werk beschreven in dit proefschrift was gericht op 
het verkrijgen van meer kennis over de RNA-producten die afgeschreven worden van de 
DM1 locus, en die waarschijnlijk aan de basis staan van het ziekteproces. Kennis over deze 
moleculaire kernspelers in DM1 is primair belangrijk om meer inzicht te verkrijgen in de 
moleculaire mechanismen die betrokken zijn bij de ziekte en kan wereldwijd worden ingezet 
in toegepast onderzoek om een succesvolle therapie voor deze ernstige degeneratieve 
genetische aandoening te ontwikkelen.
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List of abbreviations*
A adenine
a.u. arbitrary unit
ACTA1 actin, alpha 1, skeletal muscle
ACTB actin beta
ALS amyotrophic lateral sclerosis 
APA alternative polyadenylation
C cytosine
C9orf72 chromosome 9 open reading frame 72
CDM congenital myotonic dystrophy
CELF1 CUGBP/Elav-like family member 1
CNBP CCHC-type zinc finger nucleic acid binding protein
DM myotonic dystrophy (dystrophia myotonica)
DM1-AS DM1 locus antisense RNA
DM500 mouse model derived from the DM300-328 line with a (CTG)±550 repeat
DMPK dystrophia myotonica protein kinase 
DMSXL mouse model derived from the DM300-328 line with a (CTG)±1300 repeat
DMWD dystrophia myotonica WD repeat containing
DNA deoxyribonucleic acid
FISH fluorescent in situ hybridization
FPKM fragments per kilobase of exon per million fragments mapped
FTD frontotemporal dementia 
FXS fragile X syndrome
FXTAS fragile X-associated tremor/ataxia syndrome
G guanine
GAPDH glyceraldehyde-3-phosphate dehydrogenase
HD Huntington’s disease
HDL2 Huntington’s disease-like 2
hnRNP heterogeneous nuclear ribonucleoprotein
HSALR human skeletal actin large repeat (mouse model)
I inosine
IRES internal ribosome entry site
lncRNA long non-coding RNA
MALAT1 metastasis-associated lung adenocarcinoma transcript 1 (non-protein coding)
MBNL muscleblind like splicing regulator
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* Abbreviations related to gene names and symbols are in accordance with the HUGO Gene 
Nomenclature Committee (www.genenames.org). In the chapters, names of genes and 
transcripts are italicized; names of proteins are in regular case (Wain et al. 2002; PMID: 
11752283). Human genes are in uppercase, while mouse genes are in lowercase with the 
first letter capitalized. 
mRNA messenger RNA
NEAT1 nuclear paraspeckle assembly transcript 1 (non-protein coding)
NMD nonsense-mediated decay
ns not significant
nt nucleotide
ORF open reading frame
PAP poly(A) polymerase
PCR polymerase chain reaction
poly(A) tail poly-adenosine tail
pre-mRNA premature messenger RNA
qPCR quantitative real-time polymerase chain reaction
RAN translation repeat-associated non-ATG translation
RNA ribonucleic acid
RNase H ribonuclease H
RNP ribonucleoprotein
RT reverse transcription
SCA spinocerebellar ataxia
SEM standard error of the mean
SIX SIX homeobox 5
snRNP small nuclear RNP
T thymine
Tg26 mouse model with 25 tandemly integrated DMPK copies
TSS transcription start site
U uracil
UTR untranslated region
wt wildtype
XIST X inactive specific transcript (non-protein coding) 
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Curriculum vitae
Anke Gudde is geboren op 26 juli 1987 te Doetinchem. In 2005 behaalde ze haar VWO-
diploma aan het Almende College in Silvolde, waarna zij is begonnen aan de studie 
Moleculaire Levenswetenschappen aan de Radboud Universiteit Nijmegen. Tijdens de 
bachelorfase van deze studie heeft zij 10 weken stage gelopen op de afdeling Urologie van 
het Radboud universitair medisch centrum (Radboudumc) onder leiding van Dr. Egbert 
Oosterwijk. Gedurende haar master heeft Anke twee onderzoeksstages van elk 6 maanden 
uitgevoerd. De eerste stage vond plaats op de afdeling Farmacologie-Toxicologie van het 
Radboudumc, waar zij onder leiding van Dr. Jan Koenderink onderzoek heeft gedaan naar 
de expressie van een transporter van Plasmodium falciparum die mogelijk betrokken is 
bij multidrugresistentie van deze malariaparasiet. Voor haar tweede stage is zij naar de 
Verenigde Staten gegaan, waar zij onderzoek gedaan heeft bij de afdeling Genetics and 
Tumor Cell Biology van het St. Jude Children’s Research Hospital in Memphis onder leiding 
van Dr. Gerard Grosveld. Aldaar heeft zij de expressie van TEL2 (ookwel ETV7) mRNA 
onderzocht tijdens B-cel ontwikkeling en activatie, en tijdens celdifferentiatie. In januari 
2011 behaalde zij haar MSc diploma.
 In april 2011 startte Anke als promovenda bij de afdeling Celbiologie binnen het 
Radboud Institute for Molecular Life Sciences (RIMLS) van het Radboudumc. Gefinancierd 
door het Prinses Beatrix Spierfonds, heeft zij onder begeleiding van Dr. Rick Wansink en 
Prof. Dr. Bé Wieringa onderzoek uitgevoerd dat beschreven staat in dit proefschrift. 
Resultaten van dit onderzoek heeft zij gepresenteerd op verschillende nationale en 
internationale congressen. Tijdens haar promotieonderzoek heeft zij meerdere bachelor- 
en masterstudenten begeleid bij hun stages. 
 Sinds mei 2016 is Anke werkzaam als product developer bij MRC-Holland in de 
tumordiagnostiekgroep. Daar draagt zij bij aan de ontwikkeling van diagnostische testen 
voor het bepalen van veranderingen in DNA copy number op basis van de Multiplex Ligation-
dependent Probe Amplification (MLPA) techniek.
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Name PhD student: A.E.E.G. Gudde 
Department: Cell Biology 
Research School: Radboud Institute for Molecular Life Sciences 
PhD period: 01-04-2011 – 31-03-2015 
Promotor: Prof. B. Wieringa 
Co-promotor: Dr. D.G. Wansink 
 Year(s) ECTS 
TRAINING ACTIVITIES 
Courses & Workshops 
RIMLS Graduate Course 
Presentation Skills – Radboud Into Languages  
Academic Writing – Radboud Into Languages 
 
2011 
2012 
2012-2013 
 
2 
1.5 
3 
Seminars & lectures 
RIMLS Technical Forums 
RIMLS in the Spotlight 
Seminars 
Lecture series 
 
2012-2015 
2011-2013 
2011-2015 
2012-2014 
 
1.6 
1.8 
2.2 
1 
(Inter)national Symposia & congresses 
RIMLS PhD Retreat*# 
RIMLS New Frontiers in Nobel Channels 
International Myotonic Dystrophy Consortium meeting 8* 
Spierziektecongres* 
Cell Symposia: Functional RNAs* 
Spierziektecongres* 
International Myotonic Dystrophy Consortium meeting 9# 
RIMLS New Frontiers in Synthetic Life 
RIMLS New Frontiers in Regenerative Medicine 
 
2011-2014 
2011 
2011 
2012 
2012 
2013 
2013 
2013 
2014 
 
4 
1 
1 
0.25 
1 
0.25 
1.4 
1 
1 
Other 
Organizing RIMLS Technical Forum: Genomics 
Brainstorm session Prinses Beatrix Spierfonds 
 
2014 
2015 
 
0.5 
0.1 
TEACHING ACTIVITIES 
Lecturing 
Assisting computer practical 
 
2012-2015 
 
1 
Students 
Supervision of Edo Luijten 
Supervision of Laurène André 
Supervision of Daan Heister 
Supervision of Amanda de Oude 
 
2012 
2012-2013 
2013-2014 
2014 
 
2.5 
3 
1.7 
1.7 
TOTAL 34.5 
 
Oral and poster presentations indicated with a * and # after the name of the activity, respectively. 
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Dankwoord
Nadat je je door alle voorgaande pagina’s met wat zwaardere kost hebt heen geworsteld, 
is het nu tijd voor iets luchtigers. Of lees jij ook altijd eerst het einde van een boek om te 
kijken of het wel goed afloopt? Ik kan je gerust stellen, het feit dat jij dit boekje in je handen 
hebt, betekent dat we op de goede weg zijn! Maar dit boekje was er niet geweest zonder 
de steun van velen. 
Allereerst wil ik Bé Wieringa en Rick Wansink, mijn promotor en co-promotor, bedanken. 
Jullie zijn onmisbaar geweest en ik vond het een eer om samen met jullie te mogen werken. 
Ook al stonden er best een aantal beren op de weg, door jullie hulp is het tot een goed einde 
gekomen. Bé, je bent een doorgewinterde wetenschapper, gedreven door nieuwsgierigheid. 
Jouw kritische blik, zelfs op de afkortingenlijst, heeft er mede voor gezorgd dat het boekje 
in deze vorm bestaat. Rick, ik bewonder jouw optimisme, enthousiasme en compacte 
schrijfstijl. Je hebt me de afgelopen jaren enorm gesteund en ik kon altijd bij je terecht voor 
hulp wanneer dat nodig was.
Op het lab werd ik omringd door leuke en gezellige collega’s. Ik vind het erg fijn dat twee 
van jullie ook tijdens de verdeging naast me zullen staan. Walther, op het lab de nestor van 
de DM groep en vaak te vinden in een donker kamertje op zoek naar foci. Bedankt voor je 
altijd getoonde interesse en hulp waar nodig. Laurène, je begon je carrière bij celbiologie 
als student op het Spinach project. Helaas hebben we nooit veel groen mogen zien, maar 
ik ben nog altijd onder indruk van de northern blot gerund met jouw pull-down samples 
(zie figuur op pagina 147). Heel veel succes met het afronden van je eigen promotie traject. 
Ingeborg, qPCR en cel fractionering expert, ook jouw hulp bij verschillende hoofdstukken 
was onmisbaar. En Marieke, jouw energie en vrolijkheid zorgen voor een nog gezelliger lab! 
Natuurlijk wil ik ook alle andere collega’s van celbiologie bedanken: señor Anchel, Ellen 
(CRISPR-Cas koningin), Leontien, Remco van Cruchten, Wiljan, Annika, Mietske, Jan†, 
Jack, Huib (zesje?), Magda, Ineke, Mirthe, Frank (de kunstschilder), Gerda, Susan, Remco 
van Horssen, Lieke, Rinske, Esther, Julia, Cornelia, Mariska, Cindy, Linda, Manon, Lianne, 
Sjoerd, Mirjam, Katarina, Jan-Hendrik, Antoine, Gert-Jan, Pavel, Olga, Bettina, Sarah, Peter, 
Steffi, Samuel, Monique, Marieke de Vries, Alessandra, Koen, Ben en Svenja. Maar de 
zesde verdieping zou de zesde verdieping niet zijn zonder de moldiertjes en collega’s van 
biomoleculaire chemie (en jullie semi-dry blotting apparaat). Bedankt voor jullie luisterende 
oor tijdens werkbesprekingen en goede adviezen, maar ook voor de gezellige koffie- en 
lunchpauzes, kerstdiners, paaslunches en labuitjes.
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Tijdens mijn promotie heb ik vier studenten mogen begeleiden. Edo, Laurène, Daan en 
Amanda, bedankt voor jullie inzet. Ik vond het leuk om jullie te begeiden en heb veel van 
jullie geleerd. Ik hoop natuurlijk dat jullie ook wat van mij geleerd hebben.
Simon, je bijdrage aan het bioinformatische deel van het antisense verhaal was onmisbaar. 
Bedankt dat ik altijd binnen kon lopen, ook al moest ik daar wel een eindje voor afdalen in 
de RIMLS toren, en dat je altijd bereid was om te helpen.
Het onderzoek beschreven in dit proefschrift was niet mogelijk geweest zonder de financiële 
ondersteuning van het Prinses Beatrix Spierfonds. Daarnaast ben ik via het fonds ook in 
contact gekomen met DM1 patiënten op het jaarlijkse spierziektecongres in Veldhoven en 
dit heeft erg motiverend gewerkt.
Ik wil ook graag MRC-Holland bedanken voor de ruimte die zij gegeven hebben om mijn 
promotieonderzoek af te ronden naast mijn huidige baan. Ik heb het erg naar mijn zin bij 
jullie.
Naast werk is er natuurlijk ook ontspanning: vrijdagmiddagborrel bij de Aesculaaf, sporten, 
verjaardagen, festivals en weekendjes weg. Anne, Laurens, Liz, Jos, Loes, Niek, Ellen, Ruud, 
Nienke, Linda, Daan, Rik, Stefan, Bo, Sham, Leanne, Wouter en Anne S., bedankt voor jullie 
getoonde interesse, steun en gezelligheid. Mede door jullie heb ik een erg fijne studie- en 
promotietijd gehad in Nijmegen.
En dan gaan we terug naar de roots. Jennifer, Flip, Sanne, Marjolein, Frans, Froukje, Robin, 
Rachel, Roel, Esther, Ties, Lisa, Marvin, Monique, Dion en Helena, we zien elkaar misschien 
wat minder vaak, maar het is snel weer als vanouds tijdens verjaardagen en weekendjes 
weg.
Lieve schoonfamilie, ik heb er een heleboel familie bijgekregen toen ik met Jasper trouwde. 
Bedankt voor jullie interesse in mijn promotieonderzoek en gezelligheid tijdens de vele 
verjaardagen en de extra kerstdiners.
Maarten, grote broer, door jou heb ik naast DM1 de afgelopen jaren ook veel geleerd 
over PIN-terminals. Joost, mijn “kleine” broertje, je gedrevenheid en kennis van allerlei 
technische zaken is bewonderenswaardig. Ik vind het fijn om jullie zus(je) te zijn en te weten 
dat ik altijd op jullie hulp kan rekenen. Anneloes en Anne, het is leuk en gezellig om jullie 
als schoonzussen te hebben. Papa en mama, bedankt voor het fijne thuis dat jullie altijd 
gegeven hebben en waar ik altijd terecht kan. 
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Tot slot Jasper, je bent een enorme steun voor mij geweest. We zaten in hetzelfde (promotie) 
schuitje en leefden met elkaar mee tijdens de ups-en-downs. Maar er is meer dan werk 
alleen. Ik ben ontzettend blij met jou als man en ik word altijd vrolijk van jou. Ik vind je lief!
Liefs,
AA
A
